Apendicitis

2'-FL modulates pro-inflammatory cytokine production via TLR4/NF-κB pathway inhibition in preclinical models. A randomized, double-blind, placebo-controlled human trial (n=~36 overweight/obese adults, 8 weeks) found that 2'-FL supplementation significantly decreased fasting plasma IL-6 concentrations versus placebo. In vitro, 2'-FL attenuates LPS-induced inflammation by downregulating CD14 expression in human enterocytes. Evidence is strongest for gut-originating inflammation; systemic anti-inflammatory effects in healthy humans require further study.

Leaf and bark extracts of Abies spectabilis show measurable COX-1/COX-2 inhibitory activity in vitro, and in silico docking suggests suppression of TNF-α signaling. Pharmacological review studies list anti-inflammatory activity among confirmed in vivo and in vitro bioactivities. The plant is also traditionally recognized for inflammatory conditions in Himalayan folk medicine.

Acacia gum has been shown in human clinical trials to significantly reduce C-reactive protein (CRP), a key systemic inflammatory marker. Studies in haemodialysis patients and sickle cell anemia patients demonstrated significant CRP reductions alongside augmented total antioxidant capacity after 12 weeks of 30 g/day supplementation. The SCFA butyrate produced by fermentation of acacia gum is a proposed mechanistic mediator.

Human clinical trials have shown that acai berry reduces select inflammatory and oxidative stress markers, though effects on CRP — the primary inflammation marker — are inconsistent. An RCT in metabolic syndrome patients found significant reductions in IFN-γ and urinary 8-isoprostane, but hs-CRP was unaffected. A crossover trial in healthy adults demonstrated major improvements in antioxidant enzyme activity.

Acemannan modulates macrophage polarization, suppressing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. In vitro and animal studies demonstrate consistent anti-inflammatory activity via TLR-4/TLR-5 receptor activation and promotion of M2 macrophage phenotypes. Human clinical data remain indirect (via whole Aloe vera preparations), but mechanistic evidence is well-characterized.

Bioactive peptides from adzuki bean inhibit TNF-α and IL-6 expression in cell studies, while polyphenol-rich extracts lower vascular inflammatory markers in hypertensive rat models. High-fat diet mouse studies show adzuki bean reduces serum LPS-driven endotoxemia and shifts macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2. Human data are lacking but mechanistic evidence is substantive.

Multiple in vitro and in vivo studies demonstrate agrimony reduces key pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and nitric oxide. A validated animal model study confirmed anti-inflammatory activity using carrageenan-induced paw oedema. The human RCT by Cho et al. (2018) also showed reductions in liver inflammatory markers (ALT, AST) in a placebo-controlled design.

Ajoene inhibits key pro-inflammatory pathways in cell-based models, including suppression of iNOS expression and partial inhibition of LPS-induced TNF-α production in macrophages. It modulates lymphocyte proliferation and macrophage membrane-dependent functions. Evidence is preclinical (in vitro and animal); no clinical trials in inflammatory disease have been published.

Ajwain extracts have demonstrated anti-inflammatory activity in multiple animal studies, with effects at high doses exceeding those of standard NSAIDs in some comparisons. Thymol and carvacrol are the primary anti-inflammatory constituents. Evidence is preclinical (animal and in vitro); human RCTs are absent.

AKG suppresses the NF-κB-mediated inflammatory pathway and reduces pro-inflammatory cytokine production across multiple model systems. In mice, Ca-AKG supplementation lowered systemic inflammatory markers including pro-inflammatory cytokines while raising anti-inflammatory IL-10. Human mechanistic evidence is indirect, derived from clinical nutrition contexts where AKG modulates immune and inflammatory signaling.

A. muciniphila exerts well-documented anti-inflammatory effects by reinforcing the intestinal barrier, reducing LPS translocation into systemic circulation, and modulating immune cell polarization (promoting M2 macrophages, regulatory T-cells, and suppressing IL-6, TNF-α, IL-1β). In the 2019 human RCT, A. muciniphila supplementation reduced blood markers of liver dysfunction and inflammation versus placebo. Its outer membrane protein Amuc_1100 activates TLR2 to support anti-inflammatory signaling.

ALA modulates systemic inflammatory markers including CRP and TNF-α. Clinical trials in cardiometabolic populations show reductions in CRP and TNF-α with supplementation, though effects on IL-6 are inconsistent. ALA suppresses iNOS and COX-2 expression, dampening pro-inflammatory eicosanoid synthesis.

Alpha-Lipoic Acid (ALA) has well-documented anti-inflammatory effects supported by multiple randomized controlled trials and meta-analyses. Its primary mechanism involves inhibition of the NF-κB signaling pathway, suppressing pro-inflammatory cytokines such as TNF-α, IL-6, and CRP. A 2018 systematic review and meta-analysis of 18 RCTs found ALA supplementation significantly reduced CRP and IL-6 in patients with metabolic syndrome. Evidence strength is considered moderate; high heterogeneity across trials and a need for more standardized long-term studies have been noted.

Alfalfa contains flavonoids, phenolic acids, and saponins with documented anti-inflammatory properties in vitro and in animal studies. Mechanisms include inhibition of NF-κB and MAPK signaling pathways and reduction of pro-inflammatory cytokines. Human clinical evidence is currently lacking.

DHA from algal oil exerts anti-inflammatory effects by competing with arachidonic acid pathways and producing specialized pro-resolving mediators (resolvins and protectins). These mechanisms reduce circulating inflammatory cytokines including TNF-α, IL-1β, and IL-6. Higher omega-3 intake is associated with lower C-reactive protein levels in clinical populations.

Alkannin and shikonin, the principal bioactives of A. tinctoria, have demonstrated significant anti-inflammatory activity in vitro and in vivo. In a key pharmacochemical study, they efficiently reduced mouse paw edema (FCA-induced) and inhibited lipid peroxidation, performing equal to or better than standard reference compounds. Their mechanism is attributed at least partly to free-radical scavenging and modulation of key cellular inflammatory pathways.

Allantoin exhibits documented anti-inflammatory activity through inhibition of COX-2, modulation of NF-κB, and downregulation of pro-inflammatory cytokines such as IL-4, IL-5, TNF-α, and IL-8. In murine allergic models, allantoin reduced IgE levels and Th2 cytokine production. A 2022 in vitro and in vivo study demonstrated dose-dependent inhibition of mast cell degranulation and histamine release.

Allspice essential oil and its major constituent eugenol have demonstrated anti-inflammatory activity in preclinical studies. Eugenol inhibits COX enzymes and prostaglandin synthesis and modulates pro-inflammatory cytokines (IL-6, TNF-α) in macrophage models. Animal studies show significant reduction in carrageenan-induced edema. No human clinical trials exist.

Several RCTs show almond consumption reduces circulating inflammatory markers including TNF-α, IL-6, and CRP, particularly in metabolically at-risk populations. The anti-inflammatory effect is attributed to almonds' vitamin E, polyphenols, unsaturated fatty acids, and prebiotic fiber. Results in already-healthy adults are more modest.

Aloe vera contains bioactive compounds (acemannan, aloe-emodin, aloesin, emodin, aloin) shown to suppress key inflammatory mediators including IL-6, TNF-α, iNOS, and COX-2 via NF-κB and MAPK pathway downregulation. Both in vitro and in vivo evidence supports anti-inflammatory activity. A 2025 review highlights its potential against chronic inflammaging-driven conditions.

Multiple epidemiological cohort studies link higher serum carotenoid levels, including alpha-carotene specifically, to lower markers of systemic inflammation and reduced chronic disease mortality. The proposed mechanism involves carotenoid-mediated suppression of NF-kB and induction of Nrf-2 antioxidant enzyme expression, which together reduce pro-inflammatory cytokines such as TNF-α. Evidence is observational; no alpha-carotene-specific anti-inflammatory RCT has been conducted in humans.

AGIQ suppresses pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and nitric oxide primarily via inhibition of the NF-κB signaling pathway, demonstrated in cell and animal studies. Human-specific clinical evidence for AGIQ on inflammation remains limited, though its metabolite quercetin has some clinical anti-inflammatory data. The mechanistic and preclinical basis is robust.

A. galanga extracts inhibit key pro-inflammatory mediators including COX-2, TNF-α, IL-1β, and NF-κB in multiple in vitro and animal studies. The compound ACA is a well-characterised COX-2 suppressor. Anti-inflammatory activity has been corroborated in human synovial fibroblast models, though large RCTs in humans are lacking.

Amaranth contains multiple anti-inflammatory phytochemicals including flavonoids (quercetin, kaempferol), phenolic acids, squalene, and bioactive peptides. In vitro studies show inhibition of inflammatory markers including nitric oxide and immunoglobulin E. Germinated amaranth protein concentrate has demonstrated anti-inflammatory potential via NO inhibition in macrophages. The relationship is supported by mechanistic and preclinical evidence but lacks large human RCTs.

Amber contains bioactive compounds — including succinic acid, monoterpenoids, sesquiterpenoids, and diterpenoids — that have demonstrated anti-inflammatory activity in laboratory models. A 2024 review confirmed anti-inflammatory among amber's reported biological activities. Evidence is preclinical; no human trials exist.

EPA and DHA from anchovies are among the best-studied anti-inflammatory nutrients. Multiple meta-analyses of RCTs have demonstrated that omega-3 supplementation significantly reduces circulating CRP, TNF-α, and IL-6. The mechanism involves competitive inhibition of arachidonic acid eicosanoid pathways and production of pro-resolving lipid mediators (resolvins, protectins).

Andrographis paniculata and its primary bioactive compound, andrographolide, have demonstrated anti-inflammatory activity in both preclinical models and human clinical trials. The herb inhibits key inflammatory pathways, including NF-κB and MAPK/ERK, suppressing cytokines such as TNF-α, IL-1β, IL-6, and COX-2. Randomized controlled trials in chronic inflammatory conditions—specifically ulcerative colitis and rheumatoid arthritis—have produced clinically meaningful, if modest, results. Evidence is most robust for intestinal inflammation, with supportive but smaller signals in joint-based chronic inflammation.

Andrographolide, the primary bioactive diterpenoid from Andrographis paniculata, has well-documented anti-inflammatory activity supported by both mechanistic laboratory research and human clinical trials. It suppresses key pro-inflammatory pathways—most notably NF-κB—reducing cytokines such as TNF-α, IL-1β, IL-6, and COX-2. Clinical evidence is strongest for chronic inflammatory conditions including ulcerative colitis and, to a lesser extent, rheumatoid arthritis and osteoarthritis, though overall human trial data remain limited in scale.

Timosaponin AIII and sarsasapogenin from anemarrhena have been demonstrated in multiple preclinical studies to inhibit NF-κB and MAPK signaling, COX-2 expression, and pro-inflammatory cytokines (IL-1, IL-6, TNF-α). Anti-inflammatory activity is one of the most consistent and mechanistically characterized pharmacological properties of the herb.

Human clinical studies show annatto-derived delta-tocotrienol significantly reduces circulating pro-inflammatory cytokines (TNF-α, IL-6, IL-2, IL-4, IL-8) and CRP. In one RCT, 250 mg/day of annatto tocotrienol reduced CRP and malondialdehyde each by 40% and 34%, respectively. Preclinical data confirm bixin activates Nrf2 and downregulates NLRP3 inflammasome components.

Apigenin, a flavone found abundantly in parsley, chamomile, and celery, has substantial preclinical evidence for anti-inflammatory activity, primarily through suppression of NF-κB signaling and inhibition of pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, COX-2, and iNOS. Multiple systematic reviews and meta-analyses confirm these effects in cell and animal models across conditions including neuroinflammation, lung injury, cardiovascular disease, and metabolic syndrome. Dedicated human clinical trials on isolated apigenin are absent, making the current evidence base preclinical rather than clinical, though human bioavailability has been partially characterized.

Apple polyphenols, particularly quercetin and proanthocyanidins, inhibit NF-κB signaling and reduce production of pro-inflammatory cytokines in cell and animal models. Human data from RCTs show inconsistent but directionally favorable effects on CRP and inflammatory markers.

In vitro and limited clinical studies show ACV can downregulate pro-inflammatory cytokine expression. A PubMed-indexed study found ACV reduced cytokine and microbial protein expression in cell cultures. A 2023 systematic review and meta-analysis of RCTs examined ACV's effects on inflammation and oxidative stress markers.

Apricot fruit and kernel extracts have demonstrated anti-inflammatory activity in multiple in vitro and animal studies. Polyphenols such as quercetin and chlorogenic acid inhibit inflammatory signaling pathways. A 2024 study on bitter apricot kernel extract showed 77.4% inhibition of inflammation in an animal model. Traditional medicine systems also cite apricots for inflammatory and rheumatic conditions.

In vitro studies demonstrate that arabinogalactan reduces LPS-induced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and suppresses NF-κB signaling in intestinal epithelial cells. Human clinical data show modulation of TNF-α levels after LA supplementation, and a combination product containing LA reduced fecal IL-6 and IFN-γ significantly in healthy subjects. Evidence at the chronic systemic inflammation level in humans remains limited to mechanistic and small trials.

Argan oil's polyphenols, tocopherols, and phytosterols modulate inflammation via the NF-κB and Nrf2 signalling pathways. Preclinical in vitro and animal studies demonstrate reductions in pro-inflammatory cytokines IL-6 and TNF-α. Limited human data come from surrogate markers in cardiovascular trials.

Arnica's sesquiterpene lactone helenalin selectively inhibits NF-κB, a master transcription factor driving chronic inflammatory gene expression. In vitro and in vivo models document suppression of TNF-α, IL-1β, IL-6, COX-2, and 5-lipoxygenase pathways. Clinical reviews confirm these mechanisms underlie arnica's approved anti-inflammatory indications.

A systematic review of RCTs (published in Nutrition Reviews, 2025) found that Aronia melanocarpa supplementation significantly reduced CRP, TNF-α, and IL-6 while increasing anti-inflammatory IL-10 in human subjects. Positive changes in antioxidant enzyme systems including SOD, GSH-Px, and catalase were also observed. Aronia anthocyanins modulate inflammation partly by binding iron and regulating immune-inflammatory pathways.

Artichoke leaf polyphenols—particularly luteolin and cynaropicrin—inhibit NF-κB signaling and reduce pro-inflammatory cytokines. A 2024 meta-analysis found artichoke supplementation significantly reduced hs-CRP. An ex vivo clinical trial showed that human serum enriched with ALE metabolites attenuated inflammation in hepatocytes and chondrocytes.

Ascorbyl palmitate has been shown to potently inhibit NLRP3 inflammasome activation — a key driver of chronic inflammatory diseases — with greater potency and specificity than ascorbic acid. It acts by scavenging mitochondrial ROS and blocking NLRP3-NEK7 protein interaction. In preclinical models, AP attenuated LPS-induced systemic inflammation, DSS-induced colitis, and experimental autoimmune encephalomyelitis. Clinical evidence in humans remains indirect, primarily through topical anti-inflammatory effects on skin erythema.

Ashitaba chalcones suppress pro-inflammatory signaling through multiple pathways in cell and animal studies. XA inhibits NF-κB nuclear translocation, and ashitaba exudate reduces TNF-α in obese diabetic mice. In a human bioavailability study, ashitaba consumption raised plasma antioxidant status significantly. No dedicated clinical inflammation trials exist.

Ashwagandha, particularly its constituent withaferin A, inhibits NF-κB signaling and suppresses pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β in both preclinical models and human trials. A 2025 PMC review confirmed clinical evidence for anti-inflammatory effects. The herb also activates Nrf2, reinforcing antioxidant defenses that counteract oxidative drivers of chronic inflammation.

Asparagus species, particularly A. racemosus, contain saponins, flavonoids, and polyphenols documented to suppress pro-inflammatory pathways including NF-κB activation and pro-inflammatory cytokine release in cell and animal models. A 2026 human RCT in overweight adults found that A. officinalis root extract supplementation combined with HIIT reduced inflammatory biomarkers. Asparagus has been recognized in official pharmacopoeias for inflammatory conditions.

Multiple preclinical studies demonstrate that S. cusia alkaloids (indirubin, tryptanthrin, indigo) suppress inflammatory pathways including NF-κB, COX, and IL-17. Animal studies confirm significant reduction of carrageenan-induced paw edema. Clinical evidence in human inflammatory diseases (UC, psoriasis) indirectly validates broad anti-inflammatory activity.

Astaxanthin, a xanthophyll carotenoid, has demonstrated anti-inflammatory effects in multiple human randomized controlled trials, reducing key biomarkers including CRP, IL-6, and TNF-α. A meta-analysis of 14 clinical trials confirmed its efficacy in lowering CRP, with significant effects observed at doses above 12 mg/day for durations of 12 weeks or more. A 2025 systematic review of 15 human studies found consistent reductions in pro-inflammatory cytokines and oxidative stress indices. Evidence is promising but overall trial sizes remain small and long-term data are limited.

Multiple preclinical studies document that Aster root extracts and isolated constituents (shionone, caffeoylquinic acids, flavonoids) suppress key pro-inflammatory mediators including NF-κB, TNF-α, IL-1β, IL-6, NO, and PGE-2. The Chinese Pharmacopoeia designates shionone as a quality marker partly for its core anti-inflammatory role. Evidence is currently preclinical (cell and animal studies).

A 2023 review of 19 studies (1,094 participants) found astragalus enhanced immune responses and reduced proinflammatory cytokines. Key constituents including astragalosides and polysaccharides inhibit NF-κB signaling and reduce TNF-α, IL-1β, and IL-6. Preclinical data are extensive; human trial evidence is growing but mostly adjunctive.

Atractylenolides I and III are well-characterised anti-inflammatory sesquiterpenes that inhibit NF-κB, TLR4, MAPK, and JAK2/STAT3 signalling, reducing TNF-α, IL-1β, IL-6, iNOS, and COX-2 in multiple preclinical models. This is one of the most extensively documented pharmacological properties of atractylodes.

B. coagulans consistently reduces inflammatory biomarkers (CRP, IL-6, myeloperoxidase, IL-17) across multiple RCTs in IBS, RA, IBD, and depression populations. Anti-inflammatory effects are attributed to downregulation of pro-inflammatory cytokines and upregulation of regulatory cytokines. Evidence across several conditions is robust.

Baikal skullcap and its primary flavonoids baicalin and baicalein demonstrate potent anti-inflammatory activity across multiple in vitro and animal models, operating through inhibition of NF-κB, MAPK, JAK-STAT, and Nrf2 pathways. These compounds suppress pro-inflammatory mediators including TNF-α, IL-6, and IL-1β. Preclinical evidence is extensive, though large-scale human RCTs targeting chronic inflammation as a primary endpoint are limited.

Multiple preclinical studies demonstrate that bamboo extracts suppress inflammatory pathways, including NF-κB, AP-1, and COX-1/COX-2. In cell and animal models, bamboo extract (BEX) from Phyllostachys edulis reduces IL-6 and TNF-α overproduction under lipotoxic conditions. Several bamboo species are also traditionally used in Asian medicine for inflammatory conditions.

Corosolic acid, the principal active in banaba, exhibits anti-inflammatory activity in preclinical models through NF-κB and related pathways. In metabolic-syndrome rat models, dietary corosolic acid ameliorated systemic inflammation alongside hypertension and oxidative stress. Human-specific anti-inflammatory clinical trials are lacking, but mechanistic and animal-model evidence is published in peer-reviewed literature.

Baobab extracts have demonstrated anti-inflammatory activity in multiple in vitro studies and animal models. A rat study found that baobab fruit pulp reduced multiple markers of inflammation and protected the heart from damage; a mouse study showed decreased oxidative damage and reduced inflammation levels. In humans, a controlled trial examining baobab polyphenols found no adverse effects on intestinal barrier function while supporting antioxidant activity, but direct human anti-inflammatory outcome data remain limited.

Multiple clinical trials show barberry reduces CRP, an established marker of systemic inflammation. Both a metabolic syndrome RCT and a cardiovascular risk patient RCT demonstrated significant CRP reductions following barberry supplementation. Barberry's berberine and anthocyanin content together mediate anti-inflammatory effects via multiple molecular pathways.

A 2024 systematic review of 16 RCTs found that barley and oat consumption reduced inflammatory biomarkers in metabolically at-risk populations, though not in healthy subjects. Anti-inflammatory benefits appear most significant in individuals with overweight, obesity, or metabolic syndrome.

Icariin and Epimedium extracts suppress key pro-inflammatory pathways including NF-κB, TLR4/MD-2, NLRP3 inflammasome, and TNF-α in multiple in vitro and in vivo models. Anti-inflammatory activity is documented across tissues including kidney, bone, joint, and heart. These mechanisms underpin Barrenwort's broad therapeutic applications.

O. basilicum and its constituents demonstrate well-characterized anti-inflammatory activity in vitro and in animal models, acting via NF-κB inhibition, TNF-α and IL-1β suppression, and inhibition of cyclooxygenase and lipoxygenase pathways. A PMC review (2023) synthesized immunomodulatory and anti-inflammatory evidence. Human clinical evidence for chronic systemic inflammation specifically is limited.

Bayberry (particularly Myrica rubra) has been evaluated in a small human clinical trial (n=44 crossover RCT) in which bayberry juice reduced plasma markers of inflammation including TNF-α and IL-8 in young adults with NAFLD. In vitro and animal studies further document anti-inflammatory activity of myricitrin and other flavonoids via inhibition of NF-κB, nitric oxide synthase, and cyclooxygenase-2.

Bee pollen flavonoids and phenolic compounds inhibit key pro-inflammatory mediators including COX-2, NF-κB, and prostaglandin E2 in cell and animal models. Preliminary human data from menopausal and diabetic populations show reductions in inflammatory markers such as IL-6. Human clinical evidence remains limited but directionally positive.

Beetroot's betalain pigments (betanin, indicaxanthin) exert anti-inflammatory effects through NF-κB inhibition and COX-2 suppression. In vitro, animal, and some human data support reduction in inflammatory biomarkers. A small human RCT showed reduction in systemic inflammation markers after short-term beetroot juice supplementation.

In vitro and animal studies demonstrate that T. bellirica extracts suppress key pro-inflammatory mediators, including TNF-α, IL-1β, and reactive oxygen species. The fruit's polyphenols (gallic acid, ellagic acid, tannins) inhibit 15-lipoxygenase and macrophage inflammatory responses. This body of preclinical evidence is well-documented across multiple studies, though human RCT data specifically targeting chronic inflammation are sparse.

Perilla frutescens extract, the botanical source of Benegut, has demonstrated anti-inflammatory activity in activated human neutrophils via inhibition of Src family kinases and intracellular calcium mobilization pathways. Rosmarinic acid inhibits reactive nitrogen and oxygen species in LPS-activated macrophages. In vivo, the extract attenuates NF-κB and STAT3 signaling. A human RCT showed reduction of neutrophil and eosinophil infiltration in nasal lavage fluid.

Benfotiamine inhibits NF-κB activation and NADPH oxidase, reducing expression of pro-inflammatory cytokines and chemokines. In macrophage studies, it prevented LPS-induced activation of p38-MAPK, IκBα degradation, and NF-κB nuclear translocation. A clinical RCT in T2DM with cardiac autonomic neuropathy found benfotiamine reduced inflammatory markers including hs-CRP and TNF-α.

Berberine, an isoquinoline alkaloid with a long history in Traditional Chinese Medicine, has demonstrated anti-inflammatory activity in multiple randomized controlled trials and meta-analyses. It significantly reduces circulating levels of CRP, TNF-α, and IL-6 in human populations. Its primary mechanisms involve inhibition of the NF-κB signaling pathway and activation of AMPK, both of which suppress pro-inflammatory cytokine production.

Delta-tocopherol and mixed tocopherol preparations including beta and delta forms suppress key inflammatory pathways including COX-2 and TNF-alpha. Gamma- and delta-tocopherol have been shown to have stronger anti-inflammatory activities than alpha-tocopherol. Mixed tocopherol supplementation enriched with non-alpha forms reduces inflammatory markers more potently than alpha-tocopherol alone in human and animal studies.

Beta-carotene exerts anti-inflammatory effects via inhibition of NF-κB, AP-1, STAT3, and MAPK signaling pathways, reducing pro-inflammatory cytokines including TNF-α and IL-1β. Observational data link higher dietary carotenoid intake with lower circulating inflammatory markers. Lower plasma beta-carotene is consistently found in obese and inflammatory disease states.

Beta-glucan modulates innate immune activity through Dectin-1 and TLR receptors, promoting a balanced anti-inflammatory response and reducing NF-κB-driven pro-inflammatory cytokine production. Human and animal studies demonstrate reductions in CRP, IL-1β, IL-6, and TNF-α. The prebiotic fermentation of beta-glucan to short-chain fatty acids—especially butyrate—provides an additional gut-based anti-inflammatory mechanism.

Beta-sitosterol suppresses key pro-inflammatory pathways including NF-κB, NLRP3 inflammasome, and VCAM-1/ICAM-1 expression, as demonstrated in human aortic endothelial cell studies and multiple animal models. An in vitro study in TNF-α–stimulated human aortic endothelial cells showed that beta-sitosterol significantly inhibits VCAM-1 and ICAM-1 expression and attenuates NF-κB p65 phosphorylation. No dedicated human RCTs for chronic inflammatory disease endpoints have been published.

Betaine suppresses pro-inflammatory signaling, particularly the NF-κB pathway and NLRP3 inflammasome, and modulates sulfur amino acid metabolism to reduce oxidative stress. Accumulating preclinical evidence across obesity, NAFLD, and diabetes models consistently shows attenuation of TNF-α and IL-1β. Human RCT data from exercise studies (2.5–5 g/day) showed no significant change in IL-1β, IL-6, or TNF-α in young males over 21 days, suggesting inflammation effects may be disease- or context-dependent.

Betel leaf extracts exhibit anti-inflammatory activity demonstrated in multiple animal models, including carrageenan-induced paw edema and complete Freund adjuvant-induced arthritis models. Bioactive constituents modulate inflammatory mediators including cytokines and reactive oxygen species. In vitro studies show reduction of IL-33, VCAM, and TNF-α.

B. animalis subsp. lactis strains have demonstrated anti-inflammatory activity in preclinical models and some clinical contexts. B. lactis PB200 normalized levels of IL-1β, IL-6, TNF-α, and IL-10 in an antibiotic-induced intestinal injury mouse model. CNCM I-2494 modulated gut inflammation markers in a chronic low-grade inflammation model. The PMC review of BB-12 notes immune interactions including modulation of inflammatory pathways.

B. bifidum modulates both innate and adaptive immune responses to attenuate chronic inflammatory signaling. It promotes anti-inflammatory cytokine environments, including increased IL-10 and TGF-β expression in dendritic cells, and converts dietary vitamin A to retinoic acid to support immunological tolerance. Preclinical evidence is strong; human anti-inflammatory endpoints have been measured in IBS and metabolic disease trials.

B. breve exerts documented anti-inflammatory effects through modulation of cytokines, gut barrier integrity, and immune signaling. It promotes an anti-inflammatory milieu by inducing IL-10 and TGF-β while suppressing pro-inflammatory TNF-α, IL-6, and IL-1β. A clinical RCT showed B. breve B-3 reduced high-sensitivity C-reactive protein in adults with obese tendencies, and a postbiotic from B. breve BB091109 improved inflammatory status in healthy females in an RCT.

A randomized trial of B. lactis HN019 in metabolic syndrome patients demonstrated significant reductions in TNF-α and IL-6 compared to baseline and control. A meta-analysis of Bifidobacterium-containing probiotic RCTs found significant reductions in hs-CRP, TNF-α, and IL-6. B. lactis strains also restored gut barrier integrity in preclinical models, reducing inflammatory signaling.

B. longum has demonstrated anti-inflammatory effects in both clinical and preclinical settings, primarily through reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and modulation of intestinal barrier function. Clinical evidence is strongest in IBD-related inflammation, with animal and in vitro data supporting broader systemic inflammation reduction.

Bilberry anthocyanins modulate key inflammatory pathways including NF-κB, TNF-α, IL-6, and IL-1β in both preclinical and human studies. Clinical trials in metabolic disorders and UC patients show reductions in inflammatory markers with bilberry supplementation. A 2022 PMC review concluded bilberry may be useful in the prevention and treatment of chronic inflammatory disorders.

Birch bark-derived betulin and betulinic acid demonstrate anti-inflammatory activity via COX-2 inhibition and downregulation of pro-inflammatory cytokines (IL-6, IL-8) in vitro and in animal models. Betulin showed comparable efficacy to indomethacin in a TPA-induced mouse ear inflammation model. Birch leaf flavonoids (quercetin glycosides, hyperoside) also contribute anti-inflammatory activity. Human clinical evidence is indirect, coming primarily from wound-healing trials using Oleogel-S10.

A meta-analysis of 7 RCTs across conditions including metabolic syndrome, NAFLD, obesity, ulcerative colitis, and rheumatoid arthritis showed N. sativa (1–3 g/day) significantly reduced serum CRP. A 2025 meta-analysis of 82 RCTs confirmed significant reductions in multiple inflammatory biomarkers including IL-6, TNF-α, and hs-CRP.

Piperine, the primary alkaloid in black pepper, inhibits key pro-inflammatory mediators including COX-2, IL-6, and prostaglandin E2. Multiple human RCTs using curcumin-piperine combinations have documented significant reductions in CRP, hs-CRP, and IL-6 in metabolic syndrome and other inflammatory conditions. A 2026 systematic review of 20 RCTs found 15 showed significant decreases in inflammatory biomarkers.

In vitro studies using polyphenol-rich extracts of Picea mariana bark have demonstrated anti-inflammatory activity via NF-κB pathway suppression and inhibition of pro-inflammatory cytokines such as IL-8. The bark extract contains trans-resveratrol, taxifolin, and stilbene phytoalexins known for anti-inflammatory properties. These findings are preclinical; no human clinical trials have been conducted.

Clinical trials indicate that black tea consumption reduces inflammatory biomarkers including C-reactive protein (CRP). The theaflavins and thearubigins in black tea inhibit pro-inflammatory signaling pathways such as NF-κB. These anti-inflammatory actions underpin many of black tea's other health benefits.

A PMC-published study (PMC6761373) demonstrated that black walnut kernel extracts suppress production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) in LPS-stimulated human U-937 promonocytic cells in a dose-dependent manner. The anti-inflammatory effect is attributed to polyphenols including quercetin and ellagitannins shared with English walnut.

Blackberry polyphenols, especially anthocyanins and ellagic acid, suppress key pro-inflammatory pathways including NF-κB, NLRP3 inflammasome activation, and production of TNF-α, IL-6, and IL-1β, shown in cell and animal studies. Meta-analyses of RCTs with anthocyanin-rich berry interventions in humans document significant reductions in circulating C-reactive protein and TNF-α. Blackberry-specific cell studies using macrophage models (RAW 264.7 and THP-1) confirm modulation of antioxidant and inflammatory gene expression.

Preclinical studies demonstrate that A. scholaris alkaloids (picrinine, vallesamine, scholaricine) inhibit inflammatory mediators including COX-1, COX-2, and 5-LOX in both in vitro and in vivo rodent models. A PMC-indexed rat study confirmed reduction in neuropathic pain-associated inflammatory markers including TNF-α and myeloperoxidase. The mechanism involves peripheral inhibition of prostaglandin synthesis.

Fucoidan from Fucus vesiculosus inhibits NF-κB and selectin-mediated cell adhesion and reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in cell models and animal studies. A published PMC in vitro study confirmed anti-inflammatory activity of F. vesiculosus fucoidan across multiple human cell lines. Human RCT data remain limited.

Clinical and preclinical evidence shows blueberry polyphenols suppress inflammatory cytokines including TNF-α, IL-6, and CRP, primarily via NF-κB pathway inhibition. Human RCT data in metabolic syndrome subjects support reductions in circulating inflammatory markers with blueberry intake.

In vitro studies document meaningful anti-inflammatory activity in E. perfoliatum extracts. A 2011 study (Maas, Deters & Hensel, J Ethnopharmacology) showed that dichloromethane and ethanolic extracts significantly inhibited NO/iNOS production in LPS-stimulated macrophages and downregulated pro-inflammatory cytokines including IL-1α, IL-1β, CSF-3, and chemokines CCL2 and CXCL10. The flavonoid eupafolin and sesquiterpene lactones have been identified as key mediators. No human clinical trials for chronic inflammatory conditions have been conducted.

Borage seed oil is the richest plant source of gamma-linolenic acid (GLA), which is converted in the body to dihomo-gamma-linolenic acid (DGLA). DGLA competitively inhibits the synthesis of pro-inflammatory arachidonic acid-derived eicosanoids, reducing production of inflammatory mediators including IL-1β, TNF-α, PGE2, and leukotriene B4. Human studies confirm measurable suppression of these mediators following borage oil supplementation.

Borage oil's GLA raises DGLA in immune cell membranes, reducing leukotriene B4 and thromboxane production and suppressing pro-inflammatory cytokines IL-1β and TNF-α. These mechanisms are supported by controlled clinical and mechanistic studies in humans. Borage oil is recognized as having therapeutic potential against multiple chronic inflammatory diseases.

Multiple small RCTs show boron supplementation reduces circulating inflammatory biomarkers including hs-CRP and TNF-α. A 60-person study found reductions in CRP and fibrinogen after 1.5–6 mg/day for two weeks. Evidence is promising but limited by small sample sizes and short durations.

Boswellia (Boswellia serrata) has well-documented clinical evidence for addressing chronic inflammation. Its active constituents—particularly 3-acetyl-11-keto-β-boswellic acid (AKBA)—inhibit key pro-inflammatory enzymes and cytokines. Multiple randomized, double-blind, placebo-controlled trials have demonstrated significant reductions in inflammatory biomarkers and symptom improvement across several chronic inflammatory conditions. Evidence strength is moderate overall, as most trials are small and of variable quality.

Boswellic acids (BAs), pentacyclic triterpenoids from Boswellia serrata resin, have well-documented anti-inflammatory mechanisms and a substantial body of human clinical evidence. Their primary bioactive compound, AKBA (3-O-acetyl-11-keto-β-boswellic acid), potently inhibits 5-lipoxygenase (5-LOX), suppressing leukotriene synthesis, and also downregulates NF-κB signaling and pro-inflammatory cytokines. Multiple randomized, placebo-controlled trials and a meta-analysis confirm clinically meaningful reductions in pain and inflammatory markers across conditions including osteoarthritis, inflammatory bowel disease, rheumatoid arthritis, and asthma.

LBPs demonstrate anti-inflammatory properties by inhibiting NF-κB, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and modulating macrophage polarization in multiple animal models and human trials. In T2DM patients, 300 mg/day LBP significantly reduced serum TNF-α. Animal heart failure models show significant MDA and cytokine reduction after 12 weeks of LBP treatment.

Sulforaphane from broccoli activates Nrf2 and inhibits NF-κB, two central regulators of inflammatory signaling. Clinical trials in T2D patients show significant reductions in CRP and other inflammatory markers after broccoli sprout supplementation. A pilot study in HIV patients also demonstrated reduced CRP.

Bromelain, a cysteine protease complex from pineapple stem, has documented anti-inflammatory activity supported by multiple human clinical trials and systematic reviews. Its primary mechanisms include inhibition of NF-κB and COX-2 signaling and downregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and PGE-2. A 2023 PROSPERO-registered systematic review of seven RCTs found that bromelain supplementation reduced inflammatory markers in most studies, though effect consistency is limited by population heterogeneity and varying doses and durations.

Broomrape species (O. crenata, O. foetida) have been studied in rodent and in vitro models for anti-inflammatory activity. O. foetida aqueous extract downregulated TNF-α, IL-6, and NF-κB gene expression in a CCl4-induced liver injury rat model. The PPGs (acteoside, echinacoside) are considered the primary anti-inflammatory agents. Evidence is preclinical only.

A 2014 RCT (n=40 women) found brown rice intake significantly reduced CRP, a key marker of systemic inflammation. A PMC-published 2019 human crossover trial with pigmented rice (including brown rice) reported reductions in specific inflammatory and oxidative stress pathways. Brown rice protein's antioxidant peptides and polyphenols (e.g., ferulic acid, γ-oryzanol) are proposed mechanisms.

Brussels sprouts contain isothiocyanates and kaempferol that inhibit the NF-κB inflammatory signaling pathway. Epidemiological and mechanistic data link higher cruciferous vegetable intake to reduced inflammatory markers. The glucosinolate-derived metabolites (isothiocyanates, indoles) have documented anti-inflammatory activity at the transcriptional level.

In vitro and animal studies demonstrate buchu extracts inhibit key inflammatory mediators including COX-1, COX-2, 5-lipoxygenase, IL-6, and TNF-α. Constituent flavonoids quercetin and diosmin are well-characterized anti-inflammatory agents. No human trials specifically targeting chronic inflammation have been conducted with buchu.

Saikosaponins A and D from B. falcatum roots are the most studied anti-inflammatory constituents, shown in multiple preclinical models to suppress NF-κB and MAPK signaling, reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and inhibit COX-2 and iNOS. B. falcatum polysaccharides add further anti-inflammatory activity via TLR4 inhibition. Evidence is primarily preclinical; direct human RCTs are lacking.

A human RCT (Maghsoumi-Norouzabad et al., Int J Rheum Dis, 2016) in 36 knee osteoarthritis patients showed that daily burdock root tea for six weeks significantly reduced serum IL-6 (p=0.002), hs-CRP (p=0.003), and malondialdehyde, while raising total antioxidant capacity and SOD activity. These results provide direct clinical evidence of burdock's systemic anti-inflammatory effect. Mechanistically, arctigenin and arctiin inhibit key cytokines and COX-2.

Ruscogenin, the primary steroidal saponin in butcher's broom, has demonstrated anti-inflammatory effects in animal models and in vitro studies. It is proposed to suppress leukocyte migration via protein and mRNA regulation and to reduce vascular permeability. No dedicated human clinical trials specifically targeting inflammation have been conducted, but anti-inflammatory activity underlies its established clinical effects in CVI and edema.

Butterbur's sesquiterpene constituents (petasin, isopetasin, neopetasin) inhibit COX-1, COX-2, 5-lipoxygenase, and phospholipase A2, suppressing prostaglandin and leukotriene synthesis. These mechanisms are well-documented in peer-reviewed pharmacological and clinical literature, underpinning its effectiveness across multiple inflammatory conditions including migraine, allergic rhinitis, and asthma.

Tributyrin and its released butyrate suppress inflammatory cytokine production through HDAC inhibition and free-fatty-acid receptor (FFAR) activation. A 2024 study using human visceral adipose tissue showed tributyrin significantly reduced LPS-induced inflammatory cytokines and chemokines. Animal models further confirm tributyrin attenuates adipose tissue inflammation via GPR109A signaling. Human clinical evidence remains largely indirect, via butyrate class as a whole.

Butyrate exerts anti-inflammatory effects by inhibiting histone deacetylases (HDACs), activating GPR109A receptors, and reducing pro-inflammatory cytokines including TNF-α and IL-6. Clinical trials in IBD and related conditions provide human-level evidence for these effects.

Cabbage contains sulforaphane, kaempferol, and anthocyanins—compounds with documented anti-inflammatory activity in both laboratory and human studies. Cruciferous vegetable intake has been associated with lower inflammatory biomarker levels in humans. Sulforaphane activates the Nrf2/Keap1 pathway, suppressing NF-κB-driven inflammatory signaling.

Cabbage leaves contain glucosinolates that are hydrolyzed by myrosinase to isothiocyanates (including sulforaphane), which are well-characterized inhibitors of NF-κB and activators of the Nrf2 antioxidant pathway. A 2024 rodent study (MDPI, Molecules) confirmed anti-inflammatory and analgesic effects of cabbage polyphenol extract. A 2021 Frontiers in Pharmacology systematic review found evidence linking high glucosinolate diets with reduced chronic disease incidence. Human evidence is mostly indirect, as part of cruciferous vegetable intake studies.

C. crista extracts have demonstrated anti-inflammatory activity in multiple preclinical models. Seed extract showed up to 74.2% inhibition of carrageenan-induced paw edema in mice at 300 mg/kg. Leaf extract significantly inhibited 5-lipoxygenase enzyme activity, a key inflammatory mediator.

In vivo animal research published in 2026 (Applied Biosciences) found that M. cajuputi ethanolic leaf extract modulated IL-6, IL-6R, and IL-10 expression in LPS-induced lung inflammation in mice, pointing to anti-inflammatory cytokine-modulating activity. Laboratory studies also confirm the essential oil contains anti-inflammatory terpenes. Human clinical evidence is absent.

DHA and EPA from calamari oil exert well-documented anti-inflammatory effects by competitively inhibiting pro-inflammatory arachidonic acid pathways and generating anti-inflammatory resolvins and protectins. Clinical studies confirm reductions in inflammatory biomarkers including CRP, IL-6, and TNF-α with marine omega-3 supplementation.

Calendula's anti-inflammatory activity is among its most studied properties. Multiple in vitro and animal studies demonstrate inhibition of NF-κB, pro-inflammatory cytokines (TNF-α, IL-6), and NO production. EMA and ESCOP recognise its anti-inflammatory use; human evidence is primarily from wound healing and gingivitis trials.

Campesterol has demonstrated anti-inflammatory activity in multiple preclinical models, reducing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In vitro and in vivo animal studies document downregulation of inflammatory mediators. Evidence for campesterol specifically in human chronic inflammation is currently limited to preclinical data, though the phytosterol class broadly shows anti-inflammatory properties.

Multiple in vitro and animal studies demonstrate that Cinnamomum camphora and its constituents block pro-inflammatory signaling pathways. A 2019 study showed that C. camphora leaf extract reduced immunoglobulin E levels, lymph node inflammation, and chemokine production in atopic dermatitis models. A PMC review (2025) confirmed anti-inflammatory activity as one of camphor's core pharmacological properties.

In the key 2008 human RCT, camu camu juice significantly reduced inflammatory markers including C-reactive protein (CRP), IL-6, and IL-8 in male smokers, while equivalent-dose vitamin C tablets produced no effect. In vitro cell studies also show camu camu extract downregulates NF-κB/AP-1 and MAPK signaling pathways, reducing pro-inflammatory cytokine expression. Animal and ACS Omega review data further support anti-inflammatory activity via polyphenol-driven mechanisms.

Capsaicinoids inhibit NF-κB signaling and reduce pro-inflammatory cytokines including IL-6 and TNF-α in cell and animal models; anti-inflammatory effects are also documented in human contexts. TRPV1-mediated desensitization reduces neurogenic inflammation. Oral and topical routes have both shown relevant anti-inflammatory activity.

Capsanthin suppresses multiple pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, MCP-1) and inhibits NF-κB signaling in cell and animal models. These effects underlie its protective actions documented across obesity, vascular, liver, and ocular inflammation studies.

Capsaicin suppresses key pro-inflammatory transcription factors including NF-κB and COX-2, and activates antioxidant pathways (Nrf2/PPAR-γ), demonstrating anti-inflammatory properties in human cell and animal studies. Topical human evidence is demonstrated through reduced inflammatory mediators (IL-6, prostaglandin E2) in rheumatoid arthritis patients treated with capsaicin cream.

Clinical trial data and meta-analyses confirm that cardamom supplementation significantly lowers circulating inflammatory markers including hs-CRP, IL-6, and TNF-α. A 2024 meta-analysis (8 RCTs) found standardized mean differences reflecting meaningful reductions in all three markers. The mechanism involves NF-κB pathway inhibition, COX-2 suppression, and free radical scavenging.

Beta-carotene reduces oxidative stress and modulates inflammatory cytokine production. Serum carotenoid concentrations show clinically significant inverse associations with pro-inflammatory markers including IL-6 and sTNFR-II in observational studies. Antioxidant activity in lipophilic cellular compartments underpins the anti-inflammatory mechanism.

Carrots contain multiple anti-inflammatory bioactives—falcarinol, falcarindiol, beta-carotene, and phenolics—that inhibit COX-1/2, NF-κB signaling, and pro-inflammatory cytokines in cell-based and human ex vivo models. Beta-carotene blocks NF-κB activation. Human ex vivo studies demonstrate immune modulation after carrot juice intake.

BCP is one of the best-characterized natural CB2 receptor agonists with robust preclinical evidence for suppressing chronic inflammation. It reduces TNF-α, IL-1β, IL-6, and NF-κB across multiple disease models. The anti-inflammatory mechanism is confirmed by CB2 antagonist reversal experiments.

Constituents of cassia bark, particularly cinnamaldehyde, suppress key pro-inflammatory mediators including NF-κB, COX-2, iNOS, TNF-α, and PGE2 in validated cell and animal models. Clinical research in diabetes populations has also noted reductions in CRP, a systemic inflammation marker. This positions cassia bark as scientifically credible for anti-inflammatory applications.

Cat's Claw (Uncaria tomentosa) has documented anti-inflammatory activity supported by both in vitro/in vivo mechanistic research and small human clinical trials. Its primary mechanism involves suppression of the NF-κB signaling pathway, reducing pro-inflammatory cytokine production. Small controlled trials in rheumatoid arthritis and osteoarthritis patients have shown modest reductions in joint pain and swelling, though evidence remains limited by small sample sizes and inconsistent results. The NIH/NCCIH characterizes existing human evidence as insufficient to draw definitive conclusions.

Catalase is implicated in chronic inflammation through its role in controlling H₂O₂ levels, a key ROS involved in modulating inflammatory signaling pathways including NF-κB. Reduced catalase activity is observed in multiple chronic inflammatory diseases. ROS accumulation due to low catalase activity promotes lipid peroxidation, protein aggregation, and sustained inflammatory cascades.

Catechins—particularly EGCG—are well-established modulators of inflammatory signaling, suppressing NF-κB and NLRP3 inflammasome pathways, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and upregulating Nrf2-mediated antioxidant responses. Clinical trials confirm anti-inflammatory and antioxidant effects in humans.

Cowpea polyphenolic extracts have been shown to suppress LPS-induced inflammation in colonic cells and reduce inflammatory markers including ROS in vitro. A 2025 human-associated trial found biofortified cowpeas reduced inflammatory marker activation in macrophage cells. The anti-inflammatory activity is linked to phenolic and flavonoid constituents.

Sulforaphane and indole-3-carbinol (I3C) from cauliflower inhibit NF-κB, a master regulator of inflammatory cytokine expression. This dual Nrf2 activation and NF-κB suppression creates a documented anti-inflammatory profile. Preclinical and human data support reductions in CRP and inflammatory cytokines.

Capsaicin inhibits pro-inflammatory mediators including IL-1β, IL-6, and TNF-α in vitro and exerts anti-inflammatory effects through TRPV1-mediated pathways. Human evidence is primarily mechanistic and observational; robust RCT data specifically measuring systemic inflammatory biomarkers like CRP in response to oral cayenne are limited.

Celery contains apigenin, luteolin, and kaempferol, which inhibit NF-κB signaling, suppress pro-inflammatory cytokines (TNF-α, IL-1β), and reduce COX-2 expression in cell and animal studies. Human clinical data on inflammation biomarkers are indirect, derived mainly from trials measuring blood pressure and metabolic outcomes.

Aqueous and ethanolic extracts of A. aspera exhibit significant anti-inflammatory activity in carrageenan-induced edema models and albumin denaturation inhibition assays. Active compounds such as flavonoids and saponins are implicated. Evidence remains preclinical.

Chamomile contains apigenin, chamazulene, and α-bisabolol, which inhibit COX-2 and iNOS via NF-κB and MAPK pathways, reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. A 2025 systematic review and meta-analysis of 11 RCTs confirmed chamomile's anti-inflammatory efficacy in clinical settings. Germany's Commission E has approved chamomile for inflammation, underscoring its well-established status as an anti-inflammatory agent.

A. bisporus powder has been shown to attenuate NF-κB activation and pro-inflammatory cytokine production in both mouse and human macrophages. In vivo, oral delivery reduced colitis severity in a mouse model. Ergothioneine and polyphenols from A. bisporus provide additional anti-inflammatory mechanisms. These findings are at the cellular and animal level; large human RCTs for inflammatory conditions are lacking.

Multiple in vitro and in vivo studies have characterised Chen Pi's flavonoids—nobiletin, tangeretin, and hesperidin—as potent inhibitors of NF-κB signalling, COX-2, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). A 2025 Frontiers study confirmed the essential oil of CRP exhibited the most potent anti-inflammatory activity among six Citrus species tested.

Tart cherry's anthocyanins inhibit COX-1/2 enzymes and suppress NF-κB signaling, reducing pro-inflammatory cytokines. Multiple RCTs document reductions in circulating CRP. A 2023 meta-analysis of 21 RCTs confirmed moderate-certainty evidence for CRP reduction with a dose-response relationship, though effect sizes remain modest.

Chia seeds contain ALA omega-3 fatty acids, polyphenols (quercetin, caffeic acid, chlorogenic acid), and fiber that exert anti-inflammatory effects. A 2024 systematic review and meta-analysis of 4 RCTs found chia significantly reduced CRP. A University of Toronto RCT also reported a 40% reduction in CRP with 30 g/day chia over 6 months.

Chickpea consumption is associated with reductions in inflammatory markers including high-sensitivity CRP. A 12-week RCT found hsCRP decreased from 5 mg/L to 3.5 mg/L at week 6 in the chickpea group. Chickpea protein hydrolysates exhibit anti-inflammatory properties in preclinical models by modulating inflammatory gene expression in liver and adipose tissue.

Preclinical studies have demonstrated that S. media extracts possess anti-inflammatory activity, reducing ROS, IL-6, and COX-2 expression in cell and animal models. One small study also explored this in a clinical arthritis population. Evidence is primarily in vitro and animal-based with limited human data.

Chicory contains sesquiterpene lactones, chlorogenic acid, and inulin, all of which demonstrate anti-inflammatory activity. A systematic review found all 12 evaluating studies showed chicory significantly reduces oxidative stress and inflammation. Sesquiterpene lactones from chicory modulate NFAT-pathway inflammatory signaling in cell models.

Both tanshinones and salvianolic acids in Danshen suppress key pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and COX-2. This has been demonstrated in multiple in vitro and in vivo models, with supporting clinical data from cardiovascular and liver disease trials. The anti-inflammatory mechanism involves NF-κB and TLR4 signaling pathway inhibition.

Human clinical evidence supports Chlorella's ability to reduce markers of chronic inflammation. Multiple randomized controlled trials and a GRADE-assessed meta-analysis of 25 studies found significant reductions in hs-CRP following Chlorella supplementation. Proposed mechanisms include inhibition of pro-inflammatory cytokines (TNF-α, IL-6) and suppression of the NF-κB signaling pathway, mediated by bioactive constituents such as violaxanthin, chlorophyll-protein complexes, and omega-3 fatty acids. Evidence is present but rated low-to-moderate quality, indicating further large-scale trials are warranted.

Chlorophyllin demonstrates anti-inflammatory activity in multiple preclinical models via suppression of NF-κB signaling and reduction of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. Animal studies show it ameliorates high-fat diet-induced intestinal inflammation and liver fibrosis. Human clinical evidence for this mechanism is indirect (anti-inflammatory effects observed in wound healing and skin trials), but the molecular basis is well-characterized.

Chlorophyllin has demonstrated anti-inflammatory activity in preclinical models through inhibition of NF-κB activation and downregulation of pro-inflammatory cytokines including TNF-α. Animal studies have shown reductions in carrageenan-induced paw edema. Mechanistic cell studies confirm suppression of IKK phosphorylation, inhibiting the NF-κB pathway. Human evidence for systemic chronic inflammation specifically is limited, though IBD and gut studies provide indirect clinical support.

Multiple human RCTs show chokeberry supplementation reduces key inflammatory biomarkers including CRP, TNF-α, and IL-6. A 2024 systematic review of 18 RCTs found consistent reductions in pro-inflammatory cytokines and elevation of anti-inflammatory IL-10. Anti-inflammatory activity is linked to anthocyanin-mediated NF-κB inhibition and iron chelation.

Chondroitin sulfate (CS) has documented anti-inflammatory activity supported by mechanistic, in vitro, and human clinical evidence. Its primary mechanism involves suppression of NF-κB signaling, which reduces downstream pro-inflammatory mediators including IL-1β, COX-2, and PGE2. A randomized, double-blind, placebo-controlled human trial found that chondroitin combined with glucosamine lowered serum CRP by 23% and significantly reduced cytokine activity pathways. Evidence is strongest in the context of chronic low-grade inflammation associated with osteoarthritis, though the biological mechanism is not fully resolved.

Chrysanthemum extracts demonstrate well-characterized anti-inflammatory activity in vitro and in animal models. Key flavonoids suppress NF-κB signaling and inhibit pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and COX-2. A 2025 Frontiers in Pharmacology review systematically catalogued these effects across 29 studies.

Chrysin is a well-characterized anti-inflammatory compound in preclinical models, inhibiting NF-κB signaling, suppressing COX-2 and iNOS expression, and reducing pro-inflammatory cytokines including TNF-α, IL-6, IL-17A, and IL-22. It has demonstrated efficacy in models of psoriasis, atopic dermatitis, osteoarthritis, and systemic inflammation. No human clinical trials have been conducted.

Chymotrypsin exerts documented anti-inflammatory effects by degrading damaged cells, necrotic material, and inflammatory mediators. Multiple clinical trials demonstrate its combination with trypsin reduces edema, erythema, and inflammatory biomarkers. Animal studies show chymotrypsin reduces inflammation more effectively than aspirin.

Multiple RCTs and meta-analyses document that cinnamon supplementation reduces CRP, TNF-α, and IL-6 in populations with metabolic disorders. A 2024 umbrella meta-analysis of RCTs found significant reductions in SBP, DBP, and IL-6 with cinnamon. A 2025 GRADE-assessed meta-analysis of 49 RCTs confirmed significant CRP reduction.

CQ extracts inhibit COX-1, COX-2, and 5-lipoxygenase enzymes in preclinical models, and suppress NF-κB activation—mechanisms consistent with anti-inflammatory activity. Human trials have shown significant reductions in C-reactive protein (CRP), a validated inflammatory biomarker, in overweight participants. Animal models confirm attenuation of edema and pro-inflammatory cytokines.

Citicoline has demonstrated anti-inflammatory mechanisms in experimental and clinical neuroinflammatory settings, including NF-κB inhibition, reduction of TNF-α, IL-1β, and IL-6, and modulation of microglial activation. These mechanisms have been documented in pre-clinical models and human neurological studies, though dedicated human RCTs targeting chronic systemic inflammation as a primary endpoint have not been conducted.

Modified citrus pectin inhibits galectin-3, a central pro-inflammatory and pro-fibrotic mediator implicated in chronic inflammatory diseases. Human studies show MCP normalizes inflammatory cytokine ratios (IL-10/IL-12) in IBS-D. A pilot RCT with low-methoxy citrus pectin in healthy volunteers found reduced circulating TNF-alpha and other inflammatory markers.

C. sinensis polyphenols and hesperidin have been shown to downregulate pro-inflammatory cytokines (TNF-α, IL-6, hs-CRP) and inhibit COX-2 and iNOS in vitro and in human studies. A meta-analysis of RCTs confirmed hesperidin reduces C-reactive protein in humans. Limonene-rich essential oil also inhibits PGE2 and NO production.

CLA has documented anti-inflammatory properties in vitro and in animal models, primarily through modulation of NF-κB, COX-2, and pro-inflammatory cytokines. Human RCT evidence is controversial: a meta-analysis found CLA may increase CRP and TNF-α, while another found it decreases IL-6 and leptin. Effects depend on isomer, dose, and population.

Multiple Clematis species have been investigated in animal and in vitro models for anti-inflammatory activity. Key active compounds include triterpenoid saponins and the C-glycosylflavone vitalboside (from C. vitalba). The Clematis-containing multi-herb extract SKI306X has been tested in human clinical trials, demonstrating suppression of pro-inflammatory mediators such as TNF-α, IL-1β, COX-2, and PGE2.

Methanolic extract of C. indicum has been evaluated in rodent carrageenan-induced inflammation models, demonstrating significant anti-inflammatory activity. The genus review (Wang et al., 2018) catalogues C. indicum among Clerodendrum species with documented anti-inflammatory properties. Phytochemicals including flavonoids and triterpenoids are likely mediators. Evidence is preclinical only.

Eugenol from clove is well-characterized as an anti-inflammatory agent, inhibiting NF-κB, COX-2, and multiple pro-inflammatory cytokines in multiple in vitro and animal studies. Several preclinical models confirm significant reduction of TNF-α, IL-6, and IL-1β.

Clinical studies show cocoa reduces key inflammatory biomarkers including hs-CRP, TNF-α, and IL-6. The COSMOS trial found cocoa extract supplementation reduced hs-CRP by 8.4% annually versus placebo. Cocoa polyphenols modulate inflammatory signaling partly through COX-2 inhibition.

In vitro studies show VCO suppresses key pro-inflammatory cytokines including TNF-α, IL-6, IL-5, and IL-8 in human monocytes and keratinocytes. RCT data on inflammatory biomarkers such as CRP are inconsistent, with most meta-analyses showing no significant reduction in CRP vs. comparator oils.

Virgin coconut oil (derived from coconut milk) contains polyphenols and MCFAs that inhibit pro-inflammatory cytokines (TNF-α, IL-6, IL-8) in vitro and reduce inflammation markers in animal models. A pharmacology study found VCO at 80 mg/kg showed 74% inhibitory effect on chronic inflammation in rodents. Human evidence remains largely indirect via CRP reductions observed in coconut oil trials.

Virgin coconut oil (VCO) contains polyphenols and lauric acid with demonstrated anti-inflammatory properties in vitro and in animal models. A 2021 clinical study found VCO significantly lowered C-reactive protein (CRP) in COVID-19 suspect/probable cases. However, a 2022 systematic review and meta-analysis of RCTs found coconut oil did not significantly improve inflammatory markers (CRP) compared to nontropical vegetable oils in generally healthy populations.

Cod liver oil reduces systemic markers of inflammation, particularly CRP. A prospective observational study of over 1,000 athletes found CLO users had 34% lower CRP responses compared to non-users. EPA and DHA inhibit pro-inflammatory cytokine production via the COX-2 and leukotriene pathways.

Coffee fruit extract contains chlorogenic acid, epicatechin, and catechin that suppress pro-inflammatory cytokines including TNF-α, IL-6, IL-1β, COX-2, and iNOS. In vitro evidence from macrophage cell models is robust. A 10-week human RCT in type 2 diabetic patients showed green coffee extract (which shares the same key CGA constituents) significantly reduced hs-CRP compared to placebo.

Coixol—the primary phenolic compound in coix seed—has been shown in cell models to suppress NF-κB, MAPK, and NLRP3 inflammasome pathways, reducing key cytokines such as IL-1β, IL-6, and TNF-α. Coix seed polysaccharides also demonstrate anti-inflammatory activity in vivo and in vitro.

Forskolin exerts anti-inflammatory effects by elevating cAMP, which suppresses NF-κB signaling, inhibits macrophage activation, and reduces thromboxane B2 and superoxide production. These mechanisms are well characterized in vitro and in animal models, and are the pharmacological basis for several of its clinical applications.

Collagen peptides have demonstrated anti-inflammatory activity by inhibiting secretion of pro-inflammatory cytokines (IL-6, TNF-α, NF-κB pathway) in cell and animal models, and immunomodulatory effects have been observed in clinical contexts including osteoarthritis and a COVID-19 RCT. Evidence is strongest at the preclinical level but is supported by clinical inference from OA and joint trials. The detailed mechanism of collagen-induced immunomodulation in humans remains elusive.

Collard greens contain glucosinolates that break down into isothiocyanates (e.g., sulforaphane), which activate Nrf2 and inhibit NF-κB — two key regulators of the inflammatory response. A 2021 Frontiers in Pharmacology systematic review confirmed anti-inflammatory effects of cruciferous glucosinolates in both preclinical and clinical studies. Collards also provide vitamin C, beta-carotene, and other antioxidants that reduce oxidative stress-driven inflammation.

Bovine colostrum contains multiple anti-inflammatory bioactives including immunoglobulins, lactoferrin, TGF-β, and proline-rich polypeptides (PRPs) that modulate inflammatory cytokine cascades. Human clinical data show reductions in CRP and IL-6 following supplementation in athletes and clinical populations. The anti-inflammatory effects appear mediated through mucosal immunoglobulins and cytokine regulation.

Coltsfoot contains tussilagone and tussilagonone, sesquiterpenoids with documented anti-inflammatory activity in vitro and in vivo. These compounds inhibit NF-κB signaling, suppress pro-inflammatory cytokines (TNF-α, IL-6), and activate the Nrf2/HO-1 pathway. No clinical trials in humans have been conducted to confirm therapeutic benefit for chronic inflammation.

Comfrey root extract contains rosmarinic acid and allantoin, both of which have documented anti-inflammatory activity mediated through inhibition of NF-κB and MAPK signalling pathways. Clinical trials in osteoarthritis and back pain consistently demonstrate reductions in local pain and swelling markers with topical comfrey. The key bioactive constituents exert anti-inflammatory, tissue-regenerative, and bone-repair effects at a cellular level.

Multiple phytochemical and in vivo studies confirm anti-inflammatory activity for both C. myrrh and C. mukul. Guggulsterones inhibit NF-κB and suppress pro-inflammatory cytokines. Clinical evidence includes the nodulocystic acne trial, the UC remission trial, and the osteoarthritis study, all reflecting systemic anti-inflammatory effects.

Copper modulates inflammatory signaling: deficiency elevates pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and activates NF-κB in immune organs. Copper metabolism shifts during inflammation, with serum copper rising as an acute-phase response. Both excess and deficiency of copper can promote dysfunctional inflammatory states.

Berberine from Coptis chinensis inhibits NF-κB, JAK/STAT, and MAPK inflammatory signaling pathways in multiple cell and animal models. TCM has used the herb for inflammatory diseases for over 2,000 years. Human evidence from clinical trials in colitis and metabolic conditions confirm measurable reductions in inflammatory biomarkers such as CRP, TNF-α, and IL-6.

Multiple randomized controlled trials and meta-analyses provide clinical evidence that CoQ10 supplementation significantly reduces key markers of chronic inflammation, including CRP, TNF-α, and IL-6. The primary mechanism involves CoQ10's inhibition of NF-κB-mediated pro-inflammatory gene expression, coupled with its antioxidant activity in the mitochondrial electron transport chain. Results are broadly positive but some heterogeneity exists across trials, and larger studies are still warranted.

Cordyceps extracts and cordycepin suppress pro-inflammatory mediators including NF-κB, TNF-α, IL-1β, IL-6, COX-2, and PGE2 in cell and animal models. Cordycepin inhibits the NLRP3 inflammasome and has shown activity in human OA chondrocytes. A human RCT in asthmatic patients found Cordyceps lowered IgE and IL-4 significantly versus placebo. Most mechanistic evidence is preclinical; robust large-scale human trials are still limited.

Corn silk extracts have demonstrated anti-inflammatory activity in preclinical models, including reduction of inflammatory cytokines and mediators. A preclinical study documented significant anti-inflammatory effects in carrageenan-induced pleurisy rats. Corn silk's flavonoids, polysaccharides, and phenolic acids are the proposed active anti-inflammatory constituents.

Preclinical studies show corn silk extract inhibits key pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and signaling pathways (NF-κB, MAPK, COX-2, iNOS). An in vitro PubMed study confirmed TNF antagonistic and ICAM-1 inhibitory activity in endothelial cells. Animal models of carrageenan-induced pleurisy demonstrated measurable reduction in inflammatory mediators with corn silk pretreatment.

Despite CSO's high n-6 PUFA content — a class theoretically pro-inflammatory — clinical trials have not shown CSO to increase inflammatory markers in humans. A 5-day RCT found CSO reduced TNF-α and tissue factor vs. olive oil. A 4-week RCT (2025) found no increase in inflammatory markers with CSO diet enrichment. An 8-week RCT in hypercholesterolemic adults found no significant differences in inflammatory or coagulation markers between CSO and olive oil groups.

Cranberry polyphenols have demonstrated anti-inflammatory activity in multiple human clinical trials, primarily by reducing C-reactive protein (CRP), lipid peroxidation products, and NF-κB activation. Effects on pro-inflammatory cytokines (IL-1, IL-6, TNF-α) are less consistent. Evidence is strongest in individuals with elevated baseline inflammatory status such as metabolic syndrome.

β-Cryptoxanthin demonstrates anti-inflammatory activity by downregulating NF-κB, TNF-α, IL-6, and IL-8 signaling pathways. Epidemiological studies associate higher BCX intake with reduced inflammatory disease risk. Animal studies show BCX reduces macrophage M1 polarization and attenuates high-fat-diet-induced inflammatory markers.

Cucumber contains idoBR1, an iminosugar amino acid identified as an active anti-inflammatory principle that reduces TNF-α in human monocytes and ex vivo human blood. Standardised cucumber extract (Q-actin) containing idoBR1 has been tested in small human studies, including a clinical trial in older adults. The compound also inhibits sialidases involved in inflammatory signalling.

Cumin essential oil RCTs have demonstrated significant reductions in inflammatory biomarkers TNF-α and hsCRP in diabetic patients, with a corresponding increase in adiponectin. Laboratory studies show cumin oil inhibits NF-κB pathway and mitogen-activated protein kinases. Human evidence is limited to a small number of trials.

Curcumin, the principal polyphenol of turmeric (Curcuma longa), has robust clinical and mechanistic evidence supporting its role in reducing chronic inflammation. Multiple meta-analyses of randomized controlled trials demonstrate significant reductions in key inflammatory biomarkers—CRP, IL-6, and TNF-α—following curcumin supplementation. Its core mechanism involves inhibition of the NF-κB signaling pathway and downstream pro-inflammatory cytokine cascades. A key limitation across studies is curcumin's inherently poor bioavailability, which has prompted the development of enhanced formulations (e.g., piperine co-administration, nanoparticles, phospholipid complexes).

Blackcurrant anthocyanins and gamma-linolenic acid (GLA) from seed oil have demonstrated anti-inflammatory effects in human and animal studies. A randomized pilot RCT found reduced inflammatory biomarkers after 6 weeks of daily blackcurrant extract. Meta-analysis data on anthocyanin-rich berries show significant reductions in TNF-α and CRP.

Alpha-tocopherol has documented anti-inflammatory activity through inhibition of protein kinase C, suppression of arachidonic acid metabolism, and reduction of pro-inflammatory cytokines. Human trials confirm reductions in inflammatory biomarkers such as TNF-α and CRP, though the magnitude of effect is modest and context-dependent.

Animal and in vitro research shows D-glucarate reduces pro-inflammatory cytokines and modulates inflammatory signaling via inhibition of protein kinase C (PKC) and nuclear factor kappa-B (NF-κB). Its active metabolite D-glucaro-1,4-lactone exerts anti-inflammatory effects independent of beta-glucuronidase inhibition. Evidence is preclinical; no controlled human trials exist specifically for chronic inflammation.

In vitro and animal studies show daidzin and its aglycone daidzein reduce pro-inflammatory cytokines and inhibit NF-κB signaling. Anti-inflammatory activity is documented as a core pharmacological property across multiple preclinical models. Clinical confirmation in humans is lacking.

Multiple in vitro and animal studies demonstrate that dandelion extracts reduce key inflammatory mediators including TNF-α, ICAM-1, and NF-κB. Polyphenols quercetin and caffeic acid have been identified as the most active anti-inflammatory constituents. Human clinical data are absent, but the mechanistic evidence is consistent across multiple model systems.

Delta-tocopherol exerts anti-inflammatory effects through suppression of NF-κB signaling, inhibition of COX-2, and reduction of pro-inflammatory cytokines such as IL-6 and TNF-α. Mixed tocopherol preparations rich in γ- and δ-tocopherol consistently outperform α-tocopherol alone in reducing inflammatory biomarkers in preclinical and limited clinical models. In a 48-week RCT in NAFLD patients, δ-tocotrienol was more potent than α-tocopherol in reducing inflammation and apoptosis markers.

Devil's Claw (Harpagophytum procumbens) has documented human clinical evidence supporting its use against chronic inflammation, particularly in musculoskeletal conditions such as osteoarthritis and chronic low back pain. Its primary active compounds—iridoid glycosides, especially harpagoside—inhibit key inflammatory mediators including TNF-α, COX-1/2, iNOS, and prostaglandin E2. A 2014 Cochrane review and multiple controlled trials found significant, if modest, pain reduction versus placebo. Evidence quality is moderate and evidence strength is highest for standardized extracts delivering ≥50 mg harpagoside daily.

DHA (docosahexaenoic acid) has substantial human clinical and mechanistic evidence supporting its role in reducing chronic inflammation. It acts through multiple pathways, including inhibition of NF-κB, suppression of pro-inflammatory cytokines, and generation of specialized pro-resolving mediators (SPMs) such as resolvins and protectins. Meta-analyses of randomized controlled trials demonstrate reductions in CRP, particularly in populations with elevated baseline inflammation such as cardiometabolic disorders. Effects are most pronounced at intakes generally above 1–2 g/day of combined EPA+DHA.

Multiple preclinical studies show DIM suppresses key inflammatory mediators including NF-κB, TNF-α, IL-6, and IL-1β. Animal models of arthritis, autoimmune encephalomyelitis, and colonic inflammation have all shown benefit. Human clinical evidence is indirect, as inflammatory biomarkers have been monitored in cancer and prostate trials.

Diosgenin and dioscin from Dioscorea species show consistent anti-inflammatory activity in animal and cell models, reducing pro-inflammatory cytokines and NF-κB signaling. A 30-day mouse study confirmed significant reduction in inflammatory markers after oral Dioscorea extract. Human clinical evidence is currently absent.

DHA exerts well-documented anti-inflammatory effects via modulation of inflammatory gene expression, reduction of pro-inflammatory cytokines, and generation of pro-resolving mediators (resolvins, protectins). Systematic reviews of RCTs confirm DHA lowers F2-isoprostanes (a marker of oxidative stress) and promotes an anti-inflammatory oxylipin profile. These effects underlie DHA's relevance to many chronic inflammatory conditions.

Dodder (Cuscuta spp.) has demonstrated anti-inflammatory activity in multiple animal and cell-based studies. C. chinensis reduces levels of nitric oxide, malondialdehyde, and pro-inflammatory cytokines. Anti-inflammatory properties are attributed primarily to flavonoid constituents and are considered statistically significant in the pharmacological literature.

Rosa canina preparations demonstrate documented anti-inflammatory mechanisms across 24 pharmacological studies, including inhibition of NF-κB signalling, COX-1/2, 5-LOX, iNOS, and reduction of pro-inflammatory cytokines and CRP. Clinical evidence for CRP reduction exists in some OA trials, though a 28-day RA study found no significant CRP change, indicating dose- and duration-dependence. The overall mechanistic and pharmacological evidence is well-established.

Both Cornus officinalis and Jamaican dogwood display anti-inflammatory activity documented in multiple in vitro and animal studies. Cornus officinalis iridoid glycosides and polyphenols inhibit pro-inflammatory cytokines. Jamaican dogwood isoflavonoids show antispasmodic and anti-inflammatory effects in animal models. Human clinical evidence remains limited.

Dong Quai's key constituents — ferulic acid, ligustilide, and polysaccharides — have demonstrated anti-inflammatory activity in cell and animal studies. Ferulic acid modulates NF-κB, MAPK, and JAK/STAT pathways and suppresses TNF-α, IL-1β, and IL-6. Water extract of A. sinensis showed notable anti-inflammatory effects in LPS-stimulated macrophages in vitro. Human clinical evidence for isolated Dong Quai as an anti-inflammatory agent remains limited; findings largely derive from preclinical models.

DPA is a precursor to a distinct family of specialized pro-resolving mediators (SPMs) including RvDPA-series resolvins, protectins, and maresins, which actively terminate inflammatory responses. RBC DPA levels are inversely correlated with CRP in human cross-sectional studies. These mediators exert specific anti-inflammatory effects distinct from those generated by EPA or DHA.

Multiple in vitro and cell-based studies show dulse extracts reduce key inflammatory markers. A phenolic dulse extract inhibited primary human neutrophil activation, down-regulating TLR4, IL-1β, IL-6, TNF-α, ROS, NO, and myeloperoxidase. A water-extracted, thermolysin-digested dulse preparation also reduced TNF-α, IL-6, and nitric oxide in murine macrophages and mitigated carrageenan-induced paw edema in mice. One human RCT, however, found that dulse-enriched bread modestly increased CRP, suggesting complexity in the inflammatory response.

Multiple in vitro and human studies demonstrate that Echinacea extracts, particularly alkamide-enriched fractions, reduce pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8, while elevating anti-inflammatory IL-10. A 2021 PMC systematic review (105 studies including 13 human studies) found consistent anti-inflammatory signals. The mechanism involves COX-2 inhibition, PGE2 suppression, and endocannabinoid system activation via CB2 receptors.

Multiple in vitro studies using human primary macrophages confirm that E. purpurea extracts—particularly alkylamide-enriched fractions—significantly reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen/nitrogen species. In vivo, the extract modulates the TNF-α/IL-10 axis. Clinical application to chronic inflammatory disease remains under investigation.

EGCG (Epigallocatechin Gallate), the predominant polyphenol in green tea, has documented anti-inflammatory activity supported by both mechanistic research and human clinical data. Its primary molecular targets include NF-κB suppression, inhibition of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and NLRP3 inflammasome attenuation. A clinical study in 50 diabetic patients showed that 300 mg/day of EGCG for eight weeks significantly reduced high-sensitivity C-reactive protein (hs-CRP). However, human trial results are inconsistent, with at least one large RCT finding no significant effect on CRP, IL-6, or TNF-α at higher doses over 12 months.

EPA competitively inhibits arachidonic acid-derived pro-inflammatory eicosanoids and acts as a precursor to anti-inflammatory and pro-resolving mediators (resolvins, protectins). Multiple human trials across inflammatory conditions demonstrate measurable reductions in CRP, IL-6, TNF-α, and leukotriene B4.

Gondoic acid (cis-11-eicosenoic acid), the predominant isomer of eicosenoic acid, has been shown in cell-based research to suppress pro-inflammatory mediators in lipopolysaccharide-activated Kupffer cells. The mechanism involves inhibition of reactive oxygen species (ROS) production and blockade of the PKCθ/ERK/STAT3 signaling pathway. Evidence is currently limited to in vitro models; no human clinical trials have been conducted on eicosenoic acid as an anti-inflammatory agent.

Multiple in vitro and animal studies demonstrate that elecampane extracts and alantolactone suppress key inflammatory pathways including NF-κB, TNF-α, IL-1β, IL-6, iNOS, and neutrophil activation. These effects have been replicated across several independent research groups. All evidence is preclinical.

Eleuthero exhibits well-characterized anti-inflammatory activity through inhibition of NF-κB, MAPKs, and Akt pathways, and suppression of pro-inflammatory cytokines including IL-6 and TNF-α. Evidence spans in vitro, animal, and some human studies, including a registered RCT in dialysis patients examining its anti-inflammatory effects.

Ellagic acid (EA), a polyphenol found in pomegranates, berries, walnuts, and other fruits, has documented anti-inflammatory activity supported by multiple RCTs and a 2024 systematic review/meta-analysis. It suppresses key pro-inflammatory mediators including NF-κB, COX-2, TNF-α, IL-1β, and IL-6 through several converging molecular pathways. A 2024 dose–response meta-analysis of RCTs found EA supplementation significantly reduces C-reactive protein (CRP), a primary marker of systemic chronic inflammation. Evidence is strongest at the preclinical and early clinical trial level, with human data accumulating but still limited in scale.

E. littorale aerial parts exhibit documented anti-inflammatory activity in validated preclinical models including BSA protein denaturation, Freund's adjuvant arthritis, and in vitro TNF-α/IL-6 inhibition assays. Swertiamarin supplementation has also been shown to prevent obesity-related chronic inflammation in high-fat diet mouse models.

EPA (eicosapentaenoic acid) has robust clinical and mechanistic evidence for reducing chronic inflammation. It suppresses pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), inhibits NF-κB activation, and serves as the biosynthetic precursor to specialized pro-resolving mediators (SPMs) such as resolvin E1 (RvE1), which actively terminate inflammatory cascades. Multiple randomized controlled trials and systematic reviews confirm measurable reductions in circulating inflammatory markers with EPA supplementation, particularly at doses above 2 g/day.

Eucalyptus oil and 1,8-cineole suppress chronic inflammatory pathways in multiple in vitro and in vivo models, inhibiting NF-κB, MAPK, TNF-α, IL-1β, and COX-2. Clinical benefit has been documented in COPD, asthma, and rheumatoid arthritis — all conditions driven by chronic inflammation. The compound has a well-characterized steroid-like cytokine inhibition profile.

Eucommia bark extracts significantly inhibited secretion of TNF-α, IL-6, IL-8, and MCP-1 in human immune cell models (neutrophils, PBMC-derived macrophages, THP-1 cells). In animal models, eucommia reduces NLRP3 inflammasome activation, NF-κB signaling, and pro-inflammatory cytokines. These effects are mediated by lignans, iridoids, and caffeic acid derivatives.

Elderberry extracts reduce inflammatory cytokine production (IL-6, TNF-α, PGE2, NO) in multiple in vitro and animal models. One human trial with a related elderberry species (S. ebulus) found significant reductions in IL-6, TNF-α, and IL-8 after 4 weeks. The PMC 2021 systematic review found no direct clinical inflammatory outcome evidence for S. nigra specifically.

EPO's primary active component, GLA, is a precursor to the anti-inflammatory eicosanoid dihomo-gamma-linolenic acid (DGLA), providing a well-documented mechanistic basis for anti-inflammatory effects. Clinical trials across multiple inflammatory conditions show mixed results, with the strongest positive findings in rheumatoid arthritis, atopic eczema, and mastalgia. A 2024 systematic review found overall evidence heterogeneous.

Fennel contains anethole and polyphenols shown in preclinical studies to inhibit pro-inflammatory transcription factors including NF-κB and TNF-α. In vitro and animal research documents anti-inflammatory activity; dedicated anti-inflammatory human trials are limited but the mechanistic evidence is robust.

Fenugreek seeds possess documented anti-inflammatory properties mediated through inhibition of NF-κB activation, suppression of COX/LOX pathways, and reduction of pro-inflammatory cytokines such as TNF-α and IL-6. These effects are supported primarily by preclinical studies; direct clinical trial evidence in chronic inflammatory conditions in humans remains limited. Antioxidant compounds (flavonoids, trigonelline) provide concurrent protection against oxidative stress.

Asafoetida oleo-gum-resin suppresses key pro-inflammatory mediators including TNF-α, IL-6, and IL-1β in cell-based studies (PMC9453118). Multiple Ferula species reviews document anti-inflammatory activity through lipoxygenase inhibition and ROS scavenging. Clinical trial data on chronic inflammation as a primary endpoint are not yet available.

In a randomized, double-blind, placebo-controlled clinical trial in hyperlipidemic adults, ferulic acid at 1 g/day for six weeks produced a 32.7% reduction in hs-CRP and a 13.1% reduction in TNF-α versus placebo. FA inhibits NF-κB signaling and COX-2 expression, suppressing downstream pro-inflammatory cytokines. These effects have been replicated in multiple animal models of systemic and neuro-inflammation.

Parthenolide, feverfew's principal active sesquiterpene lactone, inhibits NF-κB, suppresses COX-mediated prostaglandin synthesis, and reduces cytokine (TNF-α, IL-1β) production in multiple in vitro and in vivo models. These effects establish a mechanistic basis for anti-inflammatory activity. Clinical evidence for systemic chronic inflammation specifically is limited, but the mechanistic data are robust.

Fisetin, a dietary flavonol, has well-documented anti-inflammatory activity supported by in vitro, preclinical, and limited human clinical evidence. Its primary mechanisms involve suppression of the NF-κB signaling pathway and inhibition of pro-inflammatory mediators such as TNF-α, IL-6, IL-1β, COX-2, and prostaglandins. One small randomized controlled trial in colorectal cancer patients demonstrated reduced inflammatory markers with 100 mg/day supplementation. Additional clinical trials specifically targeting chronic inflammation via fisetin's senolytic (senescent-cell-clearing) activity are currently underway but have not yet reported full results.

Fish oil, rich in the omega-3 fatty acids EPA and DHA, has robust clinical and mechanistic evidence supporting a role in reducing chronic inflammation. Multiple RCTs and meta-analyses show reductions in inflammatory biomarkers such as CRP, and clinical benefits have been demonstrated most consistently in rheumatoid arthritis. Evidence in other inflammatory conditions (IBD, asthma) is more mixed. Effects appear dose-dependent and are most pronounced in populations with elevated baseline inflammation.

Multiple randomized controlled trials and meta-analyses confirm that flaxseed supplementation significantly reduces key chronic inflammatory biomarkers, particularly CRP and IL-6. Its anti-inflammatory activity is attributed to three main bioactive constituents: alpha-linolenic acid (ALA), lignans (primarily secoisolariciresinol diglucoside, SDG), and soluble fiber. Evidence from clinical populations includes patients with rheumatoid arthritis, metabolic syndrome, and chronic kidney disease. Results are promising but heterogeneous, and effects on TNF-α appear non-significant.

Multiple preclinical studies demonstrate that C. speciosa extracts, fractions, and isolated constituents suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inhibit the MAPK signaling pathway. Active constituents include polyphenols, glucosides, and triterpenoids such as oleanolic and ursolic acids. Evidence is robust at the in vitro and animal level; no clinical trials in human populations have been published.

Forskolin demonstrates anti-inflammatory properties in laboratory and animal settings by raising cAMP, which broadly suppresses pro-inflammatory mediator release. Intraoperative infusion of a water-soluble forskolin derivative (colforsin daropate) showed anti-inflammatory effects in human cardiac surgery. Preclinical evidence is strong; dedicated anti-inflammatory RCTs in humans are lacking.

Multiple preclinical studies have characterized the anti-inflammatory properties of Forsythia suspensa extracts and its active compounds, particularly forsythoside A and phillyrin. These act via inhibition of TLR4/NF-κB and related pathways. The evidence comes from in vitro and animal studies; no human clinical trials for general chronic inflammation have been conducted.

FOS fermentation-derived SCFAs reduce NF-κB activation and lower pro-inflammatory cytokines (IL-6, TNF-α, IL-1β). Human evidence includes reductions in C-reactive protein and inflammatory markers in specific populations (e.g., NASH patients). Animal and in vitro studies show broad anti-inflammatory effects via microbiota-immune interactions.

Multiple in vitro and animal studies identify NF-κB, MAPK, and Nrf2/HO-1 pathways as targets of fritillary alkaloids, yielding measurable suppression of pro-inflammatory cytokines. The alkaloidal component peimine inhibits MAPK activation in TNF-α-induced arthritic fibroblast-like synoviocytes. Evidence is preclinical; human trials are absent.

Multiple preclinical studies demonstrate that Poria cocos ethanol extract and triterpenes suppress NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and mediators (NO, PGE2) in macrophage models. A PubMed review (2011) confirmed marked anti-inflammatory activity across multiple experimental models. Triterpenes inhibit phospholipase A2, a key enzyme in the arachidonic acid inflammatory cascade.

Fucoidan, a sulfated polysaccharide from brown seaweed, has demonstrated anti-inflammatory effects in both preclinical models and human clinical studies. Its primary mechanisms involve downregulation of the NF-κB and MAPK signaling pathways, reducing pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Human trials—particularly in cancer patients and asthmatic patients—have recorded statistically significant reductions in chronic inflammatory biomarkers. Evidence is promising but largely limited to small or open-label trials; large randomized controlled trials are still lacking.

Multiple in vitro and limited human studies show fulvic acid (FvA) reduces pro-inflammatory mediators including TNF-α and COX-2. A pilot clinical study found topical oxifulvic acid reduced allergen-induced wheal and flare comparable to 1% hydrocortisone. A randomized clinical trial of topical CHD-FA significantly reduced eczema rash in humans.

Proteolytic enzymes, including microbial/fungal-derived proteases, have shown the capacity to reduce systemic inflammatory markers such as CRP and ESR in controlled clinical trials. The proposed mechanism involves degradation of pro-inflammatory protein mediators and immune complexes. Evidence is primarily from multi-enzyme formulas rather than single-ingredient fungal protease products.

Gamma oryzanol suppresses NF-κB activation in vascular endothelial cells and macrophages, reducing pro-inflammatory cytokines. In human patients with type 2 diabetes, daily gamma oryzanol intake reduces circulating CRP, IL-6, and IFN-γ. Animal models confirm anti-inflammatory effects in colitis and obesity-related inflammation.

Gamma-tocopherol inhibits COX-2 activity and reduces prostaglandin E2 production at concentrations where alpha-tocopherol is inactive. It also suppresses TNF-α and NF-κB signaling and limits neutrophil infiltration. Human intervention studies in kidney disease, multiple sclerosis, diabetes, and asthma populations show measurable reductions in inflammatory biomarkers.

A 2025 systematic review (23 preclinical studies) confirmed that Ganoderma lucidum triterpenes significantly reduce TNF-α, IL-1β, and IL-6 via MAPK and NF-κB pathway downregulation. Beta-D-glucan polysaccharides also modulate TLR-mediated inflammatory signalling. Human RCT data on inflammatory markers remain limited but directionally consistent.

Garbanzo beans contain a range of anti-inflammatory bioactives including polyphenols (quercetin, kaempferol, formononetin, biochanin A), selenium, and fiber-derived SCFAs. Cell model studies (2025, Caco-2 and THP-1) show chickpea digests reduce IL-1β expression and upregulate IL-10. Epidemiologic data link regular chickpea consumption to lower low-grade systemic inflammation, a key driver of chronic disease.

Genipin and geniposide from Gardenia jasminoides demonstrate broad-spectrum anti-inflammatory activity across multiple preclinical models. They suppress NF-κB, MAPK, and AP-1 signaling, reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and inhibit nitric oxide production. These findings span carrageenan edema models, LPS-induced macrophage assays, and in vivo lung injury models.

Genipin and geniposide from Gardenia jasminoides have been well characterized as anti-inflammatory agents in multiple preclinical models, acting by suppressing NF-κB, MAPK, and AP-1 signaling pathways and inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, NO). These effects have been documented across carrageenan-induced edema, LPS-induced macrophage activation, colitis, arthritis, and pancreatitis models. Human data are lacking.

A meta-analysis of RCTs demonstrated that garlic supplementation significantly reduces CRP, IL-6, and TNF-α in adults. Effect sizes include clinically notable reductions of 0.61 mg/L for CRP and 0.73 ng/L for IL-6. A double-blind RCT in peritoneal dialysis patients showed significant reductions in IL-6, CRP, and ESR with 400 mg garlic extract twice daily for 8 weeks.

Garlic's organosulfur compounds inhibit key inflammatory mediators including COX, LOX, TNF-α, IL-1β, and CRP. Clinical trials document reductions in systemic inflammatory biomarkers. A trial in peritoneal dialysis patients showed garlic extract 400 mg twice daily for 8 weeks reduced IL-6, CRP, and ESR significantly.

Gastrodin and GE extracts suppress inflammatory cytokines (TNF-α, IL-6, IL-1β) and modulate NF-κB and MAPK signaling pathways in multiple preclinical models. Anti-inflammatory effects have been demonstrated in macrophage, arthritis, liver injury, and neuroinflammation models.

Genistein demonstrates well-characterized anti-inflammatory activity by inhibiting NF-κB, prostaglandin synthesis, iNOS, and proinflammatory cytokines (TNF-α, IL-6, IL-1β). Both in vitro and animal studies confirm these effects, while clinical trials show reductions in CRP and other inflammatory markers. Evidence for anti-inflammatory pharmacological effects in humans is still developing.

Gentian root contains gentiolactone and gentiopicroside, which inhibit TNF-α, iNOS, and COX-2 expression via NF-κB and MAPK pathway suppression in preclinical models. A systematic review of Gentiana lutea (53 publications) confirmed anti-inflammatory activity across multiple experimental models. Evidence is primarily in vitro and animal-based; human clinical data remain limited.

Gentian root extracts and the isolated compound gentiopicroside suppress key pro-inflammatory pathways including NF-κB and MAPK, reducing cytokines TNF-α, IL-1β, IL-6, iNOS, and COX-2 in multiple in vitro and animal models. A 2025 PMC review of the Gentianaceae family confirmed experimentally supported anti-inflammatory and detoxifying effects across gentian species. Evidence is preclinical (animal/cell-based); no dedicated human RCT exists for chronic systemic inflammation.

Gentiana macrophylla and its key bioactive gentiopicroside exhibit well-characterized anti-inflammatory mechanisms across multiple preclinical models. These include suppression of NF-κB, reduction of COX-2 and iNOS, and downregulation of TNF-α, IL-1β, and IL-6. Its anti-inflammatory activity has been observed in models of arthritis, colitis, gastric injury, and pulmonary inflammation.

Geranium EO and its constituent geraniol exhibit anti-inflammatory activity via COX-2 and iNOS inhibition in multiple in vitro and animal models. The anti-inflammatory mechanisms are well characterized. Human clinical evidence exists indirectly through pain and anxiety trials.

Ginger has well-documented anti-inflammatory bioactive compounds — primarily gingerols and shogaols — that suppress key inflammatory pathways including COX-2, LOX, and NF-κB. Multiple RCTs and several meta-analyses confirm statistically significant reductions in circulating inflammatory markers (CRP, hs-CRP, TNF-α) following supplementation. Evidence is strongest in populations with chronic inflammatory conditions such as osteoarthritis and type 2 diabetes, though effect sizes are generally modest and trial quality is variable.

A 2022 systematic review and meta-analysis of 17 RCTs (1,104 participants) found that ginkgo biloba leaf extract (GBLE) significantly reduced serum CRP and IL-6 levels. Effects on CRP were strongest at baseline levels ≥3 mg/L and doses <500 mg/day. Evidence is promising but heterogeneous, with variability in study design and populations limiting firm conclusions.

Ginseng and its principal bioactive compounds, ginsenosides, have well-documented anti-inflammatory activity supported by mechanistic, preclinical, and some human/clinical evidence. Key ginsenosides (Rb1, Rg1, Rg3, Rh2, compound K) suppress chronic inflammatory signaling by downregulating NF-κB, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and inhibiting iNOS and COX-2. Human-relevant evidence spans rheumatic diseases, inflammatory bowel disease, and chronic respiratory conditions, though large-scale randomized controlled trials remain limited.

Ginsenosides, the principal bioactive saponins of Panax ginseng, possess well-documented anti-inflammatory activity supported by extensive preclinical evidence and a growing body of early human/clinical data. Their primary mechanisms involve suppression of the NF-κB and MAPK signaling pathways and downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and enzymes (iNOS, COX-2). Multiple specific ginsenosides (Rb1, Rg1, Rg3, Rh2, Compound K) have been studied across chronic inflammatory conditions including inflammatory bowel disease, rheumatoid arthritis, and pulmonary inflammation. Clinical evidence is promising but limited; most robust data remain preclinical, and large-scale RCTs specifically targeting chronic inflammation are still needed.

GLA exerts documented anti-inflammatory effects through conversion to DGLA and subsequent production of prostaglandin E1 (PGE1) and 15-OH-DGLA, which inhibit pro-inflammatory eicosanoids. Multiple clinical trials in inflammatory conditions (RA, atopic dermatitis, rosacea) confirm measurable reductions in inflammatory markers and symptom scores. It is considered one of the few omega-6 fatty acids with a predominantly anti-inflammatory metabolic profile.

Multiple in vitro and animal studies confirm G. littoralis extracts suppress pro-inflammatory cytokines and pathways including NF-κB, MAPK, COX-2, and iNOS. The 2019 PMC systematic review (PMID 31915441) confirms anti-inflammatory properties as one of the herb's best-documented pharmacological activities.

Multiple preclinical studies demonstrate that G. littoralis extracts suppress key inflammatory mediators including NF-κB, MAPK, COX-2, iNOS, IL-6, and TNF-α. These effects have been observed in cell-based and animal models, but not yet in human clinical trials.

Glucosamine has documented anti-inflammatory activity supported by both mechanistic laboratory research and human clinical data. In vitro studies show it suppresses NF-κB activation and downstream pro-inflammatory cytokines (IL-1β, COX-2, PGE2). In a randomized controlled trial, glucosamine plus chondroitin reduced serum CRP by 23% versus placebo. Large observational cohorts (UK Biobank, NHANES) independently confirm that glucosamine users have significantly lower circulating CRP. Evidence strength is moderate: most trials co-administer chondroitin, samples are often small, and effect sizes on individual cytokines beyond CRP are inconsistent.

Glycine acts as a novel anti-inflammatory, immunomodulatory, and cytoprotective agent via glycine-gated chloride channels on immune cells, attenuating macrophage and neutrophil activation. Human clinical trials in T2D patients show glycine treatment decreased pro-inflammatory cytokines (TNF-α, IL-6) and increased interferon-gamma. GlyNAC RCTs in older adults documented significant reductions in inflammation markers.

Soy isoflavones including glycitin exhibit anti-inflammatory effects by modulating key signaling pathways and reducing the release of inflammatory mediators. A 2025 systematic review and meta-analysis confirmed that soy isoflavones (genistein, daidzein, and glycitein) reduce inflammatory cytokine activity relevant to menopausal and chronic disease contexts. In diabetic animal models, soy isoflavone fractions containing glycitin significantly decreased TNF-α and IL-6 levels after chronic administration.

LBP has documented anti-inflammatory properties in preclinical models, reducing pro-inflammatory cytokines such as IL-6 and TNF-α. In a heart failure rat model, LBP at 200 mg/kg/day significantly reduced IL-6 and TNF-α alongside lipid peroxidation markers. A 2016 European Journal of Nutrition RCT in 108 healthy adults reported reduced C-reactive protein after 12 weeks of goji juice. Human evidence remains limited.

Goldenrod contains flavonoids (quercetin, kaempferol) and phenolic glycosides (leiocarposide) with documented anti-inflammatory mechanisms. In animal models, goldenrod combinations have reduced inflammatory swelling by up to 60%. A review of 11 human studies of a goldenrod-containing herbal blend (Phytodolor) found anti-inflammatory efficacy comparable to aspirin for musculoskeletal pain. Preclinical and mechanistic evidence for anti-inflammatory activity is extensive.

A pilot clinical study found that amla extract (500–1,000 mg/day for 6 months) significantly reduced blood levels of C-reactive protein (CRP), a primary marker of systemic inflammation, alongside improvements in cholesterol. The 2023 meta-analysis also confirmed CRP reductions across pooled RCTs.

Gotu Kola triterpenes demonstrably suppress multiple inflammatory pathways including NF-κB, COX-2, TNF-α, IL-1β, IL-6, and PGE2. RCTs in venous insufficiency patients show reductions in circulating inflammatory markers. The anti-inflammatory mechanism has been confirmed in both human clinical contexts and robust in vitro/in vivo models.

A 2020 meta-analysis of 17 RCTs (668 participants) found grape polyphenol products significantly reduced CRP levels (SMD = −0.229, P = 0.013). Grape polyphenols modulate pro-inflammatory cytokines and NF-κB pathways. A separate systematic review on inflammatory markers (IL-6, TNF-α, hs-CRP) found mixed results, highlighting the need for more studies with higher doses and longer durations.

GSE significantly reduces inflammatory markers including hsCRP, sICAM-1, and VCAM-1 in multiple RCTs. In a double-blind RCT in T2DM patients, 600 mg/day GSE for 28 days significantly decreased hsCRP. OPCs inhibit the NF-κB inflammatory pathway, providing a mechanistic basis for these effects.

Grapefruit contains the flavonoids naringenin and naringin, which have demonstrated anti-inflammatory properties in multiple preclinical models via inhibition of NF-κB and reduction of pro-inflammatory cytokines. Clinical data are more limited; a 6-week grapefruit RCT reduced urinary F2-isoprostanes in high-baseline overweight adults but did not significantly lower hsCRP. Naringenin inhibits UVB-induced skin inflammation in animal models.

Gravel root has been studied in vitro and in animal models for anti-inflammatory activity. Its constituent cistifolin inhibits integrin-mediated leukocyte adhesion, and root extract reduced carrageenan-induced edema in rats in a dose-dependent manner. No human clinical trials have been conducted.

S. scardica extracts have demonstrated dose-dependent anti-inflammatory activity in multiple preclinical models. In an ethanol extract study, oral administration caused anti-inflammatory effects in carrageenan-induced rat paw edema comparable in potency to the reference drug indomethacin. High phenolic and flavonoid content (apigenin, luteolin) is considered mechanistically responsible. No large human RCT on chronic inflammatory disease has been completed.

Andrographolide, the primary active compound in green chiretta, is a potent NF-κB inhibitor and suppresses multiple pro-inflammatory cytokines in vitro and in vivo. Human clinical evidence for its anti-inflammatory effects comes primarily from trials in rheumatoid arthritis and ulcerative colitis, with preclinical evidence across a broad range of inflammatory models.

Green tea, primarily through its major catechin epigallocatechin-3-gallate (EGCG), has documented anti-inflammatory activity supported by human clinical and epidemiological studies. The core mechanism involves suppression of NF-κB signaling, which reduces downstream pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Clinical trial meta-analyses show benefits are more consistently observed in populations with existing elevated inflammation (e.g., metabolic syndrome, type 2 diabetes) than in healthy subjects. Evidence is genuine but effect sizes in RCTs are modest and results remain inconsistent across studies.

Green-lipped mussel (Perna canaliculus) has documented clinical and preclinical evidence supporting its use against chronic inflammation, primarily in the context of inflammatory joint diseases. Its bioactive lipids—including unique long-chain omega-3 PUFAs, EPA, DHA, and furan fatty acids—inhibit key pro-inflammatory pathways. A 2021 systematic review of nine clinical trials found moderate, statistically significant pain reduction in osteoarthritis patients, though evidence quality remains limited and findings are not uniform across all inflammatory conditions.

Guarana seed extracts and bioactive compounds (catechins, theobromine, caffeine) have demonstrated anti-inflammatory activity in multiple in vitro and animal models. In a rat hyperlipidemia model, guarana shifted cytokine profiles from pro- to anti-inflammatory, outperforming caffeine alone. In silico molecular docking confirms strong binding of guarana catechins to PDE4B, a key inflammatory enzyme.

Guggulsterones suppress NF-κB, a master regulator of inflammatory gene expression, and inhibit COX-2. Human studies have shown reductions in C-reactive protein (CRP) and oxidative stress biomarkers following guggulipid supplementation. This anti-inflammatory action underpins many of guggul's proposed therapeutic applications.

Gymnema sylvestre extracts demonstrate anti-inflammatory activity via suppression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and NF-κB/MAPK pathway modulation. Evidence comes from in vitro and animal studies. No large-scale human RCTs specifically targeting inflammation as a primary endpoint exist yet.

Multiple in vitro and animal studies demonstrate that Haliotis diversicolor shell extract significantly inhibits pro-inflammatory mediators. A BMC Complementary Medicine and Therapies study confirmed suppression of iNOS expression in LPS-stimulated macrophages, and in vivo anti-inflammatory effects in burn-injured rats.

Harpagoside, the primary iridoid glycoside from Harpagophytum procumbens (devil's claw), has well-documented anti-inflammatory activity supported by both mechanistic laboratory research and multiple human clinical trials. It suppresses key pro-inflammatory mediators—NF-κB, COX-2, iNOS, TNF-α, IL-1β, and IL-6—across cell and animal models. Clinical trials using standardized extracts delivering 50–100 mg harpagoside per day have demonstrated significant pain and inflammation reduction in chronic low back pain and osteoarthritis, with a Cochrane review finding strong evidence for efficacy versus placebo. Evidence strength is robust for musculoskeletal chronic inflammation specifically, though long-term RCT data on broader chronic inflammatory conditions remain limited.

Hawthorn extracts suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, COX-2) in cell and animal models. One clinical study combining hawthorn with metformin found significantly reduced hs-CRP in prediabetic patients. Triterpenoids such as maslinic acid (hawthorn acid) exhibit protective effects against chronic inflammatory diseases in vivo and in vitro.

Multiple preclinical studies demonstrate significant anti-inflammatory activity for H. spicatum rhizome extracts, with activity in carrageenan-induced paw edema models comparable to reference drugs like indomethacin and prednisolone. Bioactive-guided studies identify diterpenoids (hedychenone) and phenolic/flavonoid compounds as mediators of prostaglandin and cytokine suppression. No human clinical trials exist.

Hesperidin/hesperetin reduces circulating TNF-α in human RCTs and inhibits NF-κB-mediated pro-inflammatory signaling in vitro. A 2023 PMC meta-analysis confirmed significant reduction of serum TNF-α with hesperidin supplementation. CRP and IL-6 effects have been less consistent across trials.

Hesperidin suppresses multiple pro-inflammatory mediators including TNF-α, IL-1β, IL-6, NF-κB, iNOS, and COX-2 in both in vitro and clinical studies. A meta-analysis of RCTs found significant reduction in TNF-α with hesperidin supplementation. A 2024 updated meta-analysis of RCTs also confirmed significant reductions in CRP and adhesion molecules ICAM-1 and VCAM-1.

Clinical and preclinical data show that Hibiscus sabdariffa polyphenols reduce pro-inflammatory cytokines. A human study in metabolic syndrome patients found significant reductions in IL-6, IL-1β, and IL-8 after four weeks of HS calyx extract. A 2025 umbrella review confirmed HS modulates inflammatory markers in clinical trials.

HMR demonstrated potent anti-inflammatory effects in vitro, inhibiting LPS-stimulated TNF-alpha production by approximately 88% in THP-1 human monocytic cells and suppressing reactive oxygen species. In human aortic endothelial cells, HMR significantly reduced ICAM-1 and VCAM-1 expression and monocyte adhesion via NF-κB inhibition. These mechanisms are relevant to systemic chronic inflammation.

HMR concentration-dependently inhibited LPS-stimulated TNF-α secretion in human THP-1 monocyte cells and reduced ROS and IL-8 production in human polymorphonuclear leukocytes (PMNs) in vitro. HMR also significantly reduced ICAM-1 and VCAM-1 adhesion molecule expression in TNF-α-treated human aortic endothelial cells via NF-κB and ERK pathway attenuation. These are in vitro findings; no dedicated human RCTs on inflammatory biomarkers have been completed.

Linalool, the major constituent of ho wood, has demonstrated significant anti-inflammatory activity in peer-reviewed animal models, including suppression of carrageenan-induced edema and inhibition of prostaglandin-mediated hyperalgesia. The mechanism involves inhibition of inflammatory mediators.

Leaf and bark extracts of H. antidysenterica demonstrate anti-inflammatory and analgesic activity in experimental animal models. The steroidal alkaloids are proposed to modulate inflammatory pathways and suppress pro-inflammatory cytokines. These findings are preclinical; no human clinical trials specifically on chronic inflammation have been published.

Ethanolic extract of I. aquifolium has been shown in vitro to inhibit leukotriene B4 biosynthesis in isolated bovine polymorphonuclear leukocytes (PMNL), indicating anti-inflammatory potential at a biochemical level. The genus Ilex is broadly recognized for anti-inflammatory activity. Evidence remains preclinical.

Honey modulates key inflammatory signaling pathways including NF-κB and MAPK, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and CRP. Clinical evidence includes a human trial showing honey reduced CRP by 3.2% versus sucrose, and multiple reviews confirm anti-inflammatory activity in cell culture, animal, and human models.

Honeysuckle contains chlorogenic acid, luteolin, and iridoids that have been extensively studied for their inhibition of NF-κB, TNF-α, IL-1β, IL-6, COX-2, and iNOS across multiple in vitro and animal models. These mechanisms underpin its broad anti-inflammatory pharmacological profile documented in peer-reviewed literature.

Xanthohumol and iso-alpha acids from hops suppress pro-inflammatory cytokines including IL-6, IL-8, and TNF-alpha in vitro and in animal models. A product containing hops extract reduced C-reactive protein in patients with inflammatory diseases in a clinical study. Anti-inflammatory activity is one of hops' best-supported non-sedative pharmacological properties.

Animal and in vitro studies demonstrate that M. vulgare extracts reduce pro-inflammatory markers including TNF-α and myeloperoxidase activity. Flavonoids such as luteolin and quercetin, alongside marrubiin, contribute to COX inhibition and reduced inflammatory mediators. No human clinical trials have been conducted for chronic inflammatory conditions.

Aescin, the principal active saponin in horse chestnut seed extract (HCSE), exerts documented anti-inflammatory effects via downregulation of pro-inflammatory mediators including PGE2, TNF-α, and IL-1β. These effects are linked to upregulation of the glucocorticoid receptor, mimicking corticosteroid signaling without the associated side effects. Anti-inflammatory activity has been confirmed in preclinical models and is considered central to HCSE's clinical benefits in venous disease.

In vitro studies using human peripheral blood mononuclear cells (PBMCs) demonstrate that aqueous horseradish root extract concentration-dependently inhibits LPS-induced TNF-α release, COX-2 expression, PGE2 synthesis, and leukotriene LTB4. Sinigrin has been shown to suppress NF-κB/MAPK pathways in macrophages. Evidence is preclinical; no human RCTs for chronic inflammatory disease endpoints.

Extracts of Equisetum arvense have a documented tradition in European phytotherapy for inflammatory disorders, and in vitro research provides a mechanistic basis. A 2014 BMC study demonstrated dose-dependent inhibition of human T-cell proliferation and reduced production of IFN-γ and TNF-α by horsetail extract. A separate 2017 study confirmed that this immunosuppressive effect operates via an IL-2-dependent mechanism and is enhanced by the silica content of preparations.

Anthocyanins from Vaccinium species, which are the principal bioactives in huckleberry, inhibit NF-κB signaling and reduce pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. A 2021 meta-analysis of 44 RCTs found purified anthocyanin supplementation significantly reduced circulating TNF-α and CRP. Huckleberry shares this phytochemical profile, giving the genus-level evidence strong transferability.

In vitro and preclinical studies show that Lablab purpureus extracts and isolated compounds exhibit anti-inflammatory activity. Flower constituents inhibit IL-1β release in LPS-stimulated macrophages. Seed methanol extracts demonstrate inhibition of protein denaturation and red blood cell membrane stabilization, established surrogate markers of inflammation.

Hydrangea root contains multiple anti-inflammatory compounds including coumarin derivatives (skimmin, apiosylskimmin), loganin, and sweroside. Animal and in vitro studies have shown these compounds reduce pro-inflammatory markers such as TNF-α, IL-1β, IL-6, and nitric oxide, and inhibit infiltration of macrophages and neutrophils into inflamed tissue. All evidence is preclinical; no human studies have been conducted.

HMR suppresses TNF-α-induced inflammatory signaling in vascular endothelial cells via NF-κB inhibition and Nrf2/HO-1 upregulation. In human monocyte (THP-1) and PMN cell models, HMR concentration-dependently reduces LPS-stimulated TNF-α secretion and ROS production. Anti-inflammatory activity in human aortic endothelial cells has also been confirmed, with HMR reducing ICAM-1 and VCAM-1 expression. Evidence is presently cell-based and animal-level; human RCTs on inflammatory biomarkers are not yet published.

Hyssop essential oils and methanolic extracts have demonstrated anti-inflammatory activity in vitro, in vivo (rodent models), and in silico via COX-1 and COX-2 inhibition. Key phenolic compounds—rosmarinic acid and chlorogenic acid—appear responsible for the anti-inflammatory effect.

Arzanol, a phloroglucinyl pyrone unique to H. italicum, is a well-characterised multi-target anti-inflammatory compound that inhibits NF-κB, mPGES-1, COX-1, and 5-LOX, and suppresses IL-1β, TNF-α, and IL-6. A randomised human study in metabolic syndrome patients showed that daily H. italicum infusion significantly reduced circulating IL-6, IL-1β, MCP-1, and zonulin.

Oral SBI has been shown to reduce systemic inflammatory markers in humans with chronic gut-driven inflammation. In a 103-patient randomized double-blind trial, SBI significantly lowered IL-6 (p=0.002) over 24 weeks. Ex vivo human studies confirm SBI specifically lowers TNF-α and CXCL10 in colonic tissue models.

Multiple preclinical studies demonstrate that Impatiens extracts inhibit key inflammatory pathways including cyclooxygenase-2 (COX-2) and lipoxygenase. In vitro assays using BSA denaturation show an IC50 of 210 µg/mL for anti-inflammatory activity. Animal model studies confirm significant anti-inflammatory effects.

Bael extracts inhibit key inflammatory mediators including COX-2, TNF-alpha, IL-1beta, and IL-6 in multiple preclinical models. The anti-inflammatory activity has been demonstrated via egg albumin denaturation assay, molecular docking against HO-1, and cytokine suppression in animal models of depression and colitis. Bioactive compounds marmelosin, aegeline, and flavonoids are identified as primary drivers.

Boswellic acids — particularly AKBA — are potent inhibitors of 5-lipoxygenase (5-LOX), blocking leukotriene B4 synthesis and NF-κB signalling, two central drivers of chronic inflammation. Clinical trials across multiple inflammatory conditions consistently demonstrate reductions in CRP, ESR, IL-6, TNF-α, and PGE2. This mechanism underpins Boswellia's broad clinical activity documented in osteoarthritis, IBD, and asthma.

Human clinical trials and preclinical studies document anti-inflammatory effects of gum arabic and Acacia nilotica extracts. Gum arabic supplementation reduced C-reactive protein and inflammatory cytokines in haemodialysis patients. Acacia nilotica extracts inhibit COX-2 and 5-LOX in vitro and reduce paw edema in animal models comparably to diclofenac.

Anti-inflammatory activity of H. indicus is among its most studied pharmacological properties. In vivo animal studies using the carrageenan-induced paw edema model and other inflammation models have demonstrated significant suppression of inflammation. The activity is attributed to saponins, flavonoids, and phenolic compounds in the root.

T. cordifolia has been traditionally used for chronic inflammatory conditions, and preclinical evidence is substantial. A PMC-indexed study demonstrated that chloroform extract inhibits LPS-induced NF-κB activation in THP-1 cells and suppresses TNF-α and other pro-inflammatory cytokines. Anti-inflammatory activity is attributed to alkaloids including berberine, which inhibits the TNF-α-triggered proinflammatory cascade and reduces iNOS-mediated nitrosative stress.

Multiple preclinical studies and systematic reviews demonstrate that indigo naturalis (derived from indigo plant leaves) and its active components—indirubin, indigo, and tryptanthrin—exert significant anti-inflammatory effects via multiple pathways including NF-κB, JAK/STAT, and Th17 suppression. These mechanisms have been confirmed in human disease contexts including psoriasis and ulcerative colitis.

I3C suppresses the master inflammatory transcription factor NF-κB and downstream cytokines including IL-1β, IL-6, and TNF-α in multiple preclinical models. It also inhibits cyclooxygenase-2 and inducible nitric oxide synthase expression. Human ex vivo work in SLE patients demonstrates modulation of macrophage inflammatory cytokine balance. Direct large-scale human RCTs targeting chronic inflammation as a primary endpoint are still lacking.

Alantolactone and isoalantolactone, the principal sesquiterpene lactones of I. racemosa, have been experimentally shown to inhibit NF-κB, MAPK, COX-2, iNOS, TNF-α, and multiple interleukins in preclinical studies. These mechanisms underpin broad anti-inflammatory effects validated in multiple in vitro and in vivo models.

RCTs show inulin supplementation reduces the inflammatory marker hs-CRP in patients with conditions including rheumatoid arthritis and migraine. Inulin modulates gut microbiota, reducing endotoxemia and systemic LPS translocation, which drives lower pro-inflammatory cytokine production. Evidence is emerging but still limited in scope and size.

IMO modulates systemic and gut inflammation primarily through its prebiotic effects on microbiota composition and SCFA production. In animal models, IMO prevented HFD-induced increases in pro-inflammatory cytokines (TNF-α, IL-1β) and reduced metabolic endotoxemia. Human clinical data on inflammation endpoints are indirect.

Jiaogulan gypenosides suppress pro-inflammatory signaling via inhibition of NF-κB and MAPK pathways, reducing TNF-α, IL-1β, and IL-6. A small human study (n=24) found decreased C-reactive protein in subjects with mild hypertension after jiaogulan tea.

Jujube fruit and seed extracts downregulate pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and suppress NF-κB and COX-2 pathways in cell and animal models. The 2022 human RCT (n=48 T2D) found hs-CRP fell by ~24% within the jujube group, though the between-group difference did not reach significance. The anti-inflammatory mechanisms are well-characterized at the preclinical level.

Kale's glucosinolate-derived compounds (sulforaphane, I3C, DIM) and flavonoids (quercetin, kaempferol) suppress NF-κB signaling and pro-inflammatory cytokines TNF-α and IL-1β. Animal studies show kale reduces intestinal and systemic inflammation. Kale's sulforaphane activates Nrf2, a master regulator of anti-inflammatory and antioxidant responses.

Preclinical and in vitro studies show kanna extracts exert cytoprotective and anti-inflammatory effects, including reduced inflammatory responses in human monocytes under LPS exposure. PDE4 inhibition, which reduces pro-inflammatory cytokine production, is a recognized anti-inflammatory mechanism. A PMC review cites Bennett et al. reporting potent anti-inflammatory capacity in the context of chronic disease.

Kelp's fucoidan and fucoxanthin have documented anti-inflammatory activity. Fucoxanthin inhibits NF-κB-related inflammatory pathways in human cell models and animal studies. A systematic review confirms anti-inflammatory activity as among the top pharmacological activities of fucoxanthin. Human trial evidence is emerging, primarily from metabolic syndrome-adjacent studies.

Kidney beans are rich in polyphenols (gallic acid, catechins, flavonoids) and tocopherols that exert anti-inflammatory effects. Pre-clinical and clinical evidence for legumes/pulses broadly shows that regular consumption reduces inflammatory biomarkers, and Phaseolus vulgaris polyphenols in particular have documented anti-inflammatory properties.

Knotweed extract and its constituents—resveratrol, polydatin, and emodin—have demonstrated inhibition of key inflammatory mediators including TNF-alpha, IL-6, and COX pathways in preclinical and limited human studies. A Gulf War Illness human trial found anti-inflammatory effects with PC-derived resveratrol. PC is officially listed in the Chinese Pharmacopoeia for inflammatory conditions. Emodin regulates AMPK and NF-κB inflammatory pathways.

Krill oil contains EPA and DHA bound to phospholipids, plus the antioxidant astaxanthin, giving it documented anti-inflammatory activity. Multiple randomized controlled trials and a 2026 meta-analysis confirm reductions in CRP and pro-inflammatory cytokines. Evidence is strongest for conditions driven by chronic low-grade inflammation (osteoarthritis, cardiovascular risk, IBD), though effect sizes are modest and larger confirmatory trials are still needed.

Puerarin, kudzu's primary bioactive compound, has well-documented anti-inflammatory properties, principally through suppression of NF-κB and reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). These effects have been demonstrated in preclinical models and supported by clinical data in coronary artery disease patients. Kudzu has also been used traditionally across Asia for inflammatory diseases.

AG exerts anti-inflammatory effects by suppressing NF-κB activation, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and upregulating heat shock protein HSP70. These mechanisms are documented in both animal colitis models and human perioperative studies. AG reduces inflammatory mediators in patients undergoing major surgery.

L-carnosine inhibits pro-inflammatory cytokines (TNF-α, IL-6, IL-8) and modulates NF-κB signaling in preclinical models. Human RCT evidence is mixed: one trial in T2D patients showed reduced TNF-α, while a 2024 RCT in pre-diabetes/T2D found no significant effect on a broad panel of inflammatory markers. A pooled meta-analysis found reductions in TNF-α and CRP.

L-Citrulline supplementation has been tested in human trials for its effect on low-grade (meta-) inflammation, particularly in metabolic disease populations. A randomized double-blind trial in type 2 diabetic patients found that 3 g/day for 8 weeks significantly reduced fasting blood glucose, HbA1c, IL-6, and TLR-4 levels, though no significant inter-group difference in inflammatory markers was observed after adjustment for confounders. Animal and in vitro evidence consistently shows anti-inflammatory effects via NO-mediated suppression of oxidative stress and reactive oxygen species, but human clinical evidence remains limited and mixed.

NAC inhibits NF-κB activation and reduces pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) in clinical and preclinical studies. A 2020 meta-analysis of 28 controlled clinical trials found that NAC significantly reduces inflammatory and oxidative stress biomarkers. Its anti-inflammatory activity operates independently of, and in addition to, its antioxidant properties.

L-glutamine reduces pro-inflammatory cytokine production and supports anti-inflammatory pathways in critically ill and IBD patients. Clinical and meta-analytic data show reductions in systemic inflammatory markers with glutamine supplementation in catabolic states.

Glutathione maintains adequate redox cell signaling that controls NF-κB-mediated inflammatory cytokine production. Low intracellular GSH is associated with elevated pro-inflammatory markers across numerous chronic diseases. Human trials with GSH precursors (GlyNAC) have demonstrated measurable reductions in systemic inflammation markers.

Glycine inhibits pro-inflammatory cytokine production including TNF-alpha and IL-6 and suppresses NF-κB pathway activation. GlyNAC (glycine + N-acetylcysteine) RCT evidence in older adults demonstrates significant reduction in inflammatory markers. Glycine also modulates Kupffer cell and macrophage activity in the liver, reducing inflammatory responses.

L-histidine has documented anti-inflammatory properties, with human trials demonstrating significant reductions in inflammatory cytokines (TNF-α, IL-6) and CRP upon supplementation. Serum histidine is inversely associated with inflammatory markers and mortality in CKD patients. The imidazole side chain of histidine enables direct scavenging of reactive oxygen species underlying inflammatory cascades.

Contrary to theoretical concerns about LA promoting inflammation via arachidonic acid conversion, human evidence consistently shows higher LA levels are inversely associated with inflammatory markers (CRP, IL-6). A systematic review of 15 clinical RCTs found no support for LA increasing chronic inflammation. A 2025 cross-sectional analysis of 2,777 Framingham Offspring Study participants confirmed RBC LA inversely correlates with CRP and IL-6.

L. acidophilus modulates inflammatory cytokine profiles in both preclinical and human studies. A meta-analysis of RCTs found that L. acidophilus significantly reduced IL-6 and TNF-α levels while increasing CD4+ T-cells and IgA. Mechanistic work demonstrates suppression of NF-κB activation and pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-17) via TGF-β signaling. Effects are strain-dependent and most clearly demonstrated in models of intestinal inflammation.

L. brevis CD2 exerts anti-inflammatory effects via its high-level arginine deiminase (ADI), which competes with nitric oxide synthase and reduces pro-inflammatory cytokines including IL-1α, IL-6, IL-8, TNF-α, and PGE2. Its sphingomyelinase hydrolyzes platelet-activating factor (PAF), a potent inflammatory mediator. Clinical evidence spans periodontal disease, oral mucositis in cancer patients, and aphthous stomatitis.

L. bulgaricus produces ADP-ribose, which inhibits TNF-α-mediated cytotoxicity in vitro. EPS from L. bulgaricus OLL1073R-1 activates NK cells and induces IFN-γ, and L. bulgaricus has been shown to lower TNF-α in Crohn's disease mucosal biopsies. Animal models further demonstrate reduction of IL-6, IL-17, IL-23, and IL-1β.

Multiple clinical trials of L. casei across different inflammatory conditions (RA, metabolic syndrome, respiratory infection) have documented reductions in inflammatory biomarkers including hs-CRP, TNF-α, and IL-12. L. casei Shirota has been specifically investigated for improving intestinal permeability in metabolic syndrome, reducing LPS translocation that drives systemic inflammatory signaling. The evidence is distributed across conditions rather than a single chronic inflammation trial.

L. crispatus actively suppresses vaginal mucosal inflammation via multiple mechanisms. Its surface layer proteins (SLPs) shield TLR ligands and interact selectively with the anti-inflammatory receptor DC-SIGN, reducing NF-κB activation and lowering pro-inflammatory cytokines IL-1β and IL-8. A 2022 Lancet Microbe RCT (LACTIN-V) demonstrated that vaginal L. crispatus CTV-05 significantly reduced IL-1α and the epithelial barrier disruption marker soluble E-cadherin.

Several studies document anti-inflammatory properties of L. gasseri, including suppression of TNF-α and IL-6 in H. pylori-infected macrophages and in high-fat-diet models. The strain SBT2055 has been shown to inhibit adipose tissue inflammation and reduce intestinal permeability in mice, which are key drivers of systemic chronic inflammation.

Clinical and in vitro evidence shows L. plantarum strains suppress systemic inflammatory markers including CRP, IL-6, and TNF-α. An RCT in stable coronary artery disease patients demonstrated measurable suppression of systemic inflammation.

L. rhamnosus GG reduces chronic intestinal inflammation by inducing IL-10 production in intestinal monocytes via the STING/TBK1/NF-κB signaling pathway. It also modulates gut microbiota composition, reducing proinflammatory cytokine production. In acne, animal, and IBD models, LGG consistently lowers TNF-α and IL-6 levels.

Clinical evidence shows L. salivarius supplementation significantly reduces circulating inflammatory markers. A randomized controlled pilot study in 45 healthy volunteers found 6 weeks of L. salivarius UBL S22 significantly lowered serum hs-CRP, IL-6, IL-1β, and TNF-α versus placebo. In vitro data on strain UCC118 identify NF-κB pathway downregulation as a key mechanistic pathway.

L. lactis strains — particularly genetically modified (GM) variants secreting IL-10 — have demonstrated anti-inflammatory activity in multiple pre-clinical models. Several completed clinical trials with GM L. lactis confirmed safety and tolerability in patients with mucosal inflammatory pathologies. Wild-type strains modulate cytokine profiles (reducing IFN-γ, IL-6, TNF-α) and expand regulatory T-cell populations in colitis models. Evidence is strongest in the context of intestinal inflammation.

Lactoferrin modulates multiple pro-inflammatory cytokines and has demonstrated reductions in systemic inflammatory biomarkers across human clinical trials. A systematic review and meta-analysis found 61% of adult studies reported significant decreases in at least one inflammatory marker. Mechanisms include NF-κB suppression, cytokine downregulation, and antioxidant activity.

Lavender essential oil and its main constituents—linalool and linalyl acetate—have demonstrated anti-inflammatory activity in preclinical models, including inhibition of carrageenan-induced pleurisy and croton oil-induced ear edema. Phenolic-rich lavender extracts also show anti-inflammatory effects via inhibition of NF-κB and MAPK signaling. Human clinical data specifically for chronic inflammatory conditions remain limited.

Lemon flavonoids and vitamin C have anti-inflammatory properties with human clinical evidence. A lemon 'detox' diet study (n=84 overweight women, 11 days) found significant reduction in hs-CRP. A lemon-flavonoid extract RCT in prediabetic patients showed reductions in IL-6 (14%) and TNF-alpha (20%).

Lemongrass essential oil has demonstrated anti-inflammatory effects in human dermal fibroblasts and in vivo animal models. Citral inhibits pro-inflammatory biomarkers including VCAM-1, IP-10, and modulates NF-κB pathways. In vivo, topical and oral LGEO significantly inhibited chemically induced skin inflammation in rodents.

LEM and its mycelial fractions demonstrate anti-inflammatory activity in multiple preclinical models, suppressing pro-inflammatory cytokines (TNF-α, IL-6), NF-κB signaling, and COX-2 expression. Lentinan, AHCC, LEM, and MSCE all showed potent anti-inflammatory effects in cell lines and animal models. Evidence in humans is indirect, derived from immune modulation studies.

Glycyrrhizin and its aglycone glycyrrhetinic acid inhibit NF-κB, COX-2, TNF-α, and IL-6 through corticosteroid-like mechanisms. Multiple in vitro, animal, and some clinical studies support anti-inflammatory activity. A PubMed review of clinical trial findings (Kalaivanan et al., 2020) characterized licorice's anti-inflammatory properties as clinically relevant. Licorice flavonoid extracts also modulate MAPK/NF-κB signaling in intestinal inflammation.

Lignans and their enterolignan metabolites inhibit pro-inflammatory cytokine expression by downregulating JAK/STAT, NF-κB, and AP-1 signaling pathways. Flaxseed lignan supplement trials have shown beneficial associations with C-reactive protein in five intervention studies. Sesamin, a lignan from sesame, has been particularly studied for anti-inflammatory mechanisms.

Multiple in vitro and in vivo studies demonstrate that Syringa vulgaris extracts and isolated compounds (neooleuropein, syringin, secoiridoids) suppress key pro-inflammatory mediators including TNF-α, IL-6, IL-8, MCP-1, and ROS. The bark alcoholic extract significantly inhibited IL-8 release in vitro. Anti-inflammatory activity operates via NF-κB and p38MAPK pathway suppression.

Bioassay-guided isolation from Lilium brownii var. viridulum identified two phenylpropanoid acylglycerols that potently inhibited NO production, PGE2, IL-1β, IL-6, and TNF-α in LPS-stimulated macrophages. Anti-inflammatory activity has also been observed in cigarette-smoke mouse models. The mechanism involves NF-κB/MAPKs pathway suppression. This is preclinical evidence with no human chronic-inflammation trials published.

Lime's vitamin C and flavonoids (hesperidin, naringin, limonene) modulate pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. A 2026 animal study found citrus juice significantly reduced CRP, TNF-α, and IL-6. Epidemiological data associate citrus-rich diets with lower systemic inflammation markers.

D-limonene suppresses multiple pro-inflammatory pathways including NF-κB, MAPK, TNF-α, IL-1β, IL-6, COX-2, and PGE2, documented in numerous in vitro and animal studies. Anti-inflammatory activity has been demonstrated in models of colitis, gastric ulceration, lung injury, and arthritis. Evidence is largely preclinical; mechanistic pathways are well characterized.

Lion's Mane contains hericenones, erinacines, β-glucans, and phenolic compounds that suppress key pro-inflammatory mediators. In vitro and animal studies show inhibition of NF-κB, COX-2, TNF-α, IL-6, and IL-1β. Human clinical data on systemic inflammation are sparse but supported by mechanistic evidence.

Multiple laboratory studies demonstrate that L. gracile extracts and isolated flavone C-glycosides (especially isoorientin) significantly suppress inflammatory pathways, including NF-κB, JNK, and MAPK signaling, and inhibit neutrophil activation. A 2025 study using LPS-induced models showed that total flavonoids from the leaf reversed inflammatory responses in vitro and in vivo. Evidence is preclinical; no human RCTs are available.

Lotus seed extracts inhibit pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and NF-κB signaling in multiple in vitro and animal studies. Lotus plumule polysaccharide modulates cytokine ratios in diabetic mice. No human anti-inflammatory trials exist specifically for lotus seed.

Lutein modulates oxidative stress-driven inflammatory pathways, suppressing pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α. Clinical findings show an inverse association between serum lutein and IL-6 in coronary artery disease patients with chronic low-grade inflammation. Supplementation studies have demonstrated reductions in serum IL-6 and MCP-1 in patients with early atherosclerosis. Evidence is supported by both epidemiological data and ex vivo human cell experiments.

Luteolin, a dietary flavonoid found in vegetables and herbs, has well-documented anti-inflammatory activity across in vitro, in vivo, and limited human studies. Its primary mechanism involves suppression of the NF-κB, MAPK, AP-1, and STAT3 transcription factor pathways, reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. While preclinical evidence is robust, human clinical data remain limited, with emerging translational studies using luteolin-containing formulations showing suppression of key inflammatory biomarkers.

Flavanol-rich lychee fruit extract (FRLFE) and its standardized form Oligonol have demonstrated anti-inflammatory effects in controlled human and preclinical studies. In a clinical study on young athletes, FRLFE supplementation significantly lowered exercise-induced serum IL-6 elevation. In vitro, lychee flavanols suppress iNOS gene expression and TNF-α production in hepatocytes, while lychee seed isolates inhibit NO production in LPS-stimulated macrophages.

Multiple clinical trials and systematic reviews show lycopene reduces key inflammatory biomarkers, especially CRP and IL-6. A meta-analysis of 21 intervention trials found tomato/lycopene supplementation significantly reduced IL-6 levels. A 30-day RCT in 60 heart-failure patients demonstrated significant CRP reductions in both sexes following lycopene-enriched tomato soup (~27 mg/day). Effect is likely mediated by lycopene's singlet-oxygen quenching and NF-κB inhibition.

Macadamia nuts contain flavonoids, palmitoleic acid, and tocotrienols with anti-inflammatory properties. A review of six studies found that macadamia nuts help reduce inflammation associated with cardiovascular disease. Short-term macadamia consumption has been shown to favorably modify inflammatory markers despite increased fat intake. Broader nut research including macadamias shows modest reductions in C-reactive protein.

Multiple meta-analyses of randomized controlled trials demonstrate that magnesium deficiency promotes chronic low-grade inflammation, and that supplementation significantly reduces key inflammatory markers—particularly serum C-reactive protein (CRP). The core mechanistic link involves magnesium's role in regulating intracellular calcium and modulating pro-inflammatory cytokine pathways. Evidence is strongest in populations with pre-existing low magnesium status, such as those with metabolic syndrome. Results across RCTs remain somewhat inconsistent for markers like IL-6, and effect sizes are modest.

Honokiol and magnolol suppress multiple pro-inflammatory pathways, including NF-κB, TNF-α, IL-6, and IL-1β, documented in cell and animal studies with substantial mechanistic evidence. In vitro data from MSKCC-cited research shows magnolol and honokiol reduced TNF-α and IL-8 production in macrophages stimulated by Propionibacterium acnes. Human clinical data remains largely indirect but aligns with these mechanisms.

Isolated compounds from maitake fruiting bodies exhibit COX-1 and COX-2 inhibitory activity in vitro, with anti-inflammatory potency compared to NSAIDs such as aspirin and ibuprofen. Polysaccharides from G. frondosa also modulate pro-inflammatory cytokine pathways. Evidence is predominantly in vitro and animal-based; dedicated human inflammation trials are absent.

Vasicine from A. vasica inhibits cyclooxygenase and lipoxygenase pathways in vitro, providing a mechanistic basis for anti-inflammatory activity. Multiple pharmacological reviews confirm anti-inflammatory properties demonstrated through in vitro and animal studies.

Manganese is essential to mitochondrial manganese superoxide dismutase (MnSOD), which scavenges superoxide radicals that drive inflammatory signaling. Reduced MnSOD expression is observed in multiple inflammatory diseases, and MnSOD mimetics suppress inflammatory responses in preclinical models. The direct anti-inflammatory benefit of dietary manganese supplementation in humans has not yet been established in controlled trials.

Mango polyphenols including mangiferin show anti-inflammatory activity in preclinical models, with mixed but positive signals in human trials. In obese participants, 6 weeks of 400 g/day mango pulp significantly reduced pro-inflammatory cytokines IL-8 and MCP-1, and lowered HbA1c and PAI-1. Other human trials showed reductions in CRP.

Multiple human RCTs have shown mangosteen-based beverages reduce C-reactive protein (CRP), a key inflammatory marker. A 30-day RCT in 60 healthy adults found CRP dropped from 2.9 mg/L to 1.6 mg/L (p<0.05) in the mangosteen group. Xanthones inhibit NF-κB, COX-2, and MAPK inflammatory pathways in vitro and in human macrophages.

Maqui berry's anthocyanins, particularly delphinidins, modulate key inflammatory pathways including NF-κB and Nrf2-HO-1 in cell and animal studies. In a double-blind RCT in overweight/smoker adults, Delphinol® reduced oxidized LDL—a marker of oxidative stress linked to vascular inflammation—compared to baseline. Traditional Mapuche use of maqui as an anti-inflammatory is also well-documented.

Multiple preclinical studies have documented anti-inflammatory properties of marjoram extracts, with significant reductions in pro-inflammatory cytokines (IL-6, TNF-α, CRP) in rat models of cardiac injury and PCOS. The volatile oil constituents terpinen-4-ol and rosmarinic acid are identified as key mediators of this activity.

In vitro studies demonstrate that marshmallow root extract suppresses key pro-inflammatory cytokines (TNF-α and IL-6) in human macrophages at levels comparable to diclofenac. Polysaccharides also stimulate macrophage migration and anti-oxidative defense. Evidence is preclinical; no chronic inflammation RCTs in humans exist.

Mastic gum inhibits key inflammatory mediators including NF-κB, COX-2, iNOS, TNF-α, IL-6, and adhesion molecules VCAM-1 and ICAM-1. Small clinical trials in Crohn's disease patients found that 2.2 g/day for four weeks significantly reduced IL-6 and CRP. A 2019 PMC review of 19 studies confirmed both preclinical and emerging clinical evidence for anti-inflammatory and antioxidant activity.

A systematic review and meta-analysis of 31 clinical trials (1,517 participants) found melatonin supplementation significantly reduced pro-inflammatory cytokines including IL-1, IL-6, and IL-8. In the late phase of inflammation, melatonin downregulates inflammatory mediators and reduces oxidative stress. Evidence spans diverse populations and disease states.

Menthol demonstrates anti-inflammatory properties via suppression of pro-inflammatory cytokines (TNF-α, IL-6) and NF-κB pathway modulation, supported by preclinical studies. Human clinical evidence of systemic anti-inflammatory benefit is limited but mechanistic evidence is established.

MMSC exhibits documented anti-inflammatory properties in multiple preclinical models, including inhibition of TNF-α, iNOS, TGF-β1, and NF-κB signaling. It reduces capillary permeability in response to inflammatory stimuli. Human evidence of anti-inflammatory activity is indirect, observed through reduction of inflammatory infiltration in gastric mucosa of gastritis patients treated with MMSC.

Milk thistle's active constituent, silymarin, has human clinical evidence supporting a modest anti-inflammatory effect. Multiple RCTs and meta-analyses demonstrate statistically significant reductions in circulating inflammatory markers—particularly CRP and IL-6—in adults across conditions characterized by chronic inflammation (NAFLD, diabetes, thalassemia). The mechanistic basis is well-characterized at the molecular level, though overall evidence strength is moderate and clinical translation remains incomplete.

Millet seed polyphenols, including tannins, flavonoids, and phenolic acids, are documented to downregulate NF-κB-mediated pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and activate the Nrf2 antioxidant pathway. Animal studies show millet polyphenols reduce colonic inflammation markers. SCFA production from millet fiber further modulates systemic low-grade inflammation.

Momordica charantia extracts demonstrate anti-inflammatory activity in preclinical and limited human research. Bioactive compounds such as charantin, momordicin, and polyphenols suppress pro-inflammatory cytokines including TNF-α and IL-1β. A randomized controlled trial examined M. charantia leaf extract's effect on TNF-α levels in diabetic foot ulcer patients. Overall, the anti-inflammatory evidence is predominantly preclinical.

Mogrosides from monk fruit have demonstrated anti-inflammatory activity in multiple preclinical models, inhibiting pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. The 2025 PRISMA-guided systematic review of RCTs identified preliminary evidence of anti-inflammatory and symptom-relieving effects attributable to mogrosides. No large-scale human clinical trials focused exclusively on inflammation as a primary endpoint have been completed.

Morinda officinalis iridoid glycosides, anthraquinones, and polysaccharides suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17) and inhibit NF-κB and MAPK signalling pathways in multiple in vitro and in vivo models. M. citrifolia fruit juice demonstrated anti-inflammatory effects in a clinical trial of heavy smokers (reduced hs-CRP).

Morus leaf extracts reduce circulating inflammatory markers in human trials, including CRP, TNF-α, and IL-6. A 2024 RCT found mulberry drink significantly reduced CRP versus placebo. A 2025 meta-analysis of 15 RCTs confirmed significant pooled reductions in inflammatory biomarkers.

MSM (methylsulfonylmethane) has documented anti-inflammatory activity supported by multiple randomized controlled trials and in vitro mechanistic work. Its primary molecular mechanism involves inhibition of the NF-κB pathway, suppressing pro-inflammatory cytokines including IL-1, IL-6, and TNF-α. Human RCTs have demonstrated benefits in inflammatory joint conditions (osteoarthritis) and exercise-induced inflammation, though effect sizes are modest and evidence for broader chronic inflammation remains preliminary. Overall evidence is described as 'moderate' by systematic reviewers, with calls for larger, longer trials.

Multiple preclinical studies demonstrate that A. vulgaris extracts suppress inflammatory mediators including TNF-α, NO, and prostaglandins in rodent models. Ethyl acetate and ethanolic leaf extracts significantly inhibited formalin-induced paw edema in vivo. The key bioactive compounds — flavonoids such as luteolin and quercetin, plus 1,8-cineole — are established anti-inflammatory agents. No controlled human trials have yet translated these findings.

Multiple clinical trials and the 2025 meta-analysis of 15 RCTs show mulberry supplementation significantly lowers inflammatory markers including CRP, TNF-α, and IL-6. Anti-inflammatory effects are attributed to flavonoids, anthocyanins, and polyphenols acting through NF-κB and Nrf2 pathways.

Multiple laboratory studies have characterized anti-inflammatory activity in mullein extracts, identifying verbascoside (phenylethanoid glycoside), quercetin, and luteolin as the primary active agents. These compounds inhibit pro-inflammatory cytokines TNF-α and IL-1β and suppress NF-κB and protein kinase C signaling in cell models. Evidence is pre-clinical; no human anti-inflammatory trials exist.

Mustard's glucosinolate-derived isothiocyanates—especially allyl isothiocyanate (AITC)—suppress pro-inflammatory cytokines including TNF-α and inhibit the NF-κB signaling pathway. In vitro studies confirm anti-inflammatory activity of mustard seed extract comparable to diclofenac sodium. The isothiocyanate–Nrf2 axis also upregulates endogenous antioxidant defenses, reducing oxidative drivers of chronic inflammation.

CMO's primary documented mechanism is inhibition of the lipoxygenase and cyclooxygenase pathways of arachidonic acid metabolism, reducing prostaglandin and leukotriene production. Multiple clinical trials showing reductions in joint pain, swelling, and inflammatory scores provide indirect human evidence of anti-inflammatory activity. The mechanism parallels that of NSAID drugs, though evidence is limited to musculoskeletal contexts.

TC extracts inhibit COX-1, COX-2, 5-LOX, TNF-α, and suppress NF-κB signaling — key inflammatory mediators — across multiple preclinical models. A human crossover study demonstrated analgesic activity at a single 1,000 mg oral dose. A 12-week RCT in diabetic patients showed reduction in high-sensitivity CRP, a systemic inflammation marker.

Myrrh extracts suppress key pro-inflammatory mediators including TNF-α, nitric oxide, prostaglandin E2, and NF-κB signaling. Multiple preclinical studies confirm inhibition of MAPK/JNK pathways. The combination product Myrrhinil-Intest (myrrh, chamomile, coffee charcoal) has clinical data supporting anti-inflammatory utility in IBD maintenance.

NAG exerts anti-inflammatory effects through multiple pathways, including inhibition of NF-κB activation and suppression of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β. These mechanisms have been demonstrated in cell and animal studies, and early human data in IBD and MS contexts support systemic anti-inflammatory activity.

NAC has documented anti-inflammatory effects in multiple clinical trials, primarily through antioxidant mechanisms and NF-κB inhibition. Meta-analyses of RCTs report significant reductions in pro-inflammatory cytokines IL-6, IL-8, and TNF-α, and in the oxidative stress marker MDA, though effects on CRP are inconsistent across studies.

Naringin suppresses NF-κB-mediated inflammatory signaling, reducing TNF-α, IL-1β, IL-6, and IL-8 in both in vitro and animal models. An ex vivo study using human peripheral blood mononuclear cells from psoriasis patients demonstrated naringin inhibited pro-inflammatory cytokine expression. Preclinical evidence for chronic inflammatory pathways is strong, but dedicated human RCTs for inflammatory endpoints are absent.

Nattokinase exhibits anti-inflammatory properties through inhibition of TLR4 signaling and suppression of pro-inflammatory cytokines such as TNF-α and IL-6. Preclinical studies demonstrate reduction of LPS-induced systemic inflammation and oxidative stress. Human RCTs studying cardiovascular endpoints have incorporated inflammatory markers as secondary outcomes, supporting a plausible anti-inflammatory role, though dedicated clinical trials on chronic inflammation as a primary endpoint remain limited.

Nattokinase demonstrates anti-inflammatory activity through suppression of the NLRP3 inflammasome, reduction of vascular adhesion molecules (ICAM-1, VCAM-1, E-selectin), and inhibition of LPS-induced pro-inflammatory cytokines. These mechanisms have been characterized primarily in vitro and in animal models, with the NAPS trial also tracking inflammatory markers in human subjects.

RCT evidence in T2DM and metabolic syndrome populations shows neem extract significantly reduces circulating inflammatory markers including IL-6, TNF-α, and hsCRP. Preclinical mechanistic data point to inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes by neem limonoids. The PMC review (2021) confirms that neem extracts reduce proinflammatory cytokine release.

Stinging nettle (Urtica dioica) has documented anti-inflammatory activity supported by both mechanistic in vitro/in vivo research and human clinical trials. Its primary mechanism involves inhibition of the NF-κB transcription factor, suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-17), and inhibition of COX and 5-lipoxygenase enzymes. A randomized double-blind placebo-controlled trial in rheumatoid arthritis patients demonstrated significant reductions in DAS28 disease activity scores, CRP, and IL-17 following supplementation. The evidence base, while promising, is still limited in scale and warrants larger confirmatory trials.

Clinical trials have shown NR supplementation reduces circulating inflammatory cytokines in humans. In a randomized, double-blind, placebo-controlled crossover trial of 12 aged men supplemented with 1 g/day NR for 21 days, NR significantly depressed levels of circulating inflammatory cytokines. In heart failure patients, NR at 2 g/day correlated with decreased pro-inflammatory cytokine expression in peripheral blood mononuclear cells. These findings are consistent across multiple small human trials.

NMN activates the NAD+/SIRT1 pathway, which suppresses NF-κB and NLRP3 inflammasome activity, reducing pro-inflammatory cytokine signaling. In vitro studies in human primary endothelial cells and preclinical sepsis models demonstrate NMN attenuates inflammatory responses. A 2025 human skeletal muscle biopsy study found NMN suppressed exercise-induced TNF-α and IL-10 mRNA.

Nopal contains polyphenols, betalains, flavonoids, and omega-3 fatty acids documented to exert anti-inflammatory activity. Human trials show reductions in C-reactive protein with nopal-containing formulas in metabolic syndrome patients. In vitro and animal studies document suppression of TNF-α, IL-1β, and NF-κB pathways. A double-blind, placebo-controlled crossover trial (N=64) showed nopal extract significantly reduced markers of inflammation associated with alcohol hangover.

C. rotundus extracts demonstrate consistent anti-inflammatory activity in multiple animal models, including carrageenan-induced paw edema. The sesquiterpene constituents (cyperene, cyperotundone) and flavonoids are identified as key mediators. Inhibition of nitric oxide and prostaglandin synthesis has been documented in vitro.

Oat avenanthramides are unique polyphenols that inhibit NF-κB activation and suppress proinflammatory cytokine expression in endothelial cells. RCTs show avenanthramide supplementation significantly reduces exercise-induced inflammation markers. β-glucan also modulates inflammatory pathways via gut microbiota and SCFA production.

Okra contains flavonoids (quercetin, isoquercitrin, rutin) that suppress pro-inflammatory cytokines including TNF-α, IL-6, and MCP-1 in preclinical models. A 2023 double-blind clinical trial reported significant reductions in C-reactive protein with okra powder supplementation. In vitro and animal studies consistently show downregulation of NF-κB-driven inflammatory pathways.

OA is a well-documented natural anti-inflammatory agent. It inhibits NF-κB, COX-2, and iNOS, suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and reduces endothelial cell adhesion molecule expression. Anti-inflammatory effects have been reproduced across numerous in vitro and animal models.

Oleic acid and its derivative OEA exert anti-inflammatory effects through PPAR-α activation and downregulation of pro-inflammatory cytokines. Human dietary trials with oleic acid-rich oils show reductions in inflammatory markers in at-risk populations. OEA supplementation RCTs document improvements in inflammation and oxidative stress markers.

Olive leaf extract and its phenolic components oleuropein, hydroxytyrosol, oleacin, and oleuropein-aglycone have demonstrated anti-inflammatory activity in both in vitro human cell models and some clinical contexts. They suppress NF-κB signaling and reduce pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Human RCT evidence on standalone inflammatory biomarker outcomes is modest.

EVOO and its polyphenols (oleocanthal, hydroxytyrosol, oleuropein) are extensively documented to reduce systemic inflammatory biomarkers in human clinical trials. Oleocanthal inhibits COX-1 and COX-2 in a manner analogous to ibuprofen. A meta-analysis of 30 human intervention studies confirmed amelioration of inflammatory and antioxidant status across a broad population.

Omega-3 fatty acids (EPA and DHA) have well-documented anti-inflammatory effects supported by extensive human clinical trial data. They reduce key biomarkers of chronic inflammation—CRP, IL-6, and TNF-α—through multiple molecular mechanisms. Evidence spans randomized controlled trials in populations with rheumatoid arthritis, cardiovascular disease, metabolic syndrome, and other chronic inflammatory conditions.

Omega-6 PUFAs, especially arachidonic acid (AA), are precursors to both pro-inflammatory eicosanoids (prostaglandins, leukotrienes) and anti-inflammatory lipid mediators, making their role in chronic inflammation complex and bidirectional. Meta-analyses indicate dietary omega-6 does not significantly raise CRP or other inflammatory markers in humans, and the Framingham Offspring Study (n=2,777) found inverse associations between red blood cell LA and several inflammatory biomarkers.

Palmitoleic acid (omega-7) has demonstrated anti-inflammatory effects in human trials, primarily via reductions in high-sensitivity C-reactive protein (hs-CRP). A randomized controlled trial using 210 mg/day of purified palmitoleic acid reported a 43% reduction in CRP after 30 days in individuals with elevated baseline levels. A separate placebo-controlled crossover RCT (Sasagawa et al., Nutrients 2021), however, found no significant change in serum hsCRP, TNF-α, or IL-6 with 688 mg/day omega-7 over 8 weeks, illustrating inconsistency in the evidence.

Oleic acid (omega-9) reduces the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, partly through inhibition of NF-κB signaling. Research in both animal sepsis models and human dietary intervention studies supports an anti-inflammatory role. The primary mechanism involves PPAR-γ activation and modulation of leukocyte trafficking.

Onion and its constituents, particularly quercetin and thiosulfinates, inhibit key inflammatory pathways including NF-κB signaling and pro-inflammatory cytokine release. Human trial data show reductions in inflammatory biomarkers such as CRP and AST with onion supplementation. These effects underpin many of onion's other documented health benefits.

Multiple compounds in Ophiopogon japonicus—including ophiopogonin D, ruscogenin, and homoisoflavonoids—suppress pro-inflammatory mediators such as TNF-α, IL-6, IL-1β, and NF-κB in cell and animal models. The herb has a long TCM history of treating acute and chronic inflammatory conditions. Evidence remains largely preclinical.

Phytochemical and cell-based studies show ophiopogon root extracts suppress pro-inflammatory cytokines (IL-1β, IL-6, IL-8) and inhibit NF-κB and MAPK signaling pathways. A published study using hydrogen-peroxide-induced senescent human dermal fibroblasts (NHDFs) found Ophiopogonis Radix suppressed the senescence-associated secretory phenotype, linking anti-inflammatory activity to anti-aging biology. The homoisoflavonoids and β-fructan polysaccharides are the principal active fractions.

Multiple RCTs show that orange-derived hesperidin significantly reduces systemic inflammatory markers, including C-reactive protein (CRP), ICAM-1, and VCAM-1. A 2024 meta-analysis of 12 trials demonstrated statistically significant CRP reduction (WMD −0.56 mg/L). Orange polyphenols modulate NF-κB and inflammatory cytokine pathways.

Carvacrol and thymol, the primary phenolic constituents of oregano essential oil, inhibit COX-2 and suppress NF-κB signaling, reducing prostaglandin synthesis and pro-inflammatory cytokines such as IL-6 and TNF-α. Evidence comes from in vitro and animal model studies; direct human clinical data remain limited. Nevertheless, the molecular mechanisms are well characterized and replicated across multiple research groups.

M. aquifolium bark extract inhibits both 5-lipoxygenase and cyclooxygenase enzymes, key mediators of the inflammatory cascade. Mahonia aquifolium flower and fruit extracts reduced serum TNF-alpha and nitric oxide in a rat inflammation model. Berberine from Oregon grape suppresses NF-κB, TNF-alpha, iNOS, and COX-2 in multiple in vitro and in vivo studies. Clinical anti-inflammatory data are primarily from berberine trials, not Oregon grape whole-herb studies.

Leaf extracts of P. orientalis show well-documented anti-inflammatory activity across multiple in vitro and in vivo preclinical models. Chloroform fractions and pure diterpene compounds inhibit pro-inflammatory enzymes and suppress TNF-α and nitric oxide production in LPS-stimulated macrophages. This pharmacological finding is consistent with the plant's traditional use for inflammatory airway and joint conditions.

Rice bran (Oryza sativa) and its bioactives, particularly γ-oryzanol, ferulic acid, and anthocyanins, have demonstrated anti-inflammatory activity in both in vitro macrophage assays and animal models, reducing TNF-α, IL-6, PGE2, and COX-2 expression. Human clinical data on inflammatory biomarkers also exist for rice bran supplementation in older adults.

In vitro and animal studies demonstrate that oyster mushroom concentrate inhibits NF-κB and AP-1 signaling, suppressing TNF-α, IL-6, COX-2, and nitric oxide. A human RCT combining Pleurotus eryngii with antioxidants and vitamin D2 showed reductions in CRP and TNF-α. Direct human-only RCTs on P. ostreatus for inflammation are limited but emerging.

Multiple preclinical studies confirm P. foetida possesses significant anti-inflammatory activity. The butanol fraction of methanol leaf extract inhibited granulation tissue formation and demonstrated membrane-stabilizing activity in rat models. Proposed mechanisms include NF-κB inhibition, COX-2 suppression, and TNF-α/IL-1β reduction.

Palm oil's tocotrienol-rich fraction (TRF) exhibits anti-inflammatory activity in both preclinical and human studies. Tocotrienols suppress pro-inflammatory cytokines (TNF-α, IL-6) and inhibit NF-κB pathways. A systematic review and meta-analysis of RCTs confirmed that tocotrienol supplementation reduces markers of inflammation in humans.

Palmitic acid is a direct ligand for Toll-like receptor 4 (TLR4) on human immune cells, triggering NF-κB activation and pro-inflammatory cytokine release including IL-1β, IL-6, and TNF-α. This has been demonstrated in human dendritic cells, macrophages, and myotubes. Elevated circulating palmitic acid is positively associated with systemic inflammatory markers in clinical cohort data.

POA inhibits pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in experimental models. A small RCT found that 220 mg/day of purified POA for 30 days significantly reduced hs-CRP; a larger 2025 RCT at higher doses did not replicate this finding, indicating that the anti-inflammatory effect may be dose- and population-dependent.

Papain is a proteolytic enzyme with documented anti-inflammatory mechanisms, including degradation of pro-inflammatory proteins and immune complexes. Multiple small clinical trials using papain alone or in enzyme blends have demonstrated reductions in postoperative swelling and pain. In vitro and animal studies support inhibition of MAPK and STAT inflammatory pathways. The overall clinical evidence in humans is promising but limited in scale.

In vitro and animal studies consistently show that papaya extracts suppress inflammatory mediators including TNF-α, IL-1β, IL-6, and NF-κB. A clinical RCT using fermented papaya gel in periodontitis patients demonstrated normalization of elevated IL-1β, IL-6, and IL-10 levels, providing the strongest human-level evidence. A 2016 systematic review in Immunopharmacology and Immunotoxicology concluded that while mechanistic evidence is substantial, clinical human trials are limited.

Parsley flavonoids—particularly apigenin and luteolin—demonstrate anti-inflammatory activity across multiple in vitro and animal models, inhibiting NF-κB, reducing pro-inflammatory cytokines (IL-1β, IL-6), and suppressing COX-mediated pathways. A 2024 PMC study validated these mechanisms in human keratinocytes via JAK/STAT and NF-κB modulation.

Parthenolide, the main bioactive of feverfew, has been mechanistically characterised as a direct inhibitor of IKKβ and NF-κB, suppressing TNF-α, IL-1, IL-6, IL-8, and other pro-inflammatory cytokines. Animal and cell studies are robust; one small human RCT assessed immunological markers. This constitutes scientific evidence at the mechanistic and early clinical level.

Carica papaya preparations demonstrate anti-inflammatory activity through inhibition of NF-κB signalling, downregulation of pro-inflammatory cytokines (IL-6, IL-8, TNF-α), and antioxidant mechanisms. Clinical evidence includes a randomised trial showing significant reductions in IL-6 and IL-8 in post-COVID patients supplemented with fermented papaya. In vitro and animal data additionally support inhibition of inflammatory mediators.

Pea protein hydrolysates contain anti-inflammatory bioactive peptides. Pea fiber fermentation produces SCFAs that reduce systemic inflammation markers. An 84-day RCT measured CRP as a secondary outcome alongside pea protein supplementation.

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide with well-documented anti-inflammatory properties supported by both preclinical and human clinical evidence. Its primary mechanism involves activation of the nuclear receptor PPAR-α, which suppresses the NF-κB pathway and reduces pro-inflammatory mediators such as TNF-α, IL-1β, iNOS, and COX-2. Multiple RCTs and systematic reviews confirm its efficacy in chronic inflammatory pain conditions, including osteoarthritis and neuropathic pain. Evidence quality is promising but limited by heterogeneity across trials and a need for larger, more rigorous RCTs.

Peach extracts have been shown to reduce pro-inflammatory cytokines TNF-α and IL-1β in ex vivo and in vitro models. Peach kernel extracts inhibit NF-κB signaling and reduce inflammatory mediators. Evidence is preclinical; no human trials exist yet.

Peanuts contain polyphenols including resveratrol and flavonoids with documented anti-inflammatory activity. Clinical and epidemiological evidence from nut-consumption studies associate regular intake with reductions in inflammatory markers. Peanuts' unsaturated fats and bioactive compounds contribute to reduction of oxidative stress and inflammation.

Pear extracts demonstrate anti-inflammatory activity in vitro by inhibiting COX-1 and COX-2 enzymes. Key bioactives include triterpenoids (ursolic acid, oleanolic acid), quercetin, and chlorogenic acid. Pear peel contains 6–20× higher concentrations of these compounds than the flesh, and varieties with higher total phenolics show significantly greater anti-inflammatory capacity.

Pectin exhibits anti-inflammatory activity through multiple pathways including NF-κB inhibition, galectin-3 binding (modified citrus pectin), and SCFA-mediated effects on immune cells. Evidence spans in vitro, animal, and early human studies. Low-methoxyl pectin inhibits systemic inflammation while high-methoxyl pectin acts preferentially in the gut.

Preclinical studies, including a 2025 study published in Frontiers in Immunology, demonstrate that T. arvense extract inhibits TNF-α-mediated NF-κB inflammatory pathway activation in intestinal tissue. Its constituent isovitexin has been shown to directly mitigate TNF-α-induced epithelial cell damage. Pharmacological investigations have also validated anti-inflammatory and antioxidant capacities in compound formulations.

Total glucosides of peony (TGP) and its primary constituent paeoniflorin exhibit well-documented anti-inflammatory activity, inhibiting COX-2, prostaglandin E2, leukotriene B4, and NF-κB signaling. These effects have been validated in clinical settings for inflammatory conditions including rheumatoid arthritis and SLE.

Peptidase (proteolytic) enzymes have demonstrated anti-inflammatory activity in multiple clinical studies. They are proposed to neutralize pro-inflammatory mediators and modulate cytokine profiles. Evidence comes from trials using systemic enzyme therapy in musculoskeletal and post-exercise inflammatory states. Results are promising but often from small or industry-linked trials.

Perilla is rich in rosmarinic acid, luteolin, and apigenin, all of which suppress key pro-inflammatory mediators including NF-κB, TNF-α, and multiple interleukins. Preclinical models consistently demonstrate reduced inflammatory cytokine production. Human clinical data remain limited but support the anti-inflammatory rationale, particularly in allergic and skin inflammatory contexts.

P. amurense extract (Nexrutine) and its alkaloids berberine and palmatine exert anti-inflammatory effects through NF-κB inhibition, COX-2 suppression, and cytokine reduction demonstrated in preclinical and clinical models. The 8-week clinical RCT with P. amurense plus citrus extract in osteoarthritis patients showed significant reductions in CRP and ESR. Nexrutine is commercially used for inflammation treatment.

PC inhibits TNF-α-induced pro-inflammatory signaling in intestinal and immune cells, potentially by shifting TNF-α receptors into lipid rafts. PC also modulates macrophage polarization and gut microbiota in IBD models. Clinical evidence is primarily derived from the ulcerative colitis setting.

Phytosterols show anti-inflammatory activity in vitro and in animal models by suppressing TNF-α, IL-6, COX-2, and NO production. Human RCT data are inconsistent: some meta-analyses report small but significant CRP reductions with supplementation >4 weeks, while others find no significant effect. The evidence is suggestive but not yet definitive.

P. kurroa extracts inhibit NF-κB signaling, suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and reduce carrageenan-induced edema and granuloma formation in rodent models. This mechanistic evidence is well-documented in peer-reviewed preclinical studies, though clinical trials in chronic inflammatory diseases are lacking.

Pine bark extract is a potent anti-inflammatory agent that reduces TNF-α, IL-1β, IL-6, CRP, and NF-κB signaling in multiple clinical and in vitro studies. These effects have been documented across diverse inflammatory conditions including arthritis, asthma, and venous disease. It is one of the primary documented mechanisms of action for Pycnogenol.

Pycnogenol inhibits key inflammatory pathways including NF-κB, COX-2, 5-LOX, and TNF-α, and lowers circulating CRP in clinical studies. It has been validated as an anti-inflammatory in multiple RCTs spanning cardiovascular, joint, periodontal, and metabolic conditions. The anti-inflammatory mechanism underpins most of its documented clinical benefits.

Bromelain, pineapple's primary bioactive enzyme, exerts well-documented anti-inflammatory effects via multiple mechanisms including inhibition of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and suppression of the arachidonic acid cascade. Multiple RCTs and placebo-controlled trials confirm reductions in inflammatory markers. It is among the most evidence-supported applications for this plant ingredient.

Piperine, the principal alkaloid of black pepper (Piper nigrum), has demonstrated anti-inflammatory activity in preclinical models and several human clinical trials. Its core mechanism involves suppression of the NF-κB and MAPK signalling pathways, reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Human trials—primarily using piperine in combination with curcumin—have reported significant reductions in CRP and other inflammation markers across conditions including metabolic syndrome, IBD, and ischemic stroke. Evidence is strongest in combined-compound studies; isolated piperine human trials remain limited.

Multiple animal studies confirm anti-inflammatory activity of P. integerrima gall extracts using standard in vivo models (carrageenan paw edema, formalin-induced inflammation). Galls were more potent than leaf extracts in reducing inflammation. Mechanisms include inhibition of COX pathways and downregulation of pro-inflammatory cytokines such as TNF-α, IL-4, and IL-5.

Plant sterols have demonstrated anti-inflammatory properties in some human studies, primarily through reductions in CRP and pro-inflammatory cytokines, though clinical results are inconsistent. A meta-analysis noted a significant dose-response relationship for CRP reduction, suggesting higher doses (≥3 g/day) may be required for a meaningful anti-inflammatory effect. In vitro and animal evidence is stronger than the clinical data.

Multiple constituents of Plantago (plantamajoside, aucubin, baicalein, hispidulin, ursolic acid, oleanolic acid) are documented anti-inflammatory agents. In vitro and in vivo studies confirm NF-κB inhibition and cytokine modulation. Psyllium (P. ovata) reduces systemic inflammatory markers through gut microbiota modulation and SCFA production.

Multiple in vitro and in vivo studies have characterized anti-inflammatory mechanisms in Plantago major. Key compounds—aucubin, plantamajoside, ursolic acid, and oleanolic acid—inhibit COX enzymes, histamine release, elastase, and complement activity. These mechanisms are supported at the cellular level, though dedicated human RCTs for chronic inflammatory conditions remain limited.

Platycodin D and related saponins from PG root suppress pro-inflammatory NF-κB, MAPK, PI3K/AKT, and TLR4/MyD88 signaling pathways and reduce cytokines including TNF-α, IL-1β, and IL-6 across multiple in vitro and animal studies. These anti-inflammatory actions underpin many of PG's other documented effects.

Platycodon root extracts and platycodin D consistently suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), nitric oxide, and iNOS across multiple in vitro and in vivo models. The primary mechanism is inhibition of NF-κB, MAPK, and PI3K/AKT signaling pathways. These effects span respiratory, hepatic, skin, and gut inflammation models.

Bioactive compounds from P. tenuifolia—including tenuifolisides (xanthones and phenolic glycosides), triterpenoid saponins, and polygalacic acid—suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, NF-kB, COX-2, iNOS) in multiple in vitro and animal models. This anti-inflammatory activity is well-documented in PMC-indexed research.

Multiple peer-reviewed studies demonstrate that Polygala root extracts suppress key pro-inflammatory pathways including NF-κB, TNF-α, IL-1β, IL-6, COX-2, and iNOS in cell and animal models. A 2020 PMC study isolated compounds with potent cytokine inhibition. These are scientifically documented anti-inflammatory effects.

P. umbellatus polysaccharides inhibit key inflammatory pathways including NF-κB and Wnt/β-catenin in preclinical models. A 2025 PubMed study demonstrated significant reduction in inflammatory mediators and joint damage in a collagen-induced arthritis mouse model.

Pomegranate contains bioactive polyphenols — principally punicalagin and ellagic acid — that suppress key pro-inflammatory pathways (NF-κB, MAPK) and reduce circulating cytokines such as TNF-α, IL-1β, and IL-6. Multiple human RCTs and systematic reviews confirm measurable reductions in inflammatory biomarkers across conditions including rheumatoid arthritis and osteoarthritis. Evidence quality is graded low-to-moderate, limited by small sample sizes and short follow-up durations; larger trials are still warranted.

Pomelo peel coumarins and flavonoids (naringenin, naringin) significantly suppress inflammatory cytokines including TNF-α, IL-1β, and prostaglandin E2 in both cell-based and animal studies. A Journal of Agricultural and Food Chemistry study demonstrated inhibition of xylene-induced ear edema and carrageenan-induced paw edema in mice. Traditional Asian use for inflammation-related conditions (cough, fever, digestive complaints) aligns with these mechanistic findings.

Pregnenolone suppresses pro-inflammatory cytokine production (TNF-α, IL-6) by promoting degradation of TLR2/4 adaptor proteins TIRAP and TLR2 in macrophages and microglial cells. Decreased pregnenolone levels are observed in neuroinflammatory diseases. Its downstream metabolites exert additional anti-inflammatory actions.

Multiple preclinical studies and a 2024 Frontiers in Immunology review (PMC10853423) document that Zanthoxylum polyphenols, alkaloids, and flavonoids exert anti-inflammatory effects in animal models via inhibition of NF-κB, ERK signaling, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). In vitro studies show inhibition of nitric oxide overproduction. No human RCTs have been conducted.

A randomized crossover human trial in 28 healthy volunteers confirmed that short-term prickly pear fruit supplementation significantly improved inflammatory biomarkers and antioxidant status. In vitro and animal studies corroborate anti-inflammatory mechanisms via betalains and flavonoids.

Preclinical studies show FLL and its polysaccharides suppress inflammatory mediators including NF-κB, TNF-α, and NO production in macrophage and colitis models. The secoiridoid and triterpenoid constituents are the primary anti-inflammatory agents. Human data are absent.

Propionate exerts anti-inflammatory effects primarily through histone deacetylase (HDAC) inhibition and modulation of NF-κB signaling, reducing pro-inflammatory cytokine production. In multiple sclerosis patients, propionate supplementation has shown immunoregulatory effects and association with long-term clinical improvement. Evidence comes from preclinical models and emerging human clinical data across multiple inflammatory conditions.

Prune polyphenols (chlorogenic acids, neochlorogenic acids, anthocyanins) suppress key pro-inflammatory markers including TNF-α, IL-1β, and CRP in human studies. A 6-month RCT in postmenopausal women showed 50 g/day significantly improved antioxidant capacity and reduced inflammation biomarkers. Modulation of inflammatory pathways is now considered a primary mechanism for prune's bone- and cardiovascular-protective effects.

Both Prunus africana and Prunus domestica species exhibit documented anti-inflammatory activity. Pygeum bark phytosterols inhibit prostaglandin biosynthesis and ferulic acid esters modulate inflammatory signaling; a 2024 in-vitro study confirmed significant IL-6 reduction. Prune polyphenols (chlorogenic acids, anthocyanins) reduce inflammatory biomarkers IL-6 and TNF-α in human clinical trials.

Multiple preclinical studies show P. marsupium extracts reduce pro-inflammatory cytokines including TNF-α and IL-6. The mechanism involves COX-2 inhibition and suppression of inflammatory signaling in both metabolic and non-metabolic contexts.

Pumpkin seed oil and fruit extracts contain polyunsaturated fatty acids, phytosterols, vitamin E, and carotenoids that collectively reduce inflammatory mediators in animal models. In vivo research demonstrates significant decreases in CRP, fibrinogen, and oxidative stress markers following pumpkin oil administration. Human evidence is largely indirect via nutrient biomarker data.

Punarnava has demonstrated anti-inflammatory activity in animal models and in vitro, with punarnavine and boeravinones identified as key active compounds inhibiting NF-κB and pro-inflammatory cytokines (IL-1β, TNF-α). It is traditionally used for edema and swelling. Rodent studies show meaningful reduction in carrageenan-induced paw edema.

Clinical trials in diabetic and NAFLD populations demonstrate purslane significantly reduces CRP and NF-κB, two key markers of systemic inflammation. A 2023 meta-analysis of 13 RCTs confirmed significant reduction in CRP (WMD: −1.22 mg/L, p<0.001). Purslane's flavonoids, omega-3 fatty acids, and alkaloids mediate suppression of pro-inflammatory cytokines including TNF-α and IL-6.

A human crossover study found PQQ supplementation decreased plasma CRP and IL-6 in all 10 subjects tested. PQQ modulates NF-κB signaling and downregulates neuroinflammatory pathways in vitro. Human evidence is from a small, short-duration study but is consistent with the mechanistic data.

Multiple pre-clinical studies, including in vitro COX inhibition assays and in vivo animal models, document the anti-inflammatory activity of Filipendula ulmaria extracts. Inhibition of COX-1, COX-2, and prostaglandin E2 production has been demonstrated, providing mechanistic scientific evidence. Evidence is preclinical (no human RCTs), but the pharmacological data are published in peer-reviewed journals.

Quercetin, a dietary flavonoid, has demonstrated anti-inflammatory activity across cell, animal, and human studies, primarily by suppressing NF-κB signaling and reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, CRP). A meta-analysis of randomized controlled trials found significant reductions in circulating CRP and IL-6 specifically in participants with diagnosed diseases, though no broad effect was seen across all populations. Evidence strength is moderate: preclinical data are robust, but human RCTs are limited in number, sample size, and duration, and bioavailability remains a key variable.

Quillaja saponin extract has demonstrated dose-dependent anti-inflammatory activity in a carrageenan-induced paw edema murine model. Quillaic acid, the primary aglycone, exhibits strong topical anti-inflammatory activity in mouse models. Evidence is preclinical; no human inflammation trials exist.

A 12-week trial in overweight/obese subjects reported significant reduction in CRP—a key inflammatory biomarker—after daily quinoa consumption. Quinoa's polyphenols, saponins, and flavonoids inhibit pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, NF-κB) in preclinical and cell models. In vivo rat studies with quinoa flour extract demonstrated anti-inflammatory effects comparable to reference drugs.

Radish seeds and roots contain isothiocyanates and sulforaphane precursors that have demonstrated anti-inflammatory effects in preclinical models, including suppression of the NF-κB/p38 MAPK pathway. Animal studies using ApoE-knockout mice showed reduced aortic plaque and inflammatory markers after radish extract treatment. Evidence is preclinical; no human trials have specifically evaluated radish for inflammation.

Raspberry polyphenols—primarily anthocyanins and ellagitannins—suppress key inflammatory signaling pathways including NF-κB, MAPK, COX-2, and JAK-STAT in preclinical studies. In vitro work confirms inhibition of pro-inflammatory enzymes LOX and COX-2. A 2019 systematic review of berry consumption in humans found significant reductions in CRP and TNF-alpha across randomized controlled trials. Raspberry-specific human trials on chronic inflammation biomarkers remain limited.

Red clover isoflavones and anthocyanins have demonstrated anti-inflammatory activity in preclinical models, suppressing key pro-inflammatory pathways. In vitro, red clover isoflavones reduced expression of TNF-α, IL-1β, iNOS, and COX-2 in LPS-stimulated macrophages via NF-κB and p38 MAPK inhibition. Human clinical evidence for systemic inflammation remains largely indirect through cardiovascular and menopausal studies.

Clinical trials and meta-analyses report that RYR reduces high-sensitivity CRP (hs-CRP), a key systemic inflammatory biomarker, in dyslipidemic and metabolic syndrome populations. The anti-inflammatory effect appears to be partly indirect, mediated through lipid lowering and endothelial protection, rather than direct cytokine blockade. A 2022 triple-blind RCT (n=92) and several other trials have measured and confirmed hs-CRP reductions with RYR supplementation.

Rehmannia extracts suppress multiple pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, NF-κB) across a range of experimental models. A Korean literature review of 30 publications confirmed anti-inflammatory efficacy across dermatitis, arthritis, and metabolic disease models. The active constituent catalpol is particularly studied as the primary mediator of these effects.

R. glutinosa root extracts and isolated polysaccharides exhibit significant anti-inflammatory activity across multiple in vitro and animal models. Key mechanisms include inhibition of NF-κB, COX-2, iNOS, TNF-α, IL-1β, and IL-6. Catalpol suppresses AGE-mediated inflammation by blocking reactive oxygen species and NF-κB activation.

Reishi beta-glucans and triterpenes modulate NF-κB and suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in multiple in vitro and animal models. Human clinical studies in cancer patients showed reduced fatigue and inflammatory burden. The Memorial Sloan Kettering Cancer Center and peer-reviewed reviews confirm anti-inflammatory activity across preclinical models, with limited but supportive human data.

Resveratrol, a polyphenolic compound found in grapes and berries, has documented anti-inflammatory activity supported by multiple randomized controlled trials and meta-analyses in humans. Clinical meta-analyses confirm significant reductions in key inflammatory biomarkers—particularly TNF-α and hs-CRP—following supplementation. Results across studies are promising but show meaningful heterogeneity, and no consensus dosing regimen has been established for any specific inflammatory condition.

Rhodiola rosea and its active compounds (salidroside, rosavins) suppress key pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, and inhibit NF-κB and MAPK signaling pathways. A double-blind RCT (Abidov 2004, n=36) found CRP blood levels were lower at 5 hours and 5 days post-exercise in the Rhodiola group versus placebo. Evidence is primarily pre-clinical, with limited but existing human biomarker data. A 2019 review in Biomedicine & Pharmacotherapy confirmed protective effects across cardiovascular, neurodegenerative, and metabolic disease models.

Rhubarb's anthraquinones, particularly emodin and rhein, exert multi-target anti-inflammatory effects that have been validated in clinical and preclinical contexts. Clinical trials in pancreatitis and sepsis show significant reductions in inflammatory cytokines (IL-6, CRP, TNF-α) with rhubarb treatment. The EMA and multiple systematic reviews acknowledge this pharmacological activity.

Rhubarb root's anthraquinone constituents—especially emodin—possess well-characterized anti-inflammatory properties demonstrated in multiple preclinical and some clinical contexts. Clinical trials in SAP, sepsis, and ulcerative colitis provide indirect human evidence of its anti-inflammatory action in vivo.

Robusta coffee contains caffeine, chlorogenic acids, and other polyphenols documented to have anti-inflammatory properties. Preclinical and epidemiological evidence links these compounds to modulation of neuroinflammatory and systemic inflammatory pathways. Robusta coffee husk, which contains flavonoids and phenols, has been documented as anti-inflammatory in experimental models.

Rosehip (Rosa canina) contains specific galactolipids with documented anti-inflammatory action, reducing leukocyte chemotaxis and CRP in clinical studies. A standardized rosehip powder demonstrated antioxidant and anti-inflammatory activity in multiple RCTs involving arthritis patients. Unlike NSAIDs, rosehip's anti-inflammatory action does not cause gastric ulceration or platelet inhibition.

Rose hip extracts demonstrate documented anti-inflammatory activity through inhibition of COX-1/2, 5-LOX, and NF-κB signaling, and reduction of pro-inflammatory cytokines. Clinical studies in osteoarthritis and rheumatoid arthritis populations confirm reduced inflammatory markers. The galactolipid GOPO is considered a principal bioactive. Anti-inflammatory effects are well-replicated across multiple in vitro and clinical models.

Rosemary's anti-inflammatory bioactives—rosmarinic acid, carnosic acid, carnosol, and ursolic acid—inhibit NF-κB, COX-2, TNF-α, and IL-6 pathways, well established in preclinical models. A 2025 double-blind RCT in rheumatoid arthritis patients confirmed significant reductions in CRP and ESR after 12 weeks of rosemary leaf powder, providing direct human evidence of systemic anti-inflammatory effects.

Rosmarinic acid exerts well-characterized anti-inflammatory actions via inhibition of NF-κB, COX-2, and 5-LOX pathways, reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and complement inhibition. These mechanisms have been confirmed in vitro and in multiple in vivo animal models. A human clinical trial confirmed RA reduces neutrophil and eosinophil infiltration in allergic (inflammatory) conditions, providing direct human anti-inflammatory evidence.

A 2025 systematic review and meta-analysis of 6 RCTs found RJ significantly reduced the oxidative stress marker MDA and increased total antioxidant capacity (TAC), though hs-CRP (a key inflammatory marker) was not significantly lowered. RJ also reduced CRP by 19% in one well-controlled trial of overweight adults.

R. cordifolia and its primary constituent mollugin have demonstrated significant anti-inflammatory activity in preclinical models, inhibiting TNF-α, IL-6, IL-1β, COX-2, and the NF-κB signaling pathway. Ethanolic and methanolic extracts have shown activity comparable to standard anti-inflammatory drugs in rat models. These effects are mechanistically attributed to mollugin's inhibition of the TAK-1-mediated NF-κB/MAPK axis.

Rutin inhibits NF-κB and MAPK signaling and suppresses pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 in human macrophage cell culture and in vivo models. Human clinical trials in diabetic patients showed reductions in IL-6 and oxidative stress markers with rutin supplementation.

Rye contains alkylresorcinols, benzoxazinoids, and phenolic acids with demonstrated anti-inflammatory properties. A randomized crossover study in men with prostate cancer showed that a whole-grain/bran rye diet significantly reduced TNF-R2, e-selectin, and endostatin versus refined wheat. Rye's fermentable fiber also reduces fasting IL-1β. Evidence from large epidemiological cohorts is more limited and mixed.

S. boulardii inhibits key inflammatory signaling pathways including NF-κB and MAP kinases (ERK1/2, p38), reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8 while upregulating anti-inflammatory mediators. Clinical evidence from IBD and cirrhosis RCTs confirms reductions in inflammatory markers. These effects underpin its utility across multiple chronic inflammatory gastrointestinal conditions.

Safflower flavonoids—particularly HSYA and safflomin C—reduce inflammatory mediators including NF-κB, TNF-α, and IL-6 in cell and animal studies. A 2025 Frontiers in Nutrition review confirmed broad anti-inflammatory pharmacological activity. Indian traditional medicine uses safflower for arthritis and inflammatory conditions; Persian and Chinese traditions also cite anti-inflammatory applications.

Human RCTs show saffron supplementation significantly reduces pro-inflammatory cytokines including IL-6, TNF-α, and CRP. Effects are attributed to crocin and crocetin inhibiting the NF-κB signaling pathway and exerting antioxidant activity. Observed benefits span conditions including type 2 diabetes, rheumatoid arthritis, and metabolic syndrome.

Sage extract has demonstrated significant anti-inflammatory activity in multiple human cell-based models, reducing release of pro-inflammatory cytokines. Animal studies show reduced TNF-α, IL-12, and KC/GRO with simultaneous elevation of anti-inflammatory cytokines. Key constituents include rosmarinic acid, carnosic acid, and ursolic acid.

Salicin and the broader polyphenol matrix in willow bark inhibit COX-1, COX-2, lipoxygenase (LOX), TNF-α, and NF-κB, producing a multi-pathway anti-inflammatory effect documented in both in vitro and clinical studies. German Commission E has approved willow bark for inflammatory rheumatic conditions. Evidence is mechanistic and supported by clinical biomarker data.

Multiple preclinical studies demonstrate that Smilax extracts suppress key inflammatory mediators including NF-κB, TNFα, IL-6, and nitric oxide. A 2019 PubMed-indexed study confirmed significant anti-inflammatory and analgesic effects of Smilax ornata (Jamaican sarsaparilla) extracts in animal models. The evidence is preclinical; human trials are lacking.

Saw palmetto extract inhibits both cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways, blocking biosynthesis of inflammatory prostaglandins and leukotrienes. In vitro and animal studies robustly demonstrate anti-inflammatory and anti-edematous effects. This mechanism is considered integral to its benefit in BPH, where prostatic inflammation contributes to lower urinary tract symptoms. Direct human RCTs targeting chronic inflammation as a primary endpoint are lacking.

In vitro and animal studies show sceletium alkaloids, particularly mesembrine, exert cytoprotective and mild anti-inflammatory effects, modulating IL-6 and MCP-1 cytokines and reducing inflammatory markers. Inhibition of adrenal glucocorticoid synthesis via CYP17A1 provides a further anti-inflammatory dimension. Evidence remains preclinical.

Multiple preclinical studies across cell lines and animal models demonstrate that schisandrin A, B, and C suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) via NF-κB inhibition and NRF2 activation. The anti-inflammatory mechanism is well-characterized at the molecular level, though dedicated human RCTs specifically for chronic inflammatory conditions are not yet published.

Multiple preclinical studies confirm Schizonepeta suppresses key inflammatory mediators (NF-κB, MAPK, COX-2, TNF-α, IL-1β, IL-6) across cell and animal models. A 2025 systematic review of 13 preclinical studies confirmed anti-inflammatory mechanisms via multiple pathways. Evidence is preclinical; no human RCTs for chronic inflammation as a standalone endpoint exist.

Poria cocos sclerotium polysaccharides and triterpenes demonstrate anti-inflammatory activity in multiple preclinical models, reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β via NF-κB pathway inhibition. Reviews confirm this as one of the established pharmacological effects of the sclerotium.

Anti-inflammatory activity is one of the best-documented pharmacological properties of Scrophularia root. Multiple in vitro and in vivo studies have confirmed suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inhibition of the NF-κB pathway. Iridoid and phenylpropanoid glycosides are the primary active constituents mediating these effects.

SDG suppresses pro-inflammatory signaling through inhibition of the NF-κB pathway, reduction of TNF-α, IL-6, and CRP, and downregulation of inflammatory mediators in endothelial cells, cardiomyocytes, and colon tissue. Human RCT data show reductions in CRP and IL-6 with 600 mg SDG/day in type 2 diabetics. Animal models across multiple organ systems consistently demonstrate anti-inflammatory activity.

Selenium is an essential trace element that exerts documented anti-inflammatory effects primarily through its incorporation into selenoproteins, which regulate oxidative stress and key inflammatory signaling pathways. Clinical evidence from randomized controlled trials and meta-analyses shows selenium supplementation can reduce circulating inflammatory markers—notably CRP and IL-6—particularly in populations with elevated baseline inflammation. Evidence strength varies by route of administration and population, with intravenous selenium showing more consistent CRP-lowering effects than oral supplementation in critically ill patients.

Selenomethionine suppresses the NF-κB signaling pathway and downstream pro-inflammatory cytokines (IL-6, TNF-α, CRP), thereby attenuating chronic inflammatory responses. In both human inflammatory diseases and animal models, selenium supplementation restores depleted hepatic and serum selenium levels and increases selenoprotein biosynthesis, leading to reduced CRP production. Evidence from clinical contexts includes autoimmune thyroiditis, sepsis, and systemic inflammatory response syndrome.

Serratiopeptidase has been studied across multiple clinical specialties for its anti-inflammatory effects, including reducing inflammatory cytokines and adhesion molecules. A 2013 systematic review (Bhagat et al., Int J Surg) identified 14 RCTs covering inflammatory conditions. Evidence quality is generally rated poor to moderate, with small sample sizes, but a consistent direction of benefit is reported. It has been in clinical use in Japan and Europe for ~40 years for this purpose.

A meta-analysis of seven RCTs (310 participants) examined sesame's effect on inflammatory biomarkers; individual trials show reductions in MDA, hs-CRP, IL-6, and TNF-α, though pooled results are mixed. Sesame lignans (sesamin, sesamol) and phenolic compounds inhibit NF-κB signaling and suppress pro-inflammatory cytokine production. Evidence is present but inconsistent across studies.

Shea butter contains triterpene cinnamates and acetates that have documented anti-inflammatory activity in cell and animal models via NF-κB pathway inhibition. The most potent isolated compound, lupeol cinnamate, suppresses iNOS, COX-2, TNF-α, IL-1β, and IL-12. Human clinical evidence for systemic anti-inflammatory effects remains limited; the evidence base is primarily mechanistic and preclinical.

In vitro studies on Rumex acetosella rhizome extracts have demonstrated significant inhibition of COX-1 enzymes involved in the arachidonic acid inflammatory cascade. Traditional use for soothing inflammation is also documented across multiple herbal systems. No human clinical trials exist.

Multiple in vitro and preclinical studies demonstrate anti-inflammatory activity of Capsella bursa-pastoris extracts, including inhibition of nitric oxide, prostaglandin E2, TNF-α, and IL-6 in LPS-stimulated cell models. Phenolic glycosides isolated from aerial parts show moderate inhibition of nitric oxide in microglial cells. Evidence is preclinical; no human trials for chronic inflammatory conditions exist.

The Dai et al. (2015) randomized trial in 52 healthy adults showed daily shiitake consumption for 4 weeks significantly reduced serum CRP by approximately 30% and shifted cytokine profiles toward a less inflammatory state. Lentinan from shiitake inhibits inflammatory signaling pathways in preclinical models. Evidence is most robust for low-grade systemic inflammation.

Z. bungeanum polyphenols and essential-oil fractions suppress pro-inflammatory mediators (TNF-α, IL-6, COX-2, NF-κB) in multiple cell and animal models. Preclinical evidence covers ulcerative colitis, arthritis, asthma, and COPD models. Some clinical trials have utilised Z. bungeanum polyphenols, though direct human anti-inflammatory trials remain limited.

Multiple in vitro and in vivo studies confirm that SD's chromone and coumarin constituents inhibit NF-κB and MAPK signaling, suppressing production of NO, PGE2, TNF-α, and IL-6 in macrophage and animal models. These anti-inflammatory mechanisms are well-characterized at a molecular level. Evidence is primarily preclinical, with no large human trials.

A. julibrissin demonstrates anti-inflammatory activity in multiple in vitro and in vivo models. Triterpenoid saponins inhibit nitric oxide production in LPS-stimulated macrophages, while flavonoids quercetin and kaempferol suppress pro-inflammatory pathways. Anti-inflammatory use is also documented in traditional medicine.

Silymarin, a flavonolignan complex extracted from milk thistle (Silybum marianum), has documented anti-inflammatory activity supported by both mechanistic research and human clinical trials. It suppresses key pro-inflammatory signaling cascades—notably NF-κB, MAPK, and JAK-STAT3—reducing cytokines such as TNF-α, IL-1β, and IL-6 while elevating the anti-inflammatory cytokine IL-10. A 2025 meta-analysis of 11 randomized controlled trials found statistically significant reductions in CRP and oxidative stress markers, though evidence for long-term effects on chronic inflammation remains incomplete.

Baicalin and baicalein from S. baicalensis are extensively studied anti-inflammatory compounds, inhibiting NF-κB, COX-2, iNOS, and multiple pro-inflammatory cytokines in preclinical models. Clinical use in China for inflammatory conditions spans centuries, and baicalin has been involved in clinical trials for inflammatory diseases including acute pulmonary infection and gastrointestinal inflammation.

Ex vivo laboratory studies in IBD patient tissue demonstrated anti-inflammatory and antioxidant effects of slippery elm extract, with superoxide scavenging activity comparable to 5-ASA. The inner bark tannins and polyphenols also contribute documented anti-inflammatory activity. These are in vitro findings; no controlled human trials of slippery elm for systemic chronic inflammation have been conducted.

Multiple preclinical studies demonstrate that P. hydropiper extracts suppress pro-inflammatory mediators including TNF-α, IL-1β, NF-κB, COX-2, and iNOS. Both in vitro and in vivo models (rats, macrophages) confirm dose-dependent anti-inflammatory activity. The primary active constituents responsible are flavonoids, particularly rutin, quercitrin, and quercetin.

Multiple in vitro and animal studies demonstrate anti-inflammatory activity for Smilax extracts and their isolated flavonoids. Key constituents astilbin and related stereoisomers suppress NF-κB signalling, inhibit IL-1β, IL-6, and TNF-α production, and reduce nitric oxide in LPS-stimulated macrophage models. Evidence remains at pre-clinical (animal/cell) level without confirmed human RCTs.

Laboratory evidence shows that A. majus extract suppresses key mediators of inflammation in macrophage cell models, including iNOS, COX-2, nitric oxide, and pro-inflammatory cytokines. This in vitro scientific evidence is supported by traditional use as an antiphlogistic. No human clinical trials have been conducted.

In vitro studies of P. sibiricum rhizome extracts show inhibition of inflammatory markers including nitric oxide, TNF-alpha, and interleukins. Flavonoids and polysaccharides are the primary anti-inflammatory constituents identified in peer-reviewed phytochemical reviews. Clinical human data are lacking.

Sophora flavescens alkaloids (matrine, oxymatrine) and flavonoids (rutin, quercetin) from both Sophora species demonstrate anti-inflammatory activity in multiple in vitro and in vivo studies. Flavonoid constituents suppress pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. These mechanisms are supported by pharmacological research and form the basis of licensed TCM preparations.

A. muricata leaf and fruit extracts demonstrate anti-inflammatory activity in multiple rodent models, suppressing pro-inflammatory cytokines such as TNF-α and IL-1β. The plant has been extensively identified as an anti-inflammatory agent in both in vitro and in vivo pharmacological studies. Traditional use across Africa and South America also supports this application.

Soy isoflavones and protein have been studied for anti-inflammatory effects. Meta-analyses show mixed results on CRP overall, but subgroup analyses and RCTs in diabetic/metabolic syndrome patients show significant CRP reductions. Isoflavones suppress NF-κB, TNF-α, and IL-6 through multiple pathways.

Soy isoflavones modulate key inflammatory signaling pathways and have been examined for their effect on C-reactive protein (CRP) in multiple RCTs. Overall evidence shows a non-significant average CRP reduction, though subgroup analyses favor older participants with higher baseline CRP.

Soy isoflavones have demonstrated anti-inflammatory activity in clinical studies, with meta-analyses showing reductions in the inflammatory marker CRP in postmenopausal women. Genistein inhibits tyrosine kinase signaling involved in pro-inflammatory pathways. Animal and clinical studies show soy isoflavones can down-regulate TNF-α and other pro-inflammatory mediators.

Spearmint's primary bioactive, rosmarinic acid, exerts well-characterized anti-inflammatory effects by inhibiting NF-κB and COX-2 pathways. Spearmint phenolic extracts have reduced acute and chronic colon inflammation in rodent colitis models. Clinical evidence in humans is indirect, largely through the osteoarthritis trials.

S. indicus extracts have documented anti-inflammatory activity in multiple preclinical models, inhibiting pro-inflammatory cytokines, NF-κB, and adhesion molecules. Standardized extract NPS31807 reduced pro-inflammatory cytokines from human macrophages in vitro. The active sesquiterpene 7-hydroxy frullanoide is a key mechanistic constituent.

Spinach contains flavonoids, carotenoids, and polyphenols that modulate inflammatory pathways by scavenging reactive oxygen species and downregulating pro-inflammatory gene expression. Exercise-induced inflammatory markers including IL-6 were attenuated with spinach supplementation in a small human RCT.

Spirulina has human clinical and meta-analytic evidence supporting a moderate anti-inflammatory effect, primarily demonstrated through reductions in CRP, IL-6, and TNF-α. Its key bioactive compound, C-phycocyanin, inhibits COX-2 and suppresses NF-κB signaling, two central pathways in chronic inflammation. A 2025 systematic review and meta-analysis of 22 RCTs (5,385 participants) found significant reductions in CRP (SMD: −0.972), IL-6 (SMD: −0.532), and TNF-α (SMD: −0.579). Evidence is promising but tempered by heterogeneity across trials and variability in study quality.

SPMs (resolvins, protectins, maresins, lipoxins) are endogenous lipid mediators that actively terminate the inflammatory cascade rather than merely suppressing it. Reduced SPM levels have been documented in human tissues across a wide range of chronic inflammatory diseases. Clinical and translational studies confirm that SPM deficiency correlates with failure of inflammation resolution. Omega-3 supplementation in humans raises circulating SPM levels.

Picea abies bark contains abundant polyphenolic stilbenes, lignans, and flavonoids with documented anti-inflammatory activity, including suppression of TNF-α, IL-1β, and IL-8. In vitro studies show spruce resin extract at 20% concentration suppresses pro-inflammatory cytokines comparably to a corticosteroid. The phytochemical profile supports anti-inflammatory use across multiple tissues.

Squalene modulates multiple inflammatory signalling pathways, including NF-κB, Nrf2, MAPKs, COX-2, iNOS, and PPARγ in macrophage and monocyte models. It reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) and elevates anti-inflammatory mediators (IL-10, HO-1). A small human RCT using sublingual squalene in COVID-19 patients demonstrated its application as an anti-inflammatory adjunct.

Hyperforin, a key SJW constituent, has been shown to inhibit microsomal prostaglandin E2 synthase-1 (mPGES-1) and suppress PGE2 formation in LPS-stimulated human whole blood. Hypericin shows JAK1 inhibitory activity in silico and in vitro. These mechanisms parallel those of NSAIDs and biologic anti-inflammatories.

Stevia and its glycosides suppress NF-κB signaling and reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in animal models. A 9-month clinical RCT in CKD patients showed significant reductions in hsCRP and erythrocyte sedimentation rate with stevioside supplementation. Most human evidence is limited, with the majority of mechanistic data from in vitro and animal studies.

Stigmasterol consistently reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and mediators (COX-2, NF-κB) across diverse in vitro and animal models. Its anti-inflammatory action is one of the most extensively documented pharmacological properties. All evidence is preclinical; no human clinical trials exist.

Strawberry polyphenols inhibit pro-inflammatory signaling pathways including NF-κB and MAPK, reducing cytokines such as IL-6, IL-1β, and TNF-α in clinical studies. A meta-analysis of 11 RCTs found strawberry supplementation significantly reduced circulating CRP by 0.63 mg/L (95% CI −1.04 to −0.22). Short-term intake also attenuates postprandial increases in IL-6 and CRP in overweight adults.

S. thermophilus exerts documented immunomodulatory effects, including downregulation of pro-inflammatory cytokines (IL-18, TNF-α, IL-6) and upregulation of anti-inflammatory IL-10, in human peripheral blood mononuclear cell studies and clinical probiotic trials. These mechanisms underpin its studied role in inflammatory conditions.

Succinic acid acts as an extracellular signaling molecule through the G-protein–coupled receptor SUCNR1 (GPR91), modulating macrophage polarization and downstream inflammatory cytokine production. Succinate accumulation during inflammatory states stabilizes HIF-1α, amplifying IL-1β secretion in macrophages. This dual pro- and anti-inflammatory signaling role makes the relationship complex and context-dependent.

Sulforaphane simultaneously activates the Nrf2 antioxidant pathway and inhibits NF-κB and MAPK pro-inflammatory signaling, producing a dual anti-inflammatory effect. Multiple human studies in diverse populations confirm reductions in CRP, oxidized LDL, and inflammatory cytokines. It is one of the best-characterized dietary anti-inflammatory agents.

Animal studies demonstrate that Pfaffia paniculata extract exerts anti-inflammatory activity via suppression of pro-inflammatory cytokines and NF-κB pathways. Alcoholic root extract inhibited carrageenan-induced paw edema and reduced vascular permeability in rats. Active constituents including saponins, pfaffic acid, and phytosterols are considered responsible for these effects.

Sunflower contains vitamin E and phenolic compounds that reduce systemic inflammatory markers. A large observational study in over 6,000 adults found those eating seeds (including sunflower) ≥5 times/week had 32% lower C-reactive protein levels. Animal studies show sunflower oil reduces carrageenan-induced paw edema by nearly 80% and suppresses pro-inflammatory cytokines.

Standard (linoleic-acid-rich) sunflower oil is pro-inflammatory at high omega-6 intakes, as linoleic acid converts to arachidonic acid and pro-inflammatory eicosanoids. Topically, however, sunflower oil exerts anti-inflammatory effects via PPAR-α activation and TNF-α reduction. The net systemic inflammatory effect of dietary sunflower oil remains debated.

A. calamus demonstrates significant anti-inflammatory activity in multiple animal models, with identified mechanisms including NF-κB inhibition, prostaglandin suppression, and inflammatory cytokine reduction. PMC studies confirm anti-inflammatory, anti-oxidative, and calcium-inhibitory effects in neuropathic pain models.

Artemisinin and its derivatives from sweet wormwood inhibit key pro-inflammatory pathways including NF-κB and MAPK, and suppress cytokines such as TNF-α and IL-6. These effects are well-documented in preclinical models. Human RCT data in rheumatoid arthritis and IBD provide supporting clinical evidence.

Swertia chirayita extracts and isolated compounds demonstrate well-documented anti-inflammatory activity in multiple preclinical models. Amarogentin selectively inhibits COX-2 and blocks pro-inflammatory cytokines TNF-α and IL-6. Swertiamarin modulates the NF-κB and MAPK signaling pathways. These mechanisms have been characterized in peer-reviewed studies.

CX exerts anti-inflammatory effects through multiple molecular pathways, including NF-κB, p38 MAPK, and cytokine suppression. Its constituent compounds—TMP, ferulic acid, ligustilide, and senkyunolide I—each modulate distinct inflammatory mediators. These mechanisms have been demonstrated across multiple in vitro and in vivo studies reviewed in peer-reviewed literature.

Multiple preclinical studies have characterized the anti-inflammatory mechanisms of Aster tataricus extracts. Saponins inhibit NF-κB and MAPK pathways, suppressing pro-inflammatory cytokines including IL-6, IL-1β, and PGE-2. The compound astin C inhibits the cGAS-STING innate immune pathway. These effects have been demonstrated in multiple cell-line and rodent models.

Taurine and its metabolites taurine-chloramine and taurine-bromamine inhibit NF-κB signalling, suppressing pro-inflammatory cytokines including TNF-α, IL-6, and CRP. Clinical RCTs and a 2026 meta-analysis demonstrate significant reductions in inflammatory biomarkers with taurine supplementation.

Preclinical studies have documented anti-inflammatory activity for Dipsacus asper extracts, including suppression of inflammatory cytokines in macrophage models. The root contains iridoid glycosides, saponins, and phenolic compounds that contribute to these effects. No human clinical trials exist specifically for chronic inflammation.

Terminalia species show documented anti-inflammatory activity in both pre-clinical models and human studies. T. chebula extracts inhibit pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β) and COX-2/PGE2 pathways. A clinical adjuvant therapy study in stable coronary artery disease patients showed T. arjuna significantly attenuated ongoing inflammation and immune imbalance.

THIAA inhibits NF-κB nuclear translocation, COX-2 expression, and PGE2 production in macrophages, suppressing key pro-inflammatory mediators including TNF-α, IL-1β, and IL-6. These mechanisms have been demonstrated in multiple in vitro and animal models. Ex vivo data in human peripheral blood mononuclear cells further support anti-inflammatory activity. Clinical evidence in humans remains limited in scope.

Thymol, the major bioactive in thyme, inhibits NF-κB and MAPK signaling pathways, reducing pro-inflammatory cytokines including IL-8, TNF-α, and prostaglandins in multiple in vitro and animal models. Anti-inflammatory and mucus-regulatory effects were confirmed in a rodent pulmonary inflammation model using clinically validated thyme/primula combination. Human evidence is indirect, drawn from clinical bronchitis and dysmenorrhea trials.

Thymus vulgaris extracts and essential oil suppress pro-inflammatory cytokines including TNF-α, IL-6, IL-8, and IL-17 via modulation of NF-κB and COX-2 pathways, documented in multiple in vitro and animal studies. Carvacrol and thymol are the principal anti-inflammatory constituents. Clinical evidence in human chronic inflammatory conditions is limited, but preclinical mechanistic evidence is substantial.

T. cordifolia exhibits well-documented anti-inflammatory activity mediated through inhibition of NF-κB, suppression of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-17), and modulation of JAK/STAT signaling. Both in vitro and animal studies confirm these effects. Its alkaloid berberine specifically inhibits iNOS and the TNF-α-triggered proinflammatory cascade.

TMG exhibits anti-inflammatory properties through its role in methylation, homocysteine reduction, and AMPK pathway modulation. Preclinical evidence is strong, showing suppression of NF-κB signaling and inflammatory cytokines. Reviews of betaine supplementation in liver disease contexts document inhibition of hepatic inflammation. Robust dedicated human RCTs targeting inflammatory markers in otherwise healthy populations are limited.

Tocotrienols downregulate major pro-inflammatory cytokines including TNF-α, IL-2, IL-4, IL-6, and IL-8 in human studies. A clinical trial in CKD patients showed significant CRP reductions with TRF supplementation. However, a 2021 meta-analysis of RCTs could not provide fully conclusive evidence for anti-inflammatory effects across all studied populations.

Tomato and lycopene intake has been shown to reduce inflammatory biomarkers including IL-6 and CRP in clinical trials. A meta-analysis of 21 trials found tomato supplementation significantly reduced IL-6. Lycopene suppresses the NF-κB signaling pathway, a central mediator of chronic systemic inflammation.

GGOH inhibits NF-κB signaling in rodent models, reducing pro-inflammatory cytokines and liver enzymes after LPS challenge. In human patients with hyper-IgD syndrome (HIDS), a pilot study found GG supplementation improved inflammatory protein signatures. The mechanistic basis is restoration of protein geranylgeranylation, which restrains inflammasome activation.

Trans-pterostilbene inhibits multiple pro-inflammatory pathways including NF-κB, p38 MAPK, and COX-2/iNOS axes, reducing cytokines such as TNF-α, IL-1β, and IL-6 in numerous preclinical models. A human combination-product trial showed reductions in CRP and γ-GT. Evidence for pterostilbene alone in humans is still largely preclinical.

Tribulus extracts demonstrate anti-inflammatory activity via inhibition of COX-2 and iNOS pathways in laboratory studies, and TT supplementation in a CrossFit RCT showed a trend toward reduced inflammation biomarkers (CRP). In vitro and animal evidence for anti-inflammatory mechanisms is substantial.

Tributyrin, as a butyrate prodrug, exerts anti-inflammatory effects via multiple mechanisms including NF-κB inhibition, reduced pro-inflammatory cytokines (TNF-α, IL-1β), and increased IL-10. A pilot study in healthy humans found that 21 days of supplementation reduced high-sensitivity CRP. Preclinical data in obesity models demonstrate significant reduction in adipose tissue inflammation.

Multiple Trichosanthes species demonstrate anti-inflammatory activity in preclinical models via suppression of NF-κB, MAPK, and JAK2 signaling pathways. Peel extracts of T. kirilowii significantly inhibit NF-κB activation and reduce pro-inflammatory cytokines including TNF-α, IL-6, and iNOS. Evidence is currently limited to in vitro and animal studies with no published human RCTs specifically targeting chronic inflammation.

Triphala consistently suppresses pro-inflammatory cytokines (TNFα, IL-1β, IL-6) and enzymes (COX-2, iNOS, 5-LOX) in preclinical models. A preliminary human RCT in post-COVID-19 patients demonstrated significant reductions in oxidative stress and systemic inflammation markers. Preclinical evidence is robust; human clinical evidence is emerging.

Trypsin and its combination preparations have demonstrated anti-inflammatory effects through multiple mechanisms including modulation of protease-inhibitor balance, fibrinolysis, and cytokine regulation. Clinical evidence supports reduction of inflammatory biomarkers following oral enzyme therapy. Memorial Sloan Kettering notes observational support but acknowledges clinical data remain limited for purely chronic conditions.

Turmeric's principal bioactive, curcumin, has been extensively studied in human clinical trials for its anti-inflammatory effects. It targets key pro-inflammatory pathways—most notably NF-κB, JAK/STAT, and MAPK—and downregulates cytokines such as TNF-α, IL-6, and IL-1β. However, a 2019 systematic review and meta-analysis of 19 RCTs found no statistically significant reduction in circulating inflammatory markers (CRP, hsCRP, IL-6, TNF-α), and a 2023 GRADE-assessed meta-analysis found positive aggregate effects on the same markers, reflecting ongoing debate. Poor oral bioavailability is the primary factor limiting clinical translation.

Tylophorine and related alkaloids from Tylophora have demonstrated anti-inflammatory activity in laboratory and animal models, including inhibition of NFκB and AP1 signaling, lysosomal enzyme inhibition, and reduction in pro-inflammatory cytokines. The flavone fraction from Tylophora leaves showed statistically significant inhibition of adjuvant-induced arthritis lesions in animal models, comparable to indomethacin.

CoQ10/ubiquinol has documented anti-inflammatory effects in clinical trials, reducing markers such as CRP, IL-6, and TNF-α in diverse patient populations. It modulates redox-sensitive molecular pathways including NF-κB, reducing pro-inflammatory cytokine production. Meta-analyses in metabolic syndrome patients confirm improvements in inflammatory biomarkers.

Human RCTs consistently show that UA supplementation reduces circulating inflammatory markers including CRP and plasma acylcarnitines. UA inhibits NF-κB signaling and suppresses pro-inflammatory cytokines in preclinical models. Clinical researchers describe it as targeting 'inflammaging'—the low-grade chronic inflammation associated with aging.

Vanillin, vanilla's primary bioactive phenolic compound, has been shown across multiple preclinical studies to inhibit pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and suppress the NF-κB and MAPK signaling pathways. These are well-replicated findings in in vitro and animal models. Human clinical trials are lacking, limiting this to preclinical scientific evidence.

MP seeds and extracts demonstrate anti-inflammatory properties in vitro and in preclinical models, including inhibition of NF-κB signaling, COX-2 activity, and lipid peroxidation. In clinical studies, MP treatment reduced markers of oxidative inflammation (lipid peroxides) in human seminal plasma. The 2025 systematic review recognized anti-inflammatory activity as a key therapeutic property contributing to PD benefit.

A 2024 systematic review and meta-analysis of 15 RCTs (European Journal of Nutrition) found that niacin supplementation significantly reduced CRP levels (SMD: -0.88, p=0.003) and TNF-α, indicating a meaningful anti-inflammatory effect. Niacin acts on the GPR109A receptor on immune cells, suppressing NF-κB signaling and pro-inflammatory cytokine production.

Clinical and epidemiological evidence supports a meaningful inverse relationship between vitamin C status and markers of chronic inflammation, particularly CRP and IL-6. Randomized controlled trials have demonstrated that vitamin C supplementation can significantly reduce these inflammatory biomarkers in at-risk populations. The primary mechanism involves vitamin C's antioxidant capacity and inhibition of pro-inflammatory signaling pathways, though effect sizes and consistency vary by population and dose.

Substantial clinical and mechanistic evidence supports a role for vitamin D in modulating chronic inflammation. Vitamin D deficiency is causally linked to elevated C-reactive protein (CRP), a primary biomarker of systemic inflammation, with correction of deficiency reducing CRP levels. Multiple meta-analyses of randomized controlled trials confirm that supplementation significantly reduces key pro-inflammatory markers including CRP, TNF-α, and IL-6, though benefits appear strongest in those with pre-existing deficiency. Evidence spans diverse chronically inflamed populations including patients with metabolic disease, respiratory disease, and cancer.

Vitamin E, primarily as α-tocopherol, has well-documented anti-inflammatory effects supported by multiple RCTs and meta-analyses. It reduces key biomarkers of chronic inflammation—CRP, IL-6, and TNF-α—through antioxidant-mediated suppression of pro-inflammatory signaling pathways. Evidence is strongest for subclinical, low-grade chronic inflammation; translation to hard clinical endpoints (e.g., prevention of cardiovascular disease) remains inconsistent across large trials.

6-MSITC from wasabi potently suppresses key inflammatory mediators including COX-2, iNOS, IL-6, and TNF-α, and blocks NF-κB and AP-1 signaling pathways in multiple in vitro and animal models. These anti-inflammatory mechanisms have been well-characterized at the molecular level. While direct human RCT data on inflammatory biomarkers are limited, the mechanistic evidence is robust.

Human RCT evidence demonstrates that watercress extract reduced protein carbonyl (PCO) content and inflammatory markers in hemodialysis patients. A controlled exercise study in 19 healthy adults showed that watercress consumption promoted stronger anti-inflammatory downregulation of IL-6 and TNF-α during the post-exercise recovery phase compared to control. The 2025 systematic review of 7 RCTs found mixed but generally positive effects on inflammatory biomarkers.

Bacopa monnieri has demonstrated anti-inflammatory activity in vitro and in clinical studies. A 2024 systematic review of 22 clinical trials confirmed that BM can reduce NF-κB phosphorylation and pro-inflammatory cytokine levels.

Watermelon's lycopene and citrulline possess documented anti-inflammatory activity. Lycopene down-regulates NF-κB signaling and reduces inflammatory cytokines; clinical trials show modest reductions in inflammatory markers in cardiovascular-risk patients.

Whole wheat and wheat bran contain ferulic acid and related polyphenols that have demonstrated anti-inflammatory activity. A clinical RCT in overweight adults found whole-grain wheat consumption reduced inflammatory markers. Ferulic acid inhibits COX-2, TNF-α, and IL-6 in cell and animal studies; a human RCT with isolated ferulic acid (1,000 mg/day, 6 weeks) showed reduced inflammatory biomarkers in hyperlipidemic subjects.

Wheat germ and its oil contain bioactive compounds including octacosanol, beta-sitosterol, alpha-linolenic acid, and spermidine that have demonstrated anti-inflammatory properties. In vitro studies show inhibition of COX enzymes and reduction of LPS-induced IL-6 and nitric oxide in macrophages. Fermented wheat germ extract has been investigated in rheumatoid arthritis.

Wheatgrass exhibits anti-inflammatory effects attributed to chlorophyll, apigenin, and flavonoids that suppress NF-κB activation and pro-inflammatory cytokines in preclinical models. A human trial in colon cancer patients receiving chemotherapy showed significantly higher anti-inflammatory cytokine IL-10 in the wheatgrass group. These effects are documented in vitro and in limited human data.

Whey protein's bioactive components—including lactoferrin, alpha-lactalbumin, glycomacropeptide, and cysteine—exert anti-inflammatory effects primarily via glutathione synthesis and downregulation of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). Clinical evidence shows whey supplementation reduces pro-inflammatory cytokines and increases endogenous antioxidant enzymes, with cytokine reductions reported particularly in individuals over 50.

Oak bark tannins and flavonoids have been documented in multiple laboratory studies to inhibit release of pro-inflammatory compounds. Quercetin, rutin, and gallic acid isolated from oak bark have demonstrated anti-inflammatory effects in cell and animal models. No human clinical trial evidence for chronic systemic inflammation specifically exists.

White willow bark's salicin is metabolized to salicylic acid, acting as a non-selective COX-1/COX-2 inhibitor that blocks prostaglandin synthesis and down-regulates inflammatory mediators including TNF-α and NF-κB. Multiple clinical trials have demonstrated dose-dependent anti-inflammatory and analgesic effects in chronic inflammatory conditions. The German Commission E has approved white willow bark for rheumatic ailments and headaches. Typical dosing used in trials is 120–240 mg salicin daily.

Diosgenin and dioscin from Dioscorea villosa have demonstrated anti-inflammatory activity in preclinical models, with mechanisms involving inhibition of NF-κB, NLRP3 inflammasome, and pro-inflammatory cytokine production. A published animal study (Lima et al., BMC CAM 2013) confirmed antinociceptive and anti-inflammatory effects of D. villosa extract in rodents. No human RCTs specifically for chronic inflammation exist.

Willow bark extract suppresses multiple inflammatory mediators through COX-2 inhibition, TNF-α downregulation, and NF-κB nuclear translocation blockade. In vitro studies with standardized extracts (e.g., STW 33-I) show significant concentration-dependent anti-inflammatory activity in human monocytes and macrophages. These mechanisms underpin its clinical use in musculoskeletal and rheumatic inflammatory conditions. The anti-inflammatory activity cannot be attributed solely to salicin; polyphenols and catechol metabolites contribute meaningfully.

Gaultheria procumbens extracts have demonstrated anti-inflammatory activity in vitro and ex vivo through inhibition of NF-κB, COX-2, and pro-inflammatory cytokines. The primary active glycoside gaultherin releases salicylate in vivo (confirmed in animal models), which inhibits cyclooxygenase enzymes similarly to NSAIDs. Human clinical trial data for wintergreen-specific anti-inflammatory use are absent.

In vitro and animal studies have demonstrated that Betonica officinalis polyphenolic-rich extracts inhibit COX-1, COX-2, and lipoxygenase enzymes, with anti-inflammatory activity exceeding that of diclofenac in a rodent model. These are laboratory findings without human trial confirmation.

X. strumarium extracts and its primary sesquiterpene lactone xanthatin have been extensively characterized for anti-inflammatory mechanisms in preclinical studies. Xanthatin suppresses NF-κB, MAPK, and STAT3 signaling pathways and reduces TNF-α, IL-1β, IL-6, NO, and PGE2 in LPS-stimulated macrophage models. These findings establish scientific mechanistic grounding, though no human clinical trials for chronic inflammatory conditions have been completed.

Multiple studies in animals and humans demonstrate that XOS reduces pro-inflammatory cytokines and inflammatory markers. XOS modulates gut microbiota to favor SCFA-producing bacteria, which dampen colonic and systemic inflammation. In rodents, XOS supplementation significantly counteracted high-fat-diet-induced inflammatory cytokine elevation.

Yarrow contains sesquiterpene lactones, flavonoids (apigenin, luteolin), and terpenes (camphene, limonene) that inhibit COX enzymes, prostaglandin E2 synthesis, NF-κB, and human neutrophil elastase, constituting a well-documented multi-target anti-inflammatory profile. Both in vitro and in vivo data support this action.

Berberine, the dominant alkaloid in Yellow Root, demonstrates anti-inflammatory activity in vitro, in animal models, and in human trials — reducing CRP, TNF-α, and IL-6. A meta-analysis of RCTs in metabolic syndrome patients confirmed significant reductions in inflammatory markers. Traditional use also supports Yellow Root as an anti-inflammatory herb.

A 2025 crossover RCT found that 8 weeks of yerba mate consumption significantly reduced blood pressure, inflammatory cytokines, chemokines, and colony-stimulating factors in both healthy adults and those at cardiovascular risk. Polyphenols in YM (chlorogenic acids, quercetin, rutin) inhibit NF-κB and reduce markers such as CRP and IL-6.

Yucca contains multiple phytochemicals with documented anti-inflammatory mechanisms. Yuccaols (A–E) and resveratrol inhibit NFκB transcription and suppress iNOS expression in macrophages, reducing nitric oxide. The phenolic fraction also inhibits COX-1, COX-2, and 5-LOX enzyme activity in vitro. A 2023 PMC review (PMC10044844) identified 92 phytochemicals across the Yucca genus with antioxidant and anti-inflammatory activities.

Zanthoxylum species demonstrate robust anti-inflammatory activity in preclinical models, suppressing NF-κB, MAPK, and COX-2 pathways and reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). A 2024 mechanistic review confirmed these effects across multiple species, though human trials are lacking.

A double-blind, placebo-controlled supplementation study found that lutein, zeaxanthin, and meso-zeaxanthin together significantly decreased pro-inflammatory cytokines IL-1β and TNF-α and reduced serum oxidized LDL in human participants. Zeaxanthin's antioxidant structure enables it to quench reactive oxygen species and modulate inflammatory signaling pathways. Evidence is strongest for the combination of macular xanthophylls rather than zeaxanthin in isolation.

Clinical and preclinical studies document mild anti-inflammatory effects of zeolite clinoptilolite. The 2015 athlete RCT found anti-inflammatory effects alongside improved gut integrity. An exploratory RCT in IBS patients observed modulation of inflammation-associated markers. Cell studies show suppression of NF-κB, TNF-alpha, and IL-1B pathways. Human evidence is preliminary and confined to gut-adjacent inflammation.

Zinc has well-documented anti-inflammatory activity supported by multiple human clinical trials and meta-analyses. It inhibits NF-κB activation, suppresses pro-inflammatory cytokines (IL-6, TNF-α), and reduces oxidative stress markers such as CRP and MDA. Meta-analyses of RCTs confirm significant reductions in CRP and IL-6 with zinc supplementation in adults, though effect sizes vary by population, dose, and duration.

Adrenal cortex extract has been traditionally used for inflammatory conditions, grounded in the well-established physiological role of cortisol as the body's principal endogenous anti-inflammatory hormone. No clinical trial has demonstrated that OTC adrenal cortex supplements reduce chronic inflammatory markers in humans. The use of glandular preparations for inflammation predates synthetic corticosteroids.

Bacopa has a well-documented traditional Ayurvedic role in treating inflammatory conditions such as arthritis. Mechanistic studies show selective COX-2 inhibition and suppression of pro-inflammatory cytokines TNF-α and IL-6. While in vitro work using human blood cells supports anti-inflammatory activity, no dedicated human RCT has been conducted specifically for chronic inflammation.

Cnicin, the primary active constituent of blessed thistle, has demonstrated anti-inflammatory activity in vitro and in animal models, including reduction of markers such as TNF-α, IL-6, and MPO. Pharmacological screening in rat paw edema tests showed efficacy comparable to indomethacin. No human clinical trials have confirmed anti-inflammatory effects in chronic inflammatory conditions.

Caraway contains carvone, limonene, and flavonoids with documented anti-inflammatory properties in in vitro and animal studies. In vivo preclinical studies show anti-inflammatory and immunomodulatory effects. Human clinical evidence for chronic inflammatory conditions is absent.

In vitro and animal studies demonstrate M. pruriens seed extract inhibits pro-inflammatory cytokines and NO production in LPS-stimulated macrophages and microglial cells. The plant has traditional use for arthritis and inflammation-related conditions. No human RCT has evaluated anti-inflammatory outcomes as a primary endpoint.

Goldenseal is traditionally used as an anti-inflammatory herb, and its principal alkaloid berberine has demonstrated anti-inflammatory mechanisms in preclinical research including inhibition of inflammatory signaling pathways. No direct human clinical trials have examined goldenseal for general chronic inflammation.

Red root's anti-inflammatory actions are attributed to its flavonoid and tannin content and are documented in traditional use for chronically inflamed lymphoid, splenic, and hepatic tissue. In vitro evidence supports antioxidant and anti-inflammatory activity of flavonoids from Ceanothus species. No human clinical trials on inflammatory markers have been conducted with Ceanothus americanus.

Indigenous California tribes used Rosa californica preparations to relieve general inflammation and pain. The anti-inflammatory use is documented across multiple tribal traditions and is consistent with the well-characterized flavonoid and polyphenol content of wild rose hips.

Stillingia was used in Eclectic and folk medicine for chronic inflammatory conditions including chronic rheumatism, chronic bronchial inflammations, and chronic skin eruptions. Its alterative action was believed to reduce chronic inflammation by improving eliminative function. No clinical studies exist.